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Cardiovascular disease (CVD) is currently the leading cause of death worldwide resulting 
in 647,000 annual deaths in the United States alone. A common treatment is revascularization to 
bypass arterial blockages from CVD; however, currently clinical options are associated with a high 
failure rate1. The field of tissue engineering holds promise, and several groups have been working 
towards the development of an appropriate tissue engineered vascular graft. This dissertation 
focused on the development and in vivo testing of three different graft options: (1) custom silk 
(Antheraea assama (AA) and Bombyx mori (BM)) functionalized with macrophage attractant (C-
C motif chemokine ligand 2, CCL2) loaded microparticles or (2) cellular secretions (conditioned 
media, CM), and (3) BM silk functionalized with extracellular vesicles (EVs). Each graft was 
assessed after 1 week and 8 weeks for patency and remodeling in a rat model. All graft types 
showed increased acute patency after 1 week in comparison to blank controls (scaffold only, no 
payload); however, graft failure due to stenosis was observed in the CCL2 and CM groups after 8 
weeks. An increased macrophage presence and higher occurrence of stenosis was observed in 
response to both the CCL2 and CM functionalized scaffolds when compared to the EV group. 
Additionally, an increased occurrence of stenosis was observed in response to the inclusion of AA 
silk compared to BM silk possibly due to the increased RGD binding sites present within the AA 
silk fibroin. Overall, results have shown a more complete and positive remodeling response to BM 
silk treated with EVs characterized by increased patency, neotissue formation, extracellular matrix 
deposition, and a reduction in stenosis. The three TEVGs tested in this dissertation, particularly 
 iv 
the EV functionalized BM silk scaffold, show promising potential for future studies and 
translation. The development of a TEVG which leverages the positive remodeling effects of 
cellular secretions, yet is cell-free, offers a lower risk of immune rejection and more easily 
translatable arterial graft option in comparison to previous cell-based options. A successful TEVG 
technology has the potential to improve the outcomes of small diameter revascularization 
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This dissertation aimed to develop a cell-free tissue-engineered vascular graft (TEVG) for 
the treatment of blockages requiring revascularization, e.g. arterial blockages. To lead toward a 
clinically translatable technology, this project has tested various combinations of extracellular 
proteins, materials, and bioactive factors to stimulate in vivo vascular tissue formation. However, 
to develop a successful TEVG, it is important to understand the underlying anatomy of the vascular 
tissue we aim to replicate and the limitations of current clinical treatments and in the field of 
vascular tissue engineering. This initial introductory chapter will focus on the anatomy of the 
arterial tissue and review the current state of CVD treatments and the field of TEVGs to give a 
clearer understanding of the work done and the potential impact of the resulting findings. 
1.1 Cardiovascular System Overview 
The cardiovascular system is comprised of the heart and a closed system of arteries, veins, 
and capillaries that deliver fluids, nutrients, cells, and bioactive signals throughout the body2. The 
heart acts as the muscular pump, which circulates the blood to the organs and tissues, delivering 
necessary nutrients and signaling factors. This complex delivery system is broken into two main 
circuits: [1] The pulmonary circuit, which provides blood flow to the lungs for re-oxygenation, 
and [2] the systemic circuit which is responsible for circulating the oxygen-rich blood throughout 
the rest of the body2. This dissertation focuses on finding a vascular replacement suitable for the 
arteries of the high-pressure systemic system.  
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The systemic circulation can be divided into two halves, arterial (blue) and venous (red) 
(Figure 1)3, which combine to form the circulatory system. Blood travels throughout the 
pulmonary system to exchange carbon dioxide for oxygen. The reoxygenated blood returns to the 
left atrium of the heart to begin its journey through the arterial system. As the heart contracts, 
blood is expelled from the left ventricle and into the aorta4. The aorta branches multiple times to 
form a network of vessels (in descending size: aorta, arteries, and arterioles) that vary in size from 
30 mm (aorta) to 10 μm (smallest arterioles) inner diameter (ID)4. The arterioles then connect to 
the capillaries (smallest vessels connecting the arteries to veins), which allow for cargo exchange 
(e.g., oxygen delivery and carbon dioxide uptake) between the blood and tissues due to their thin 
walls3. Deoxygenated blood is carried back through the capillaries, which converge at multiple 
points to form the venous network of venules (smallest), veins, and finally, the vena cava (largest), 
which returns into the heart4.  
The veins and arteries of the systemic system are further divided by their functionality and 
environment. Two main factors that contribute to the different environmental stressors of vessels 
are flow rate and pressure2-4. The blood flow rate, or the velocity of flow through a specific level 
of vessel hierarchy, is inversely proportional to the total cross-sectional area of the vessels in that 
level. Although the diameter of each individual artery becomes smaller with more branching, the 
overall cross-sectional area of all the branching arteries increases, becoming far larger than the 
aorta itself and hence having a slower flow rate2.  
The pressure observed within the vessel refers to the force of the blood against the vessel 
wall as it circulates throughout the body. Blood ejecting from the left ventricle of the heart into the 
aorta and branching arteries causes an increase in force upon the vessel walls and a corresponding 
increase in observed pressure2,4. The highest pressure is observed within the left ventricle itself 
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and is propagated to the aorta and branching arteries; luminal pressure lessens as the blood travels 
further from the heart. This decreasing pressure gradient translates to much higher pressures within 




Figure 2. Gross anatomy of arteries vs. veins 
 
As shown in Figure 2, the gross anatomy of arteries and veins differ. Even further, arteries 
themselves can be broken into elastic and muscular subtypes based on their size and distance from 
the heart5. Elastic arteries are the largest arteries, such as the aorta and pulmonary arteries, which 
are closest to the heart2,4. To receive ejected blood at high pressures, elastic arteries contain higher 
amounts of collagen and elastin when compared to muscular arteries. Muscular arteries branch 
from elastic arteries drawing blood flow towards the extremities. The tunica media of muscular 
arteries is thicker and contains more vascular smooth muscle cells (VSMCs) to maintain blood 
flow. Additionally, they also contain well defined elastic layers at the intima/media and 
media/adventitia interfaces4. This dissertation focuses on the development of an elastic arterial 
 5 





Figure 3. Muscular vs. elastic arterial wall cross-section 
1.2 Coronary Artery Disease 
Cardiovascular disease (CVD) is currently the leading cause of death within the United 
States, resulting in a staggering 647,000 annual deaths6. The term “CVD” encompasses a broad 
range of disorders of the heart and vasculature, ranging from heart attacks to strokes. In many types 
of CVD, revascularization is a potential treatment where the damaged vasculature is bypassed with 
a vessel like conduit. Due to the broad nature of CVD, many types of TEVGs have been developed 
for specific applications including arteriovenous fistulas (connecting a vein and artery for use in 
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hemodialysis)7,8, large diameter vascular grafts (suited for larger arteries such as the carotid)9,10, 
and small diameter vascular grafts (designed for coronary artery bypass and peripheral artery 
revascularization applications)11-20. The sheer volume of illnesses associated with CVD makes a 
complete summary of each beyond the scope of this dissertation. Instead, I have chosen to focus 
specifically on coronary artery disease (CAD) and current treatments.  
CAD is the most common type of CVD, accounting for about 365,000 annual deaths 
associated with heart disease6,21. Nearly 18 million adults have CAD or about 6.7% of the US 
population22. Of these diagnosed patients, approximately 371,000 revascularization surgeries 
requiring a bypass graft occur each year21. CAD refers to the narrowing or complete blockage of 
the arteries supplying blood to the heart23. The blockage of the coronary arteries restricts oxygen 
and nutrient supply to the myocardium, eventually leading to cardiac failure23,24. Blockages usually 
form over time, beginning with the narrowing of the luminal space due to intimal hyperplasia and 
progressing into plaque blockage known as atherosclerosis. 
Intimal hyperplasia describes the narrowing of the vessel’s luminal space due to the 
accumulation of cells within the tunica intima25. VSMC proliferation and migration within this 
layer cause an increased number of cells and intimal thickening (Section 1.2.2). While intimal 
hyperplasia is described here as a diseased state, it is actually a wound healing response to vascular 
injury. Most occurrences of intimal hyperplasia are associated with vascular cell activation, which 
can be affected by injury, age, and increased inflammation.5. Vascular cells undergo phenotypic 
changes in response to vascular injury (Sections 1.2.1.1 and 1.2.2.1), which, if left activated, 
progresses into intimal hyperplasia5. Even in a healthy individual, the natural expansion of vascular 
cells over time leads to hyperplasia26, which is reflected in the high occurrence within aging 
populations26. Over time, hyperplasia progresses into atherosclerosis. 
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Atherosclerosis refers to the narrowing of the arteries supplying blood to the heart due to 
plaque accumulation within the lumen23. Atherosclerosis usually begins with increased 
accumulation of low-density lipoprotein cholesterol (LDL) particles from circulating blood into 
the intimal layer, where they are oxidized into pro-inflammatory particles27 activating the 
surrounding vascular cells (Sections 1.2.1.1 and 1.2.2.1). The inflammatory state is further 
exacerbated as inflammatory cells are attracted and lead to large plaque formations within the 
luminal space27. Both genetic and environmental factors play a role in the development of 
atherosclerosis23,24. Studies have linked 15 genetic variants to an increased propensity for CAD 
associated with LDL, arterial hypertension, triglycerides, high-density lipoprotein cholesterol, and 
thrombosis23,28. In addition to these genetic risk factors, many lifestyle choices increase CAD 
occurrence and atherosclerosis progression such as diabetes29, smoking30, sedentary lifestyle31, and 
consumption of a high-fat diet32.  
Both intimal hyperplasia and its progression into atherosclerosis can occur in many 
different ways; however, the main causes of CAD can be traced to endothelial cells (EC) (Section 
1.2.1), VSMC (Section 1.2.2), and the vascular extracellular matrix (Section 1.2.3)24. 
1.2.1 Endothelial Cell Function 
The lumen of arteries consists of a monolayer of endothelial cells (EC) acting as a buffer 
between the vessel wall and blood33. This continuous endothelium lines the entirety of the 
circulatory system regulating nutrient delivery and blood flow throughout every part of the body. 
The importance of this single layer of cells cannot be overstated and is evident through the sheer 
number of ECs, up to 6 x 1013, working to regulate vessel function34. The endothelium plays many 
roles ranging from cellular to whole organ functions. At an organ level, the continuous lining of 
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ECs acts as a buffer between tissue and blood. At a cellular level, with slight variation throughout 
the vascular tree, the endothelium is responsible for regulating the exchange of nutrients between 
blood and tissue, thrombosis, blood flow through vascular tone, host inflammatory response, and 
angiogenesis3,35,36. Cellular EC functions such as secretion, proliferation, and migration are 
regulated through environmental cues allowing for the maintenance of surrounding tissues35,37. 
Two of the main roles of ECs are providing an antithrombotic lining at the blood interface and 
controlling vascular tone. 
The endothelium encounters all circulating molecules, toxins, and potential threats and acts 
as a protective barrier. There are a host of surface proteins and cellular secretions associated with 
ECs aimed at preventing platelet aggravation and thrombosis35,36,38. In particular, ECs produce 
tissue plasminogen activator (tPA) that aids in breaking down blood clots after repair of the vessel 
wall38. Another anti-thrombotic function of ECs is the production and surface binding of tissue 
factor pathway inhibitor to inhibit tissue factor (TF), the receptor for factor VII, a pro-
coagulant36,38. Healthy ECs also regulate coagulation through the expression of many different 
anticoagulants (thrombomodulin, endothelial protein C receptor, heparin-like proteoglycans, 
etc.)39. Through these modes of anti-platelet adhesion, clot disruption, and anti-coagulation, 
vascular ECs work to prevent clot formation. This cellular function of the endothelium to prevent 
thrombosis is an important factor in TEVG development.  
The second role of ECs that will be discussed in this section is a broader organ systems 
function: regulation of vascular tone. The control of vessel tone is less relevant in the development 
of TEVGs since the main goal is to simply restore flow around a small portion of the vasculature; 
however, it is an important homeostasis function and must therefore be discussed. Vascular tone 
is regulated by the ECs through the secretion of vasodilatory (nitric oxide (NO), endothelium-
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derived hyperpolarizing factor, and prostacyclin) and vasoconstrictive (thromboxane and 
endothelin-1) factors40. For example, the endothelium can respond to excessive shearing forces by 
producing endothelin – 1 causing vasoconstriction. Similarly, ECs can stimulate vasodilation in 
response to various mechanical and environmental stimuli through the production of NO36,41. This 
regulation of vascular tone is essential in maintaining blood pressure and proper flow within organs 
and tissues.  
Overall, healthy ECs maintain a non-thrombogenic lining and maintain vascular tone. EC 
activation leads to disruption of the functions described above and eventual vascular dysfunction 
such as hyperplasia5. 
1.2.1.1 Endothelial Cell Dysfunction and CAD 
EC activation can be induced in multiple ways, including uneven flow (such as at branching 
points), infection, and physical injury. Activation of vascular ECs is usually the first stage of 
intimal hyperplasia and is characterized by the loss of normal EC functioning (vascular tone and 
anti-coagulation) combined with an increased expression of VSMC-activating and inflammatory 
cell-attracting factors5. Increased EC secretion of platelet-derived growth factor (PDGF), 
fibroblast growth factor (FGF), and stromal cell-derived factor 1 activate surrounding VSMCs 
(Section 1.2.2.1). Dysfunctional ECs secrete pro-inflammatory factors (various interleukins (IL), 
tumor necrosis factor α (TNF-α), monocyte chemoattractant protein 1, monocyte colony-
stimulating factor and granulocyte-monocyte colony-stimulating factor) to attract and regulate 
circulating leukocytes5. Activated ECs express adhesion molecules (vascular cell adhesion 
molecule 1, intracellular adhesion molecule 1, P-selectin, and E-selectin) which enable leukocyte 
binding and migration into the intima5. Additionally, dysfunctional ECs have shown an increased 
permeability to circulating LDL leading to an accumulation of both macrophages and LDL within 
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the intimal space42. This combined increase in VSMCs and inflammatory environment leads to the 
thickening of the intima and subsequent narrowing of the luminal space (i.e., intimal hyperplasia).  
Another component of EC dysfunction relevant to this dissertation is the increased risk of 
clot formation. As previously described (Section 1.2.1), a healthy endothelium provides an anti-
thrombotic lining between the blood and tissue, whereas dysfunctional endothelium loses many of 
its anti-thrombotic properties39. Firstly, activated ECs, recruited leukocytes, and activated VSMCs 
can secrete TF, increasing the production of thrombin39. Secondly, activated ECs express a host of 
surface receptors and cellular secretions (VWF, P-selectin, angiopoietin-2, and endothelin-1) to 
promote platelet aggregation in response to injury39. These two effects increase the risk of 
thrombus formation due to EC activation. 
1.2.1.2 Endothelial Cells and TEVGs 
In the case of vascular grafts, EC function is a crucial component of TEVG success as ECs 
are the “first responders” to vascular injury. While the idea of a TEVG is to bypass an occluded 
artery to restore proper blood flow, the act of implanting a scaffold creates a new “site of injury” 
at each anastomosis. As with any wound, the body responds with a cascade of immune and 
inflammatory responses controlled through cellular communication using soluble molecules or 
cytokines. The location of the endothelium between the affected tissue and circulating blood means 
it plays a crucial role in producing a variety of cytokines to attract circulating leukocytes35,36,43,44. 
An applicable example is the secretion of monocyte chemoattractant protein 1 (MCP-1) or C-C 
motif chemokine ligand 2 (CCL2) by vascular endothelial cells to attract circulating macrophages 
to the site of injury36,45,46. In addition to leukocyte migration into the scaffold, we also must 
consider EC migration and proliferation into the vacant lumen. 
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In the case of a cell-free scaffold as a vascular conduit, a break in the endothelium is 
created, causing an increased potential for clotting. One of the previously mentioned roles of ECs 
is angiogenesis or the development of new vasculature from preexisting endothelium33,36,43. While 
healthy, undisturbed, ECs remain quiescent, events such as injury or hypoxia can stimulate ECs 
migration and proliferation into new vessels35,47. The ability of vascular ECs to quickly migrate 
and proliferate in response to local stimulation allows for endothelium formation within an 
implanted scaffold. As the endothelium represents the regulatory lining between the blood and 
body, rapid endothelialization is preferential to restore this barrier quickly. After long term graft 
remodeling, the presence of an intact endothelium becomes important in normal vascular function 
as described above (nutrient transport, vessel tone, etc.). In response to the significant role of ECs 
within vascular grafts, many different studies have attempted to culture and pre-seed scaffolds 
before implantation48-50.  
1.2.2 Vascular Smooth Muscle Cell Function 
VSMCs are the most abundant cell type within the vascular wall. They play a diverse role 
ranging from direct regulation of vascular tone to cellular deposition of new ECM4,51,52. In healthy 
individuals, VSMCs respond to paracrine cues from the endothelium to relax and contract to alter 
the vascular tone. Healthy VSMCs maintain a quiescent phenotype characterized by the presence 
of various contractile proteins necessary in cellular contraction (vessel contraction)4,51,53. On a 
cellular level, VSMCs also play a role in ECM deposition, arterial repair, and transport of 
substances from the blood to the surrounding tissue. To maintain these various functions in 
response to physiologic cues, VSMCs display a high level of plasticity53.  
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VSMCs can range in phenotype from quiescent and non-proliferative in a healthy state to 
synthetic and proliferative in response to vascular injury51,54. Healthy, contractile cells can be 
identified through the presence of contractile proteins within the cell, including -actin, 
smoothelin, and caldesmon55. In contrast, synthetic cells can be identified through the absence of 
contractile proteins (and a corresponding loss of contractile abilities). The transition or rather 
activation of VSMCs from a contractile to a synthetic phenotype can be triggered through many 
pathways (Section 1.2.2.1) and is generally associated with vascular dysfunction or injury55. In 
reverse, synthetic VSMCs can shift back towards a contractile phenotype, often referred to as “re-
differentiation.”55,56 Both directions of phenotypic switching are important considerations in 
TEVG design (Section 1.2.2.2).  
1.2.2.1 Vascular Smooth Muscle Cell Dysfunction and CAD 
In the case of injury or vascular disease, VSMCs undergo a phenotypic change towards a 
synthetic state. This change is associated with increased organelle formation to allow for cellular 
migration and proliferation. While this unique plasticity allows for vessel repair, it can also be 
detrimental and contribute to various vascular dysfunctions, including intimal hyperplasia53,57,58, 
atherosclerosis53,59,60, and hypertension57,58,61. The switch towards a synthetic state, particularly in 
the case of CAD), may be triggered by several factors including circulating signaling molecules 
(such as PDGF and VEGF)53,58, mechanical cues (low shear stress)62,63, inflammation53,58,60, and 
signaling from the endothelium (PDGF, FGF, TGF-β)33,34,53 (Section 1.2.1.1).  
VSMCs play a critical role in the severity and progression of vascular disease. VSMCs 
express many different endothelial-derived growth factor surface receptors, including receptors 
for PDGF, FGF, and stromal cell derived fator-1, which are all upregulated during vascular injury 
by activated ECs (Section 1.2.1.1) causing increased migration into the intima. The increased 
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quantity of VSMCs within the intima causes vessel wall thickening and lumen narrowing, further 
propagating the inflammatory environment. Over time, the combined VSMC increase, 
macrophage infiltration, and LDL accumulation (Section 1.2.1.1) within the intimal space leads 
to formations of dead cells and lipid pockets that harden into plaque. Further VSMC and 
macrophage apoptosis triggered by the inflammatory environment can cause the release of matrix 
vesicles into the lipid pockets, causing plaque calcification and hardening64.  
While the plastic nature of VSMCs allows for vessel repair and formation, the prolonged 
activation of cells can be detrimental over time. In the context of vascular grafts, VSMC migration 
into the scaffold is required for vascular remodeling. 
1.2.2.2 Smooth Muscle Cells and TEVGs 
After TEVG implantation, host VSMCs must migrate into or otherwise become present in 
the scaffold pores and proliferate, which requires a synthetic phenotype55. In most cases, this 
VSMC activation occurs due to injury at each end of the implant, and no additional stimuli are 
required. Once within the scaffold, the cells are also responsible for new ECM deposition (with 
the aid of recruited fibroblasts) as the scaffold degrades52,55. This early vascular remodeling 
heavily relies upon the infiltration and propagation of VSMCs to form the bulk of newly formed 
tissue (neotissue). Once the graft has been repopulated, and new ECM deposited, the engrafted 
cells must then re-differentiate towards a contractile state56. 
Completely remodeled TEVGs should consist of mostly contractile type VSMCs similar 
to elastic arteries. The re-differentiation of VSMCs back into a contractile state is currently a 
limiting factor in many TEVG designs65,66. Failure of VSMC differentiation back into a contractile 
phenotype oftentimes results in graft stenosis and occlusion55,67. Ideally, VSMC re-differentiation 
occurs naturally as the graft remodels due to reduced inflammation, alignment of cells in response 
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to shear, and ECM maturation (vs. scaffold degradation)55,56,68. Although simply stated, this 
environmental change requires TEVG design considerations, including scaffold degradation rate 
(Section 1.3.1.4), porosity (Section 1.3.1.2), and material type (Section 1.3.1.1) that each alter the 
VSMC behavior.  
Overall, VSMCs are a major contributor to TEVG remodeling and overall success. Their 
unique plasticity can lend to successful remodeling as well as graft failure depending on the design. 
In our attempts to develop an effective TEVG, we have established the presence of VSMCs as a 
key indicator of graft success. 
1.2.3 Extracellular Matrix Components 
The two main ECM components in arteries are elastin and collagen. Elastin is the most 
prominent ECM component within the artery wall and is produced by VSMCs in the tunica media. 
It provides the vessel with the ability to recoil after distention from the high systolic pressures of 
pulsatile flow4,51,69. As elastin plays a key role in arterial response to pressure, the amount found 
in the vascular wall depends on the distance from the heart (as previously mentioned, as arteries 
branch pressure decreases, Section 1.1.1)4. In addition to the tunica media, elastin is also found in 
a layer called the internal elastic lamina lying between the intima and the media. Similarly, an 
external elastic lamina is present between the media and adventitia in larger, elastic arteries but 
not within muscular arteries51,69,70. Within the vessel wall, elastic fibers are organized into distinct 
fenestrated sheets called lamellae circumferentially aligned around the artery4,51,69. Smaller elastic 
fibers interconnect the lamellae and collagen to form an interwoven elastic structure4,51,69, which 
anchors VSMCs forming a network of structural support.  
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While elastin is responsible for the recoil of the vessel wall in response to pressure, collagen 
is the load-bearing element4,70,71. The role of collagen is to provide mechanical strength within an 
acceptable range. An excess of collagen will cause a stiff matrix inducing VSMC differentiation 
towards a synthetic phenotype and reduce the vessels' ability to flex with high pressures and 
increase the risk of cardiovascular disease67,69,72. In reverse, an artery with too little collagen is 
likely to dilate without the mechanical strength to withstand blood pressure. There are 28 known 
types of collagen occurring throughout the body; however, types I, III, and IV are the most 
prominent within the arterial wall71,73. Each type of collagen is a triple helix woven fiber with 
varying signaling functions and patterns71. Within the tunica media (and adventitia), collagen types 
I and III fibers are incorporated into the elastin and VSMC structure, which combined provide 
recoil (elastin), contractility (VSMCs), and strength (collagen).  
1.2.3.1 Extracellular Matrix Dysfunction 
Healthy vascular ECM supplies a dynamic network of mechanical and environmental cues 
dictating vascular cell function. Deviations in ECM properties such as stiffness and abundance can 
detrimentally affect CAD. For example, a component of atherosclerosis is vascular fibrosis 
characterized by an excess of ECM within the vascular wall74. As discussed, arterial wall 
thickening occurs primarily due to VSMC migration and proliferation within the intimal space 
where they begin to secrete ECM components, mainly collagen, in their activated state (Section 
1.2.2.1). Since little to no elastin is produced beyond adolescence, the gradual increase in collagen 
from constant remodeling over a lifetime results in a slow stiffening of the arterial wall74. This 
stiffening is amplified in many cases of vascular diseases, such as atherosclerosis, due to the highly 
inflammatory environment. Many studies have also shown that collagen can induce vascular cell 
activation, intensifying the progression of hyperplasia74.  
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1.2.3.2 Extracellular Matrix and TEVGs 
Elastin formation in vivo occurs almost exclusively within embryonic development and 
early infancy lasting for the duration of an individual's life75,76. While many studies have attempted 
to stimulate in vitro elastin formation, the complex, highly organized elastic networks are 
exceedingly difficult to reproduce75. Elastin itself has a half-life of about 74 years77 and is highly 
stable, yet many genetic disorders exist associated with abnormal elastin production, including 
Williams-Beuren Syndrome. Additionally, elastin degradation is related to factors including age78, 
lifestyle (smoking)79, and disease (Marfan Syndrome)80. Since elastin production in adults is 
negligible, stimulating elastin production with vascular grafts presents a unique challenge. In 
response, various labs have attempted to incorporate elastin artificially within TEVG models with 
some success14,81-83. Elastin production within a construct in vivo has been attempted through the 
delivery of regulatory factors, including TGF-β84,85, altering mechanical properties11, and other in 
vivo modulatory factors86,87. Additionally, the elastic recoil properties of elastin within the arterial 
wall have been mimicked through the scaffold material itself however scaffold degradation over 
time makes this an infeasible long term option88,89. 
In comparison to elastin, VSMCs, and ECs, collagen is readily available and easily 
produced by cells in vivo90,91. While collagen remains an important component of the arterial wall, 
it is not a limiting factor when designing a vascular graft. Overall, the presence of both elastin and 
collagen within a remodeled TEVG is a good indicator of success. To mimic an artery, a remodeled 
graft must possess the ability to both recoil and withstand pressure as would a native vessel.  
Overall, ECM plays a role in healthy vascular function as well as the progression of 
vascular disease. The design of a TEVG will ideally mimic the elasticity and strength of a native 
vessel to not only maintain flow but also prevent chronic vascular cell activation.  
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1.2.4 Current CAD Treatments 
There are two main treatment options for CAD, percutaneous coronary intervention (PCI), 
also known as “stenting”92, and bypass. Approximately 480,000 PCI procedures (formally called 
angioplasty) are performed annually in the US93. During PCI, a mesh tube known as a stent is 
inserted at the blockage site to expand and hold open the lumen of the vessel. There are many types 
of clinically available coronary stents including bare metal, drug-eluting, and resorbable, often 
deployed through a catheter and expanded using a balloon94. PCI offers a less invasive option in 
comparison to graft revascularization but is associated with a high occurrence of restenosis (lumen 
re-narrowing after treatment). In most cases, restenosis is triggered by VSMC dysfunction in 
response to the stiff metal implant. Newer drug-eluting stent options include antiproliferative and 
antimitotic drugs to mitigate excessive neointimal proliferation, but the restenosis rate remains 
about 10%66. Overall, PCI is a quicker, less invasive option but is associated with risks including 
an increased chance of blood clot formation within the stent, excessive bleeding at the catheter 
insertion site, heart attack during the procedure, kidney damage from the dye used during 
implantation, stroke due to plaque loosening during catheterization, and coronary artery damage 
during balloon deployment66.  
The second most common treatment is a bypass procedure (371,000 annual procedures in 
the US93) implanting a graft to reroute blood flow around the blockage to resume circulation53. 
Coronary artery bypass grafting (CABG) is usually recommended over PCI in cases of blockage 
in any of the major coronary arteries (right coronary, left main coronary, and left anterior 
descending) and previous PCI failure95. While PCI is less invasive and quicker, bypass grafts have 
been shown to have better long term results with lower occurrences of re occlusion96. Current 
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arterial revascularization surgeries utilize two types of grafts: synthetic scaffolds or autografts 
isolated from the patient, both of which are accompanied by complications.  
Synthetic grafts currently used in clinical applications include polyethylene terephthalate 
(PETE manufactured by Dacron©) and polytetrafluoroethylene (ePTFE manufactured by 
Gore©)97. Completely synthetic grafts have many advantages including high reproducibility, ease 
of manufacturing, and “off the shelf” availability. These options are only suitable in larger diameter 
arteries (>6mm in diameter) due to the larger luminal space reducing the risk of thrombotic failure. 
In comparison, synthetic grafts in small diameter applications result in high failure rates due to 
actue thrombosis98. An ideal graft should be similar to an artery in strength (collagen), elasticity 
(elastin), non-thrombogenicity (endothelium), and viscoelasticity (SMCs). Synthetic options offer 
suitable strength and elasticity but lack the biocompatibility of cell-based options. After implant 
of a synthetic graft, coagulation factors and adhesive proteins, such as fibrin, are bound to the graft 
surface due to hydrophobic interaction between the material and blood as well the phenomenon of 
protein adsorption known as the Vroman effect99,100. These surface-bound molecules initiate 
platelet aggregation and fibrin aggregation resulting in thrombus formation99. At larger diameters, 
the high flow rates and larger lumen prevent synthetic graft occlusion due to this protein 
adsorption; however, small diameter grafts (<6mm) quickly clot and are therefore an unsuitable 
graft option. Another limiting factor of synthetic grafts is their inability to grow with the patient, 
particularly in pediatric applications. While tissue-based grafts can remodel and grow, synthetic 
conduits must be replaced once the patient outgrows the graft requiring another surgery.  
The second graft option, an autograft, is the current clinical gold standard. Autografts are 
isolated from the patient and commonly include the internal mammary artery/internal thoracic 
artery (ITA)101,102, radial artery103, and saphenous vein103-105. The ITA and saphenous vein are the 
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most commonly used graft types95,106. The ITA results in promising long term patency107, although 
there are limited long term studies as the use of ITAs only became more popular in recent years. 
There are two ITAs delivering blood to the chest and breast tissue running along each side of the 
sternum. In bypass surgeries using the ITA, one end is isolated and sutured below the arterial 
blockage101 to reroute the flow of blood. Despite promising results utilizing ITA autografts, ITA 
failure is more common in patients with multiple revascularizations, intermediate left anterior 
descending artery stenosis, and multiple blockages108. Additional limitations include blockage 
location, number (if more than two blockages occur), and ITA unsuitability due to poor quality in 
already disease patients (i.e., diabetes, obesity)108.  
The other gold standard autograft is the saphenous vein graft (SVG) isolated from the upper 
leg. SVGs are a popular choice for bypass conduits due to their length and accessibility; however, 
long term results using SVGs show failure rates exceeding 50% after ten years109 due to intimal 
hyperplasia and atherosclerosis. Due to the compliance and strength difference between veins and 
arteries, the much weaker vein graft (Section 1.1.1) dilates due to high pressures triggering 
VSMCs activation and hyperplasia. Over time, this progresses into atherosclerosis and the high 
long term failure rates associated with SVG105,109. Overall, SVGs remain a popular graft option 
due to the available length as a single SVG is sufficient for multiple bypasses103. Various methods 
are currently employed to strengthen SVGs eliminating graft dilation, including coating the graft 
in a polymer sheath110.  
Another less commonly used autograft option is the radial artery (RA) which is the major 
artery within the forearm. Previously, the RA has been associated with high occlusion rates but 
has become more popular with the advancement in surgical methods and drug treatment103. The 
main complication associated with RA grafts is an arterial spasm or spontaneous contraction of 
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the VSMCs, preventing flow103, which is treated using calcium channel blockers. Although there 
is a resurgence of RA use in bypass procedures, limitations include plaque already existing within 
the artery and RA hypersensitivity to trauma (due to its muscular nature), resulting in a higher rate 
of atherosclerosis formation103,111. Additionally, harvesting the RA may cause nerve damage and 
altered sensation of the arm and hand in approximately one-third of patients112.  
As outlined, the low long term patency rates and high risk of thrombosis associated with 
current clinical options indicate a need for a more suitable graft option. The low biocompatibility 
and inability of polymer grafts to grow in pediatric cases make them less than ideal options in 
many cases. The increased risk of thrombosis previously described eliminates them as a small 
diameter conduit option completely. The high failure rates, complications, and need for secondary 
surgical sites for graft isolation also render autografts an unappealing option. One additional 
concern regarding patient-derived grafts is the potential for coexisting morbidities. The patient 
cohort requiring a bypass graft due to an arterial blockage may likely have atherosclerosis and 
stenosis within their ITA, RA, and SVG as well. The rising number of patients affected by CVD 
and the potential of a more suitable graft option has fueled the field of tissue engineering towards 
the development of a tissue-engineered vascular graft. 
1.3 Tissue Engineered Vascular Grafts 
Researchers in the field of biomedical engineering have been investigating the production 
of an ideal tissue-engineered vascular conduit for over thirty years113. As was discussed in Section 
1.1.1, arteries are complex and extremely difficult to replicate. There are also design requirements 
for TEVGs that depend on their intended application. One potential application mentioned in 
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Section 1.2 is to provide a connection between the artery and vein known as an AV fistula. This 
surgical connection facilitates hemodialysis and faces many different barriers to translation than a 
coronary artery bypass graft (ability to withstand continuous puncture, different pressures, 
etc.)98,114. Another type of TEVG focuses on large diameter applications in pediatric patients to 
allow for vessel growth over the patient’s lifetime9,10. Since the different types of vascular grafts 
have unique sets of requirements, this dissertation will focus on the development of a small 
diameter (<6mm) TEVG for application in cardiac bypass surgeries. Small diameter TEVGs 
(simply called TEVGs throughout the remainder of the dissertation) must provide a biomimetic 
channel to reroute blood flow around an arterial blockage. This section will focus on the 
progression of development of small-diameter arterial TEVGs and the current state of the field.  
1.3.1 Scaffold Material Requirements 
Various material types have been tested for use in TEVGs over the years, generally chosen 
for their mechanical strength, tunability, and durability. Polymer-based grafts alone offer many 
advantages, including that they are easy to manufacture, shelf-stable, and reproducible; however, 
the lack of biocompatibility mentioned in Section 1.2.4 and an increased risk of clotting are the 
limiting factor of these grafts. Many labs, including ours17,18,20,115, have attempted to combine 
synthetic but biodegradable scaffolds with biologic components, such as stem cells, to increase 
graft patency and acceptance with a high level of success12,116,117. Synthetic scaffolds augmented 
with various anti-thrombogenic coatings have also seen success in research studies114,118-122. Other 
studies have focused on scaffolds fabricated from naturally derived materials, including 
elastin11,123, collagen123,124, silk fibroin15,125-127, and decellularized ECM13,14. These natural 
material options offer higher biocompatibility in comparison to synthetic materials but lack the 
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durability and ease of fabrication associated with polymer-based grafts. Overall, material type is 
an important factor in the resulting graft and affects four major TEVG qualities: biocompatibility, 
porosity, mechanical strength (compliance), and degradation.  
1.3.1.1 Material Options and Biocompatibility 
Biocompatibility refers to the level of compatibility between the graft material and host 
tissues. A successful graft must allow for positive interactions between the surrounding host cells 
and material surface, i.e., cells must migrate in and bind to the artificial scaffolding. All implanted 
devices, ranging from prosthetics to bone grafts, must consider biocompatibility when choosing a 
material type; however, TEVGs present a unique challenge in this regard due to their direct contact 
with blood. The biocompatibility of TEVGs must also account for platelet aggregation and VSMC 
activation, as discussed in Sections 1.2.4 and 1.2.2.1. Immediately after implantation, the 
prevention of acute thrombosis in response to material type is critical in overall graft success. In 
the field of vascular tissue engineering, biocompatibility falls on a scale of compatibility ranging 
from low, eliciting a higher immune response, to high, showing very little rejection. Generally 
speaking, synthetic materials fall on the low end of the scale and natural materials towards the 
higher end.  
While most entirely synthetic TEVGs are not suitable, many labs have attempted to 
increase graft acceptance and biocompatibility by adding biologic elements (e.g. cells18,20,116, 
coatings128-131, etc.). Such approaches leverage the strength, tunability, and reproducibility of 
synthetic based grafts that are often difficult to achieve using entirely natural options. One main 
group of synthetic materials used is biodegradable polymers including poly(lactic-co-glycolic 
acid) (PLGA)132,133, polyglycolic acid (PGA)134,135, poly-lactic acid (PLA)136,137, poly-l-lactic acid 
(PLLA, an isomer of PLA)136,138,139, polycaprolactone (PCL)137,140, polyurethanes (PU)17,18,20,141, 
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poly(glycerol-sebacate) (PGS)142-144 and numerous combinations therein. These polymers display 
varying degrees of biocompatibility and are often supplemented with a biologic component in 
response (Section 1.3.2). Similarly, these grafts have shown promising results when combined 
with biologic elements such as cells18,20,86. Overall, synthetic materials augmented with biologic 
components to increase biocompatibility and cellular infiltration offer a promising TEVG option 
(Section 1.3.2).  
Naturally sourced materials (elastin, collagen, and silk) have the added advantage of 
natural binding sites to promote cellular infiltration145 as well as less toxic degradation byproducts 
making them an appealing option compared to synthetic materials. Additionally, many natural 
scaffold designs utilize ECM components which are already present within the body. For example, 
elastin is naturally occurring within arteries (Section 1.1.3.2) and plays a role in VSMC regulation, 
prevention of thrombosis, and modulation of inflammation75, which makes it an excellent scaffold 
material. However, entirely elastin-based scaffolds are expensive to fabricate and lack the 
mechanical strength necessary for an arterial conduit. Collagen is also present within the arterial 
wall and can provide the mechanical strength necessary to withstand blood pressure but can also 
bind von Willebrand Factor (vWF), a blood glycoprotein, and other blood coagulation proteins 
increasing the risk of thrombosis146. Silk based vascular grafts have been explored by many 
labs15,16,127,147,148 and remains a promising material option. Silk fibroin isolated from silkworm 
cocoons or glands offers a natural material option that is both biocompatible and tunable. Previous 
studies of silk at the blood interface showed no signs of platelet activation126,149 (i.e., anti-
thrombogenic), the mechanical strength to withstand blood pressure16, and the promotion of 
cellular infiltration16,148. Overall, silk for use in TEVGs is a relatively new area of study but shows 
great potential.  
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Another popular natural scaffold type is decellularized ECM. Decellularized ECM 
scaffolds are fabricated from allogenic or xenogeneic tissues, with the cells removed via 
decellularization. These scaffold types have the added advantage of a preexisting ECM structure 
that is very difficult to replicate artificially. Decellularized veins150 and arteries as TEVGs have a 
readily made ECM network for cellular infiltration and appropriate mechanical properties151, yet 
allogenic sourcing remains an issue. Other human decellularized ECM options include any tubular 
structure of compatible size, including umbilical arteries152,153 and small intestine submucosa154, 
but these options are still limited in availability. Most studies using decellularized ECM are 
xenogeneic grafts151, which addresses the limited availability of human tissues155. Another popular 
approach to ECM based scaffolds is cell-derived ECM13,156,157. Notably, this method has been 
explored by Dr. Robert Tranquillo’s lab by culturing VSMC or fibroblasts in a tubular fibrin gel 
to allow for ECM deposition followed by decellularization13,158. Dr. Laura Niklason and colleagues 
at Humacyte have also explored cell-derived ECM in both benchtop and clinical trials of AV fistula 
with promising results 157,159. Cell-derived ECM remains a promising option but may face barriers 
to clinical translation due to the time, cost, and cell culture required (Section 1.3.2).  
Both synthetic and natural materials types have varying advantages and disadvantages. 
Research using all of the mentioned materials types has also explored scaffold augmentation with 
biologic components such as cells (Section 1.3.2), coatings (Section 1.3.4), and signaling effects 
(Section 1.3.3) to address many of the disadvantages.  
1.3.1.2 Porosity 
Another scaffold property affecting graft success is having sufficient porosity to encourage 
cellular migration. In healthy tissue, a network of ECM provides the scaffolding for cellular 
attachment and migration. Previous research has shown cells interact and function (including 
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migration, proliferation, signaling, phenotypic changes, etc.) in response to environmental cues, 
including porosity160-162. Pore size and interconnectivity must be tuned to allow for VSMC into 
the pores and EC migration along the lumen of the scaffold. A study implanting scaffolds with 
small (10-30μm ID), medium (30-90μm ID), and large (90+ μm ID) pore sizes showed maximal 
cellular infiltration in medium-sized pores. In contrast, a lower cell count and incomplete 
endothelium were observed in the smaller and larger pores163.  
Various methods of fabrication can alter the graft porosity, including salt leaching164, phase 
separation88, and electrospinning88,165. Increased porosity is most often accompanied by decreased 
graft strength resulting in graft dilation under physiologic pressure. Many TEVGs utilize a 
bilayered approach combining a porous inner layer encouraging cellular migration with a denser 
outer layer adding the necessary mechanical stability. Our lab has worked with two different 
bilayered graft types, PEUU17,88, and silk-based127, both combining an inner porous layer with an 
outer electrospun layer producing a biomimetic scaffolding.  
1.3.1.3 Compliance, Elasticity, and Burst Pressure 
Given that an artery is a mechanically functional organ, the mechanical properties of a 
replacement must be considered carefully. In the field of vascular biomechanics, compliance 
describes the ability of a vessel to distend and increase luminal volume in response to increased 
pressure. For example, veins have high compliance (high volume increase) at low pressures, but 
low compliance (comparatively lower volume increase) at high pressures), which is one of the 
critical factors for SVG failures in arterial bypass applications105. In the case of vein grafts, a highly 
compliant vein replacing a lower compliance artery results in dilation of the vein166. This dilation 
activates VSMCs to migrate and proliferate inducing intimal hyperplasia and eventually graft 
occlusion105,166. Compliance mismatch also causes disturbance in flow through the graft, 
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increasing the risk of thrombosis, particularly in a low flow application105. Ideally, compliance 
should match that of the native artery (4.5-6.2% mmHg-1 x 10-2 in human arteries167). 
The elasticity of the graft must also reflect the host artery. In a healthy vessel, elastin allows 
the vessel to recoil under pulsatile flow (Section 1.2.3). In TEVGs, the elastic property can be 
provided by the material itself. A scaffold without elasticity will be unable to recoil after 
deformation resulting, in time, in graft dilation and potential rupture. Arterial stiffening occurs 
naturally with age as elastin fibers degrade, and stiffer collagen fibers remain. This stiffening 
activates VSMC migration and proliferation, eventually leading to atherosclerosis168. A similar 
phenomenon occurs in stiff scaffolds resulting in high rates of graft failure. Arterial wall stiffness 
is measured using the β stiffness index and can similarly be applied to scaffolds. Various studies 
have used both the saphenous vein (β-stiffness = 16.9±7.1) or, more ideally, the arterial wall 
(femoral β-stiffness = 23.7±0.8)169 as the gold standard to match. 
The third measure of TEVG mechanical properties is burst strength. An implanted scaffold 
must be strong enough to withstand pulsatile flow and blood pressure in vivo. Burst strength is 
most commonly compared to the saphenous vein (~1680 mmHg)98,170 as the clinical gold standard. 
Unlike compliance and stiffness, many grafts both over167,171,172- and under173-175-match this value 
with successful results with different modes of remodeling indicating it may not be as important 
to match; however, burst pressure is a required ISO measurement towards clinical translation. 
1.3.1.4 Degradation 
Lastly, the graft material for small diameter arterial bypass or replacement should be 
biodegradable. The end goal of any TEVG is to provide a temporary scaffolding to promote 
vascular tissue formation in its place, requiring a degradable material. The rate of degradation 
should match the rate of new tissue formation, which varies in response to different material types. 
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Numerous studies have designed quickly degrading grafts designed to promote rapid cellular 
infiltration and quick scaffold degradation in hopes of reducing a prolonged inflammatory 
response138,164,176. Notably, fast degrading scaffolds have been intensively studied by groups, 
including Shinoka11,138, Breuer11,138, and Wang177,178 as potential TEVG options. Promising results 
have been observed in rat178 and mouse138 models, but scaling this technology into a human-sized 
graft remains the current challenge. In comparison, slow degrading materials such as PCL 
(exceeding 24 months)179 are more suitable for slow tissue healing. In scaffolds types with slower 
observed cellular infiltration rates, a longer degradation time may be beneficial to provide 
mechanical support during neotissue formation. Another concern is the toxicity of scaffold 
degradation byproducts. Natural materials are more favorable in this sense as their degradation 
byproducts can be quickly metabolized and excreted. Synthetic materials, while biocompatible, 
are associated with prolonged inflammatory responses to lingering material180. Overall, the 
tunability of scaffold degradation rates is an important consideration in TEVG design. There is a 
delicate balance in timing between cellularization/new tissue formation and scaffold degradation, 
which must be reached and differs with each TEVG type. 
1.3.2 Cells in TEVG Applications 
The incorporation of cells within scaffolds has evolved over the history of vascular graft 
research. The addition of cells to both synthetic and natural scaffolds helps overcome many of the 
biocompatibility limitations outlined. In terms of cell type, a large variety of cells have been 
studied in TEVGs (Section 1.3.2.1), but all meet a few base requirements: (1) non-immunogenic, 
(2) easily obtained, and (3) able to perform their intended function (e.g., EC must be able to adhere 
and proliferate within the scaffold)98,181. Some studies116, including those in our lab18,182, focused 
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on autologous cell sourcing to minimize the risk of rejection and disease transfer, as observed with 
xenogeneic cells98. More recent studies have studied allogeneic cells as a potential cell 
source183,184, but much is still unknown regarding immune response to these cells.  
There are currently many different techniques to incorporate cells into scaffolds181. One 
common method is static cell seeding, where a cell suspension is applied directly to the scaffold 
surface and relies on gravity and cellular adhesion to penetrate the entire scaffold114,185. This 
method is appealing due to its simplicity but often results in uneven cellular distribution, long 
incubation times necessary for cellular attachment (up to 9 days), increased risk of contamination 
due to long culture times, and low overall cellular attachment (especially in synthetic 
scaffolds)114,185,186. Dynamic cell seeding addresses many of these issues by utilizing vacuum 
pressure17 or centrifugal force186 to increase cellularity and seeding homogeneity as well as 
decrease the time required. To date, vacuum cell seeding into porous scaffolds remains a popular 
option offering even cellular distribution within minutes17,116 compared to weeks for cell culture 
methods; however, this method relies heavily on the scaffold material qualities (porosity, elasticity, 
and strength) to achieve ideal seeding181. Dynamic seeding methods also exist to pre-form an 
endothelium before implantation. Bioreactors mimicking physiologic flow and shear on luminal 
seeded ECs can induce EC proliferation and migration into a full endothelium in vitro49 but are 
limited similar to static seeding in cell culture cost, time and potential for infection.  
1.3.2.1 Cell Types and Considerations 
Cells for use in TEVGs fall into two categories: vascular cells (particularly ECs) and stem 
cells. Many early and current studies utilizing cells focused on integrating vascular cells into the 
scaffold prior to implantation in attempts to implant a graft more closely mimicking the native 
artery48,187. Endothelial cells and endothelial progenitor cells (EPCs) can be isolated from bone 
 29 
marrow and incorporated into an autologous graft. A pre-formed monolayer of mature ECs is a 
popular approach48,140,188,189 to prevent thrombosis. Many of these studies observed positive results 
in graft patency with the inclusion of an endothelium190,191 but required extensive bioreactor 
culture. Alternatively, other studies have used EPCs, which can differentiate into ECs, to lessen 
culture time and eliminate the need for bioreactor culture114,192. Mixed results have been observed 
using ECs and EPCs depending on the cell sourcing, seeding strategy, and scaffold material188,193. 
While the incorporation of endothelial cells has been a large area of study, smooth muscle cells 
are generally not pre-seeded due to the potential downfalls of inducing VSMC proliferation and 
intimal hyperplasia. Additionally, the inherent plasticity of VSMCs introduces the risk of 
phenotypic change in response to the mechanical stress of seeding. 
An alternative cell type is mesenchymal stem cells (MSCs)187. MSCs are readily available 
in a number of tissues such as adipose194,195, bone marrow196, and umbilical vein blood197, making 
them more convenient to harvest than primary vascular cells. MSCs are highly proliferative in 
vitro198 and can easily reach volumes necessary for a human-sized graft. They are also 
immunomodulatory198, can recruit ECs and VSMCs115,198, and can differentiate into vascular cell 
types (ECs and VSMCs) making them an ideal TEVG cell source.  
Another less commonly used cell type is induced pluripotent stem cells (iPSCs) genetically 
modified to resemble embryonic stem cells and then differentiated into vascular cells199. iPSCs 
offer an appealing alternative to EPCs and ECs in terms of availability but may face regulatory 
hurdles due to the extensive differentiation and cell culture required199.  
Each of these cell types has seen success in various TEVG designs but are all limited by 
regulations around cell culture. FDA regulations around the use of stem cells and stem cell culture 
is a clear barrier to stem cell-based TEVG translation200,201. As stem cells and cell-based 
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technology continues to progress, guidelines governing these technologies also continue to change. 
In general, the FDA strictly regulates ex vivo handling (i.e., culture expansion, exposure to culture 
media, etc.), making any technology using culture-expanded cells difficult to translate200-202. In 
order to limit cell manipulation and reduce the time between cell isolation and graft implantation, 
the Vorp lab has been working with the stromal vascular fraction (SVF) of cells directly isolated 
from patient adipose tissue20. Cell types within the SVF include fibroblasts, macrophages, 
preadipocytes, and MSCs203. SVF isolation takes ~4 hours and potentially eliminates the need for 
culture expansion if enough adipose tissue is available. This elimination of culture provides a more 
translatable technology; however, it is a relatively new cell source as applied to TEVGs and 
requires additional investigation before its potential is fully known. Similarly, bone marrow 
mononuclear cells (BM MNCs) refer to the cellular isolate from bone marrow before purification 
into MSCs. This particular cell population includes EPCs, ECs, MSCs, immune cells, and MSCs114 
and has been used in place of MSC with success116.  
1.3.2.2 Role of Stem Cells within TEVGs 
As the field of tissue-engineered vascular grafts continues to grow and change, so has the 
rationale behind the use of stem cells within grafts. Many early studies incorporated MSCs into 
different TEVG types hypothesizing MSC differentiation into vascular cells12,17. Implanting a pre-
seeded scaffold was intended to increase graft acceptance by providing already engrafted cells able 
to differentiate into appropriate vascular phenotypes rather than rely on recellularization from 
surrounding tissue and circulating cells. As more studies focused on the mechanisms behind 
scaffold remodeling, it was discovered that initially implanted cells are not present within the 
remodeled graft disproving this hypothesis65,116,127,204. Rather, the cells play a signaling role within 
the scaffold. Stem cells are able to communicate with surrounding cells through the secretion of 
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signaling molecules, vesicles (Section 1.3.3.2) and cell surface interactions114,205. To summarize 
the scope of cells within grafts, this section will use the term stem cells to refer to MSCs, BM 
MNCs, and SVF as they all play similar signaling roles within TEVGs. Stem cells influence graft 
acceptance and remodeling in three main ways: (1) anti-thrombogenicity, (2) immunoregulation, 
and (3) promotion of remodeling. 
The first role of the stem cells is to prevent thrombus formation. Studies from our lab18,86, 
as well as others116,206,207, have shown improved acute patency immediately after implant in 
scaffolds with stem cells vs. unseeded scaffolds. This improved patency is observed within the 
first days post-implantation, indicating an immediate thrombogenic regulatory role of the stem 
cells. While the exact mechanisms behind this anti-thrombogenic effect are unknown, some ideas 
can be drawn based on the current understanding of stem cells. Thrombosis occurs in two main 
ways: protein adsorption due to blood and material interactions (intrinsic) or the release of tissue 
factor (TF) from injured cells (extrinsic)100. Vascular injury due to graft implantation extrinsically 
activates clotting, but this may be counteracted through stem cell secretions. Stem cells secrete 
urokinase-type plasminogen activator (uPA), which plays a role in plasmin formation and thereby 
fibrin (clot) degradation19. Alternatively, stem cells may function to lessen protein adsorption to 
the graft surface. As discussed in Section 1.2.4, synthetic materials naturally bind blood serum 
proteins (the Vroman effect100), including albumin and fibrinogen, which then bind platelets205. 
Pre-seeding scaffolds, particularly along the lumen, may decrease this effect. While the mechanism 
behind stem cell regulation of thrombosis (or perhaps, a combination of multiple mechanisms) is 
unknown, various studies have observed a reduction in platelet adhesion through the delivery of 
stem cells19,86,116.  
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Stem cells also play an immunoregulatory role in inflammatory cell recruitment and 
polarization. The entire secretome is still an area of study, but more recent studies have focused 
on inflammatory mediated graft remodeling, particularly through macrophage 
interaction138,178,204,208. A focus of Dr. Breuer and Dr. Shinoka’s65 TEVG work is the increased 
secretion of CCL2 from seeded cells to promote graft remodeling (Figure 4204). They hypothesized 
that stem cells attract macrophages through the secretion of chemokine (C-C motif) ligand 2 
(CCL2, also known as monocyte chemotactic protein-1 or MCP-1). These engrafted macrophages 
then take over the remodeling process. Additionally, secretions have been shown to mediate 
macrophage polarization from a pro-inflammatory (M1) state towards an anti-





Figure 4. Proposed methods of graft remodeling via host inflammatory response 
This proposed mechanism of TEVG remodeling was proposed by Dr. Breuer and Dr. Shinoka204. 
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Lastly, the stem cell secretome (Section 1.3.3) contains potent pro-remodeling (by way of 
inducing cell migration) signals115. One mode of potential graft remodeling is the recruitment of 
surrounding vascular cells, which then take over remodeling (i.e., endothelium formation by ECs 
and ECM deposition/contractile SMCs layer formation by VSMCs). Engrafted cells may provide 
localized signaling to surrounding host cells to migrate towards and into the scaffold, specifically 
for EC migration and proliferation210. As mentioned, VSMC dysfunction caused by injury or 
chronic inflammation is a potential mode of graft failure through intimal hyperplasia. A major role 
of stem cells is to regulate VSMC phenotype and inhibit VSMC proliferation211. Much is left to be 
discovered regarding the role of stem cells in TEVGs and their signaling effects.  
1.3.3 Cytokine Signaling in TEVGs 
The term cytokine signaling encompasses all cell-secreted proteins and vesicles, which is 
beyond the scope of this dissertation. This section will focus specifically on three aspects of 
signaling relevant to this project: (1) macrophage recruitment through MCP-1, (2) MSC secretome 
applied to vascular cells, and (3) extracellular vesicles.  
1.3.3.1 Macrophages and CCL2 
The idea of inflammatory mediated graft remodeling is currently being investigated in 
many labs but was introduced by Dr. Breuer and Dr. Shinoka204. In an early study focusing on 
stem cell immunoregulation in TEVGs, they discovered high levels of CCL2 secreted from seeded 
cells204. Further, increased local delivery of CCL2 encouraged early monocyte recruitment into the 
scaffolds to begin the wound healing process. The idea of graft remodeling can be thought of by 
analogy to wound healing and its stages (inflammation, tissue formation, and tissue remodeling). 
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In vascular injury, endothelial cells secrete CCL2, which attracts tissue-resident and circulating 
neutrophils and monocytes46. From there, tissue-specific signals cause monocyte differentiation 
into macrophages to begin tissue regeneration212. This macrophage population then undergoes 
polarization (phenotypic change in response to environmental cues) into either classically activated 
(M1) and alternatively activated (M2) macrophages. The full description of macrophage 
phenotypes is beyond the scope of this dissertation, but a basic understanding of the M1 and M2 
exemplary phenotypes is important in understanding TEVG remodeling.  
A pro-inflammatory environment polarizes macrophages towards an M1 type. The M1 
macrophage population in healthy tissue remodeling is responsible for microbe phagocytosis and 
the production of additional pro-inflammatory cytokines to initiate the immune response. This 
stage of increased inflammation usually occurs within the first days after injury and is a necessary 
step in the tissue remodeling process; however, prolonged M1 expression can cause chronic 
inflammation and improper healing213,214. One particular macrophage population expresses 
chemokine receptor CCR2, which binds CCL2. These CCR2 macrophages are recruited 
immediately after injury and play an inflammatory role (M1)212. After the initial inflammatory 
response, the recruitment of macrophages changes from M1 towards an M2 phenotype associated 
with cellular migration, proliferation, and new ECM deposition. M2 type macrophage secretions 
promote host cell migration (VSMCs and ECs) into the injury site (i.e., the scaffold), and promote 
collagen production from surrounding cells213,214.  
1.3.3.2 Conditioned Media 
As described in Section 1.3.2.2, cellular secretions from stem cells have many different 
effects on TEVG remodeling. Cells in culture secrete a unique combination of growth factors and 
vesicles containing proteins, surface markers, and mRNA into the media. MSCs, in particular, can 
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secrete a wide variety of signals affecting neighboring cell migration, proliferation, differentiation, 
chemoattraction, etc215. In vivo, these secretions vary in response to environmental cues to regulate 
cell function. As discussed in Section 1.3.2.2, stem cell secretions within TEVGs also have 
multiple roles whose exact mechanisms are unknown; however, several MSC cellular secretions 
(in addition to CCL2) are known to play a role specifically in vascular remodeling: VEGF140,216, 
TGFβ217,218, and uPA19,219.  
VEGF mostly affects endothelial cells, which play a regulatory role in vascular healing and 
TEVG remodeling (Section 1.1.2.1)220. VEGF is secreted by smooth muscle cells and 
macrophages (both M1 and M2)221, during wound healing. As indicated by its name, VEGF’s main 
role is to promote EC growth and proliferation and inhibit EC apoptosis222. Many different studies 
have functionalized scaffolds with VEGF to promote rapid endothelialization and observed 
improved patency and endothelium formation140,216.  
TGF-β is a growth factor that promotes VSMC and EC proliferation and migration223, 
macrophage polarization towards an M2 phenotype224, and ECM production by VSMCs225. In 
vivo, increased TGF-β secreted by VSMC and EC can have detrimental effects leading to intimal 
hyperplasia217. TEVG studies focusing on TGF-β have shown inhibition of TGF-β receptors 
improve graft patency and stenosis217,218.  
Lastly, uPA plays an anti-thrombogenic role within TEVGs (Section 1.3.2.2). The 
secretion of uPA from cells within the scaffold works to break down clots as they form. Our lab 
has shown decreased uPA production of seeded cells increases graft failure via acute thrombosis19.  
Conditioned media has the advantage of containing the entirety of the cell secretome - a 
feat impossible to achieve artificially. Delivery of conditioned media in place of engrafted cells 
has the potential to mimic the robust cell secretome without requiring the cells themselves, which 
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bypasses the many regulations around stem cell technologies (Section 1.3.2). However, this 
potential application faces limitations around cell culture and the inclusion of xenogeneic 
components within the media, including fetal bovine serum (FBS) and bovine serum albumin 
(BSA).  
1.3.3.3 Extracellular Vesicles 
Extracellular vesicles (EVs) are also contained with the conditioned media and are an 
important means of intercellular communication. EVs are lipid bilayer encased packages naturally 
secreted from cells. There are various types of EVs identified by size and contents that are secreted 
(Figure 5226). Microvesicles usually range from 100-1000nm in diameter and are loaded with 
growth factors and genetic information, though they cannot replicate like a cell. As shown in 
Figure 5, microvesicles bud from the lipid bilayer of cells and therefore contain surface proteins 
that can provide surface protein communication between cells226. Exosomes are smaller, 30-150 
nm in size, and are produced when multivesicular bodies filled with intraluminal vesicles fuse with 
the cell membrane releasing into the intracellular space226. Lastly, apoptotic bodies are vesicles 
released from a dying cell and can attract immune cells for removal via phagocytosis226. All three 
types fall under the umbrella term “extracellular vesicle” and provide a more complex signaling 
effect than growth factors alone. Vesicles have an advantage over conditioned media since 
unnecessary culture media components (fetal bovine serum, fungizone, penicillin, streptomycin, 





Figure 5. Formation and contents of cell-secreted bodies 
1.3.4 Acellular Grafts 
Despite all the positive effects of stem cells within TEVGs, they also provide the main 
limiting factor towards clinical translation. Some labs have attempted to design a more easily 
translatable129,138,178, cell-free graft in response to the strict FDA regulations surround stem cells200-
202. The main limitation of acellular grafts is the low biocompatibility of any material, synthetic or 
natural, at the blood interface. One popular approach to increasing graft patency and compatibility 
is to encourage host cell recruitment through the delivery of various peptides, growth factors, and 
antibodies. As mentioned in Section 1.3.1.1, many synthetic materials lack cellular binding sites 
slowing the rate of host cell infiltration. Various labs have coated synthetic materials with arginine-
glycine-aspartate (RGD) peptides128,129,227,228 to provide EC binding sites in attempts to stimulate 
early endothelium formation and thrombosis prevention. Various studies have combined other EC 
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binding peptides with RGD to enhance rapid endothelization, including YIGSR229,230, mussel 
adhesive proteins188, REDV230, and cRRE231. This popular approach shows promising results in 
vivo to enhance EC cell recruitment228,232,233, but effective RGD binding to the graft material 
remains a limiting factor. 
Another approach to acellular grafts is the inclusion of anticoagulants such as heparin. A 
regiment of anticoagulants is generally prescribed following any revascularization surgery, but 
inclusion into the scaffold itself offers localized, sustained delivery at the site at risk of 
clotting130,131,234. Grafts have been coated in heparin through cross-linked collagen234 and luminal 
surface modifications130,235, yet a long term, controlled delivery at the blood interface has yet to be 
developed. Some studies combined multiple anticoagulants such as heparin, nitric oxide, or 
thrombomodulin to provide a more robust anti-clotting treatment131,236,237. This multi-factor 
delivery is similarly limited by failing to achieve a sustained, controlled release, which is further 
complicated with the delivery of multiple treatments.  
1.3.5 Current In Vivo Studies 
As is clear from the considerations and previous research explained above, there are many 
different approaches to TEVGs currently under investigation. Below, Table 1 summarizes a list of 
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2.0 Chapter 2: C-C Motif Chemokine Ligand 2 Functionalized Silk Scaffolds 
Many different approaches to tissue-engineered vascular grafts combine a base scaffold 
with a biologic component. This chapter focuses on a novel combination of silk-based scaffolds 
and CCL2 loaded microparticles (MPs) for use as a TEVG. This study was the result of a 
collaboration between Dr. David Vorp’s Vascular Biomechanics Laboratory (VBL) at the 
University of Pittsburgh, Dr. Biman Mandal from the Indian Institute of Guwahati, Dr. Steven 
Little at the University of Pittsburgh, Dr. Morgan Fedorchak at the University of Pittsburgh, and 
Dr. Charles Sfeir from the University of Pittsburgh. 
 Previous work from the VBL combined polyester(urethane urea) (PEUU) scaffold with a 
variety of stem cell types producing promising results in rat models17-20,250. Collectively, these 
studies showed increased patency in cell-seeded constructs compared to unseeded scaffolds 
indicating a signaling role played by the engrafted cells (Section 1.3.2.2). Despite these promising 
results, the regulations governing stem cell use in implanted devices limit the translatability of 
cell-based constructs (Section 1.3.2.1). To circumvent this barrier, we have developed a cell-free 
immunoregulatory-based TEVG comprised of a silk scaffold functionalized with CCL2-loaded 
MPs fabricated in collaboration with Dr. Sfeir. By incorporating CCL2, we had hoped to encourage 
early host macrophage recruitment to the scaffold to begin the wound healing process (Figure 4).  
Additionally, this study utilized silk-based scaffolds in collaboration with Dr. Mandal. As 
discussed in the introduction (Section 1.3.1), silk offers many potential advantages in tissue 
engineering due to its natural biocompatibility. There are many types of silk isolated from different 
kinds of silkworms and spiders that have been applied to tissue engineering147,251,252. Very broadly, 
the types of silkworm silk can be isolated into two classes based on the main diet of the silkworm: 
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mulberry and non-mulberry. The majority of studies applying silk-based scaffolds to the 
cardiovascular application have utilized mulberry silk, specifically Bombyx mori (BM) silk, due 
to its tunability (elasticity, mechanic strength, porosity) and ease of access; however, the study of 
non-mulberry silk is a relatively new area of study253. Dr. Mandal’s laboratory is one of the leading 
labs exploring non-mulberry silk-based scaffolds for tissue engineering147,251,254 with a specific 
focus on Antheraea assama (AA) silk. The novel research using AA silk has shown scaffold 
tunability and the ability to support vascular cell growth in vitro251,255. AA silk also contains a 
naturally occurring RGD peptide, which has been shown to prevent acute thrombosis in vivo228, 
making it a promising material choice for a TEVG.  
2.1 Methods 
2.1.1 Silk Scaffold and MP Fabrication 
Silk scaffolds were designed and fabricated in collaboration with Dr. Biman Mandal and a 
Ph.D. student visiting from Dr. Mandal’s lab, Prerak Gupta. Silk fibroin (SF) was isolated and 
purified following a related, previously published protocol147 and stored at 4°C in dehydrated 
pellets until use. Two aqueous SF solutions were made from (1) cocoons of BM silk in a 6% w/v 
solution and (2) glands of matured fifth instar larvae of AA in a 2% w/v solution. The two solutions 
were combined in a 1:1 ratio resulting in a 4% w/v custom silk blend and injected into custom 
tubular molds of rat aortic size (Figure 6). This custom blend was designed to leverage the 
biocompatibility and tunability of BM silk with the increased potential for cellular infiltration 





Figure 6. Silk scaffold fabrication mold. 
 
The solution was then incubated at 37°C for 20 minutes to allow for hydrogel formation. 
After gelation, the mold cap and stainless steel center rod were removed to reveal the lumen of the 
scaffold. The scaffold was then frozen at -20°C overnight (12-18 hours) before lyophilization for 
24 hours. After lyophilization, the scaffolds were removed from the mold and soaked in 80% 
ethanol to form a porous, tubular scaffold. This porous tube was then electrospun (ES) with a 1:1 
mixture of 10% w/v polycaprolactone (PCL) (Sigma Aldrich) and 10% w/v BM silk in 1,1,1,3,3,3-
Hexafluoro-2-propanol (HFIP, Sigma Aldrich). To ES, the mixture was ejected from a 5 mL 
syringe at 100 μL/min through a 23 gauge blunt tip needle placed 10 cm from the scaffold. The 
scaffold was mounted to a linear (50 mm/sec) and rotation motor (200 rpm) in a chemical hood at 
~25°C. The resulting custom, bi-layered scaffold is called a “lyogel” scaffold. 
CCL2 was loaded into PLGA microparticles following a previously published protcol256,257 
in collaboration with Dr. Sfeir. Water loaded PLGA MPs served as a negative control throughout 
this study fabricated in collaboration with Dr. Little and Dr. Fedorchak. Cargo was loaded using a 
water-oil-water double emulsion procedure resulting in loaded PLGA MPs containing CCL2 or 
water. 
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Scaffolds were functionalized with CCL2 loaded (or unloaded “blank”) poly(lactic-co-
glycolic acid) (PLGA) microparticles (5-15 μm in diameter) by incorporation into the silk solution. 
After the 4% w/v custom silk solution was fabricated, 3mg of MPs were incorporated into 1 mL 
of the SF mixture and blended to form a homogenous solution. The scaffolds were then assembled 
in the same way as described above. Three types of scaffolds were tested: (1) “lyogel” fabricated 
using just lyogel silk, (2) “Blank” fabricated using water loaded PLGA microparticles loaded into 
lyogel silk (negative control), and (3) “CCL2” fabricated using CCL2 loaded microparticles in 
lyogel silk.  Even MP distribution throughout the length of mold was tested by incorporating 
fluorescein isothiocyanate (FITC) loaded MPs into scaffolds. Scaffolds were then divided 
longitudinally into five equally sized pieces and imaged using an upright fluorescent microscope 
(Eclipse 90i, Nikon) and imaging software (NIS Elements, Nikon). The resulting images were 
qualtitatively assesed for MP distribution. 
2.1.2 Measuring CCL2 Release 
The release of CCL2 from the MPs was assessed to ensure proper release after 
incorporation into silk scaffolds. Approximatly 0.5 cm long scaffolds of each type (lyogel, CCL2, 
and Blank, n=4 of each) were weighed prior to release. Each scaffold was then placed in 2.0 mL 
Eppendorf tubes filled with 1 mL of phosphate buffered solution (pH 7.4, PBS, Gibco), mounted 
in an end-over-end turner, and incubated at 37°C for 24 hours. Each day, the scaffolds were 
removed and placed in a new 1 mL PBS. The remaining releasate was centrifuged at 16,000 rpm 
to remove any silk or PLGA degradation. The resulting supernatant was isolated and stored at -
20°C until use. Samples were then analyzed using a CCL2 ELISA kit (DY479, R&D Systems) and 
ancillary reagent kit 2 (DY008, R&D Systems) following the manufacturer’s protocol. Absorbance 
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was measured using a plate reader (Synergy HT, BioTek Instruments) and normalized to the initial 
weight of each scaffold portion.  
2.1.3 Scaffold Implantation 
All animal protocols were approved by the Institutional Animal Care and Use Committee 
(IACUC, University of Pittsburgh, Pittsburgh, PA) to ensure the ethical treatment of each animal. 
Each MP-impregnated construct was implanted as an abdominal, infrarenal, interposition graft in 
a Lewis rat (Figure 7). Rats were anesthetized using 4% isoflurane (Butler Schein) and maintained 
using a mixture of 1% isoflurane and ketamine (50 mg/kg hydrated in lactated ringers electrolyte 
solution). Deep anesthesia was assessed through respiratory rate monitoring and a lack of deep 
pain response (pedal reflex). After anesthesia, the abdomen was shaved and prepared using a 7.5% 
povidone-iodine solution followed by a 70% ethanol wash. A midline incision was made along the 
prepared abdomen, and the aorta was then exposed. Using micro forceps, a 3 cm portion of the 
aorta between the renal branches and lower trifurcation was isolated, and micro clamps (Vascu-
Statt II) were applied to stop blood flow through the isolated portion. The aorta was then severed 
in the middle of the clamped length resulting in a ~1cm gap due to elastic recoil. A 1cm scaffold 
was dipped in a 5% heparin solution (McKesson Medical-Surgical) and sutured as end-to-end 
anastomoses with 6-10 interrupted sutures per end (10-0 prolene, J496G, Ethicon). Once the graft 
was secured, the distal then proximal clamps were removed to restore blood flow. If leaking was 
detected, clamps were replaced for a maximum of 10 minutes, and additional sutures were applied, 
followed by a bolus of 5% heparin solution over the suture site to avoid stagnant blood clotting 
within the graft. The muscle and skin layers were closed separately using running 3-0 polyglactin 
resorbable sutures (J215H, Ethicon). Rats recovered on heating pads and were monitored for signs 
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of distress for 24 hours post-implantation. Post-operation, each rat received a subcutaneous 
injection of 0.05mg/kg buprenorphine every 12 house for 48 hours. Anticoagulants were 
administered orally for 4 weeks post-operation (dipyridamole – 250 mg/kg for the first 7 days, 100 
mg/kg for the following 3 weeks; aspirin – 200 mg/kg for the first 7 days, 100 mg/kg for the 




Figure 7. Diagram of TEVG implant in a rat model. 
TEVGs were implanted as infrarenal aortic interposition grafts as depicted.  
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2.1.4 TEVG Explant and Patency Determination 
Grafts were explanted at 1 and 8 weeks to observe the early macrophage and late 
remodeling response to the implanted materials (Figure 8). The rats were anesthetized with 5% 
isoflurane and euthanized by a lethal intracardiac injection of a 1:1 mixture of heparin (40IU, 
McKesson Medical-Surgical) and potassium chloride (100mg/kg, Kospira). Immediately after 
euthanasia, a 22G catheter (22G x 1 in, Safelet IV catheter, Exel Int.) was inserted into the left 
ventricle of the heart, and a contrast agent (Isovue (iopamidol injection), Bracco) was injected 
under angiography (GE OEC 9800 Plus, GE) to determine patency. The graft was then removed 








Figure 8. Depiction of angiography at explant. 
Angiograms were taken to determine patency (left). Then, the grafts were explanted and divided into four 
sections (right): (A) proximal aorta and graft, (B) small ring, (C) medial graft, and (D) distal graft and aorta.  
 
Angiography was used to determine graft patency with binary “patent” or “not patent” 
results. Successful detection of contrast distal to the graft after injection was deemed “patent,” 
while no contrast detected was labeled “not patent” (Figure 9). Inconclusive angiograms occurred 
due to limited visibility caused by stenosis or branching arteries, in which case patency was 






Figure 9. Angiography was used to determine the patency of each graft. 
Angiograms were taken to assess patency. Images after contrast injection showed either flow through the 
graft (patent, left) or no flow indicated by a lack of constrast distal to the graft (occluded, right). 
 
If grafts were removed early due to hind limb ischemia and signs of distress, no angiogram 
was recorded. Instead, patency was determined by isolating a portion of the aorta distal to the graft 
prior to euthanization and bisecting it to observe the flow. If no blood flowed out, the graft was 






Figure 10. Depiction of graft patency determination without angiography. 
Three grafts occluded due to acute thrombosis and explant was performed before the intended timepoint due 
to animal distress. Patency was determined by bisecting the distal aorta and observing flow through the graft. 
No flow indicated, not patent, and flow indicated patent. 
2.1.5 Macrophage Staining 
Section C (Figure 8, medial graft portion) of the 1-week explants was fixed in a 4% 
paraformaldehyde solution (FisherScientific) for 45 minutes before being paraffin-embedded and 
sectioned onto glass slides (McGowan Institute for Regenerative Medicine (MIRM) Histology 
Core). Slides were then immunofluorescently stained following the manufacturer's protocol with 
the following primary/secondary antibodies: CD68 (1:100 ab31630, monoclonal, Abcam)/Cy5 
(1:100 ab_2340820, Jackson ImmunoReseach Laboratories Inc.), CD86 (NBP2-25208, 
monoclonal, Novus Biologicals)/Cy3 (1:100 ab6939, Abcam), and CD206 (1:100 18704-1-AP, 
polyclonal, ProteinTech) Cy5 (1:100 ab_2340820, Jackson ImmunoReseach Laboratories Inc.). 
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CD68 is a glycoprotein highly expressed on most macrophages, monocytes, and peripheral blood 
granulocytes. For this study, CD68 was used as a pan-macrophage marker to determine total 
macrophage quantities. The whole macrophage population within the sections was also stained for 
M1 (CD86) and M2 (CD206) macrophage-specific markers. All sections were co-stained with 
bisbenzimide H 33258 (Sigma Aldrich, St. Louis, MO), which stains DNA (cell nuclei). Each 
round of staining included a rat spleen (positive control) and each slide included a primary delete 
(negative control using secondary antibody alone, used to determine non-specific binding) to 
ensure true staining for each intended marker. Stained slides were imaged using an upright 
fluorescent microscope (Eclipse 90i, Nikon) and imaging software (NIS Elements, Nikon), and 
while cross-sections were imaged at 10x magnification. Each image was digitally segmented into 
an inner (porous layer) and outer (ES) area. For each explant, a total cell (nuclei stain), total 
macrophage (CD68), M1 type macrophage (CD86), and M2 type macrophage (CD206) count was 
determined using a custom Matlab code (Appendix A.4). Briefly, stained images were blinded to 
identity of the explant to prevent user bias. Each image was manually segmented into inner 
(porous) and outer (ES) layers. A separate threshold for the inner and outer layers was determined 
by three users and averaged (Figures 11 and 12). The Matlab code then determined a cell count 
based on the threshold chosen yielding positively stained cells per area. Significance was 
determined in GraphPad Prism 8 (GraphPad) using a one way ANOVA and Tukey’s multiple 





Figure 11. Representative section used for cell counting using a custom Matlab code. 
Sections of the 1 week explants were stained for CD68 (pink) and DAPI (blue) to detect macropahges (left). 
Images were then run through a matlab code which determine a cell count based on thresholding (right). 
2.1.6 Vascular Cell and ECM Staining 
Successful detection of remodeling was based on immunofluorescence (IFC) and 
immunohistochemistry (IHC). Positive graft remodeling was determined through the presence of 
three key cell types/components: (1) contractile vascular smooth muscle cells [calponin (1:100 
ab46794, Abcam)/Cy5( 1:100 ab150075, Abcam) and -smooth muscle cell actin (1:100 ab7817, 
Abcam/Cy5 (1:100 ab_2340820, Jackson ImmunoReseach Laboratories Inc.)], (2) a full 
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endothelial luminal lining (von Willebrand Factor (vWF) preconjugated with FITC, Abcam), and 
(3) ECM deposition (hematoxylin & eosin (H&E) and Verhoeff-Van Geison (VVG)). All IFC was 
performed using established protocols, and all IHC was completed at the MIRM Histology Core. 
All 8-week stains for cell phenotypes and ECM components were qualitatively assessed. 
2.2 Results 
2.2.1 Silk Scaffold Characterization 
All three construct types (lyogel, blank MP loaded, and CCL2 MP loaded)  were ~1.5 cm 
long with a wall thickness of 580 ± 118 μm (490 ± 120 μm inner and 128 ± 18 μm outer layer). 
Each scaffold had an outer diameter of 1040 ± 82 μm and inner luminal diameter of 2194 ± 230 
μm (Figure 12). Lyogel and MP loaded lyogel scaffolds displayed sufficient porosity, pore 
interconnectivity, and pore size (53 ± 30 and 43 ± 24 for lyogel and CCL2 functionalized lyogel 
respectively) for application as a rat TEVG. Homogeneous longitudinal distribution of MPs was 






Figure 12. Lyogel scaffold macro image (left) and scanning electron microscopy image (right). Images 






Figure 13. FITC MP loaded scaffolds were sectioned and fluorescently imaged to observe MP distribution 
(A) Silk solution loaded with FITC MPs was injected into a custom scaffold mold. (B) Each mold was 
allowed to gel while standing vertically with a top cap. (C) To test for even distrubtion of the MPs 
throughout the length of the mold, n=2 FITC MP loaded scaffolds were sectioned into five portions 
and imaged. (D) An qualitatively even distribution of MPs was observed in each section suggesting 
that MPs do not settle to the bottom of the mold during gelation. 
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2.2.2 CCL2 Loaded Scaffold Release Profile 
Releasates from the CCL2 MP functionalized lyogel scaffolds were collected and measured 
at day 1, 4, 5, 6, and 7. An initial burst release of contents was observed within 24 hours (Figure 
14) which was above level of detection. The initial burst release at day 1 was 567.5 pg/scaffold; 
however, this amount was above the level of detection so is likely higher than measured. Since 
samples were not collected on days 2 and 3, the day 4 sample represented the release within days 
2-4 which was 28.3±16.2 pg/mg scaffold. After day 4, no CCL2 release was detected. Additional 
testing on diluted day 1 samples as well as releasates from days 2 and 3 were intended but omitted 




Figure 14. Release profile of CCL2 functionalized lyogel silk scaffolds.  
Release from CCL2 MP loaded scaffolds (n=4) was measured using an ELISA. (A) The standard curve was 
analyzed in GraphPad Prism 8 following the manufactuerer’s prtocol. (B) The total amount of CCL2 
normalized to scaffold weight was measured within each sample collected (day 1, 4, 5, 6, and 7). (C) A 
cumulative profile combining the previous CCL2 measurments was also graphed. *Day 1 samples were above 
level of detection so the reported value of ~600 pg/mg scaffold is innaccurate and likely higher than reported. 
**Days 5, 6, and 7 samples were below level of detection and displayed as 0. 
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2.2.3 1- and 8-week Explant Patency and Gross Histology 
Gross histology of the 1 week explant (Figure 15) showed signs of early stenosis at 1 week 
in one of the CCL2, one of the lyogel, and two of the Blank MP explants; however, the level of 
stenosis could not be quantified due to a loss of sample during tissue processing at the McGowan 
Institute’s Histology Facility. Specifically, after paraffin embedding, neotissue was lost in ~50% 
of the samples, leaving only the unremodeled portions of graft. Some quantification could be 
performed by imaging whole cross sections of H&E stained explants; however, this analysis was 
not completed due to shut down of research in response to the pandemic. Therefore, cross sectional 
macroscopic images were used to qualitatively assess remodeling. Of all the implants in all groups, 
three grafts from the blank group were removed early due to loss of hind limb function (Figure 
10) and were determined to be not patent due to acute thrombosis. Patency rates of 50% (7/14), 
100% (10/10), and 100% (5/5) were observed in the Blank MP, CCL2 MP, and lyogel groups 
respectively after 1 week in vivo. A significant increase in patency was observed between the 
CCL2 and Blank groups after 1 week (p=0.0188) (Appendix A.3). 
Patency for the 8-week explants was determined through angiography, consultation with 
Dr. Tzeng, and distal bisection of the aorta (Figure 9). All explants not patent before or at one 
week were also included within the 8-week study. Ten of the forty-eight angiograms at 8 weeks 
were inconclusive due to stenosis limiting flow to an undetectable amount. Explants were 40% 
(8/20), 54% (7/13), and 73% (11/15) patent for Blank, CCL2, and lyogel scaffolds, respectively. 
Overall, the 8-week patency rate for CCL2 trended higher than Blank but not significantly 
(p=0.2451). In comparison to the 1-week explants, a decrease in patency was observed in the Blank 






Figure 15. Macroscopic imaging of the medial portion of graft explanted after 1 week. 
Grafts removed before 1 week are indicated with implant duration times in the lower right corner. Cross 
sectional imaging of the Blank (top 4 rows), CCL2 (middle 3 rows), and lyogel (bottom two rows) were taken 
to qualitatively observe signs of stenosis, neotissue, and thormbus formation. (patent = green border, not 





Figure 16. Macroscopic imaging of medial portions of explanted grafts after 8 weeks in vivo.  
Grafts removed before 1 week are indicated with implant duration times in the lower right corner. Grafts 
that were occluded in the 1 week explants were also included within the 8 week results. Cross-sectional 
images of 8-week explants showed signs of neotissue formation and stenosis in all groups.(patent = green 
border, not patent = red border). 
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2.2.4 Macrophage Activity After 1 Week In Vivo 
Overall macrophage presence was indicated by positive CD68 staining. No significant 
difference in the density of CD68+ cells was observed between any of the groups. A significantly 
higher density of CD68+ cells was observed within the outer vs. inner layer of both the CCL2 and 
Blank MP groups (p<0.0001) indicated in Figure 17. Macrophage densities within the inner 
portions were 33±6 (n=11), 26±3 (n=10), and 25±2 (n=4) macrophages per square mm for the 
Blank, CCL2, and lyogel scaffolds respectively (error represents standard error of mean, SEM). 
Macrophage densities within the inner portions were 705±149, 705±61, and 383±60 macrophages 







Figure 17. Quantification of CD68+ cells. 
TEVGs explanted after 1 week were stained using CD68 (displayed in pink) to detect macrophages and 
bisbenzimide (blue) to detect all cell nuclei. Whole cross sectional images of each explant (left, each scale bar 
represents 500 μm) were constructed by tiling higher resultion images (middle, each scale bar represents 100 
μm). Quantification of CD68+ was analyzed as positively stained cells per area of TEVG (left, shown as 
average CD68+ cells/area with SEM). A significantly lower density of macrophages were observed between 
within the inner compared to outer regions of both the CCL2 and Blank MP groups (p<0.0001). 
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2.2.5 Scaffold Remodeling After 8 Weeks In Vivo 
Positive remodeling was detected in all three scaffold types that remained patent after 8 
weeks in vivo. Contractile SMCs, a continuous endothelium, and early ECM deposition were 
detected (Figure 18). Qualitatively, a lower amount of calponin positive cells was observed in the 








Figure 18. IFC staining of 8 week explants for VMSCs and ECs. 
IFC staining showed the presence of contractile VSMCs (calponin and αSMA shown in pink) and ECs (shown 
in green) within all groups after 8 weeks in vivo. Nuclei of all cells were stained using bizbenzimide shown in 





Figure 19. IHC staining of 8 week explants showed gross histology and early ECM depositon. 
IHC staining for overall cellularity (H&E, left) and elastic fibers (VVG, right) of 8 week explants showed 
neotissue formation in all three groups and early elastic fibers within the neotissue. H&E revealed low 





In this study, we were able to successfully fabricate novel, rat-sized silk based bilayered 
scaffolds functionalized with CCL2 MPs. An initial burst release of CCL2 was observed within 
the first four days in vitro, ensuring the release of cargo from the MPs after incorporation into the 
scaffold. In vivo assessment of the scaffolds revealed a significant increase in acute patency after 
1 week with the delivery of CCL2 compared to Blank MPs (p=0.0188). After 8 weeks in vivo, no 
significant differences in patency were observed between the three groups (lyogel, CCL2 MPs, 
and Blank MPs). Additionally, no differences in neotissue cell phenotypes/ECM were observed 
after 8 weeks; however, differences in remodeling were qualitatively assessed through cross-
sectional gross histology. 
Three main types of remodeling were observed within the 8-week explants: luminal 
ingrowth, neotissue formation, and stenosis (Figure 20). The first type of remodeling was termed 
“luminal ingrowth,” characterized by a localized infiltration of cells within the lumen forming an 
obstruction (Figure 20). Gross inspection of the explants showed the highest occurrence of 
“ingrowth” in the blank scaffolds (7 of the 16 explants that remained for the full 8 weeks) followed 
by CCL2 explants (3 of 13); however, no ingrowth cases were found in the lyogel group. IFC 
analysis of one luminal ingrowth explant showed infiltration of CD68 positive cells through the 
ES layer indicated by the cell alignment and portions of scaffold within the neotissue (Figure 21). 
This may suggest a chemotactic response from surrounding tissue-resident macrophages to the 
scaffold itself or rather an accumulation of circulating blood leukocytes (also CD68 positive)258. 
As previously mentioned, (Section 2.3.3), neotissue growth within the lumen and lack of 
cellularity within the scaffold itself may be due to insufficient luminal porosity. Since no luminal 
ingrowth was observed within the lyogel group, this may be related to the PLGA MPs or PLGA 
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byproducts themselves. Further, in vitro testing of cellular growth onto MP loaded scaffolds would 




Figure 20. Depiction of the three types of graft remodeling after 8 weeks. 
The three types of remodeling observed were (top) luminal ingrowth, (middle) neotissue formation, (bottom) 






Figure 21. IFC of 8 week CCL2 functionalized lyogel scaffolds. 
Total macrophages were detected using IFC for CD68 (pink in the top right and middle right). Additional 
staining for vWF positive cells (ECs or platelets) and VSMCs (αSMA shown in pink in the top left and bottom 
right) was used to detect the presence of vascular cells. The luminal neotissue was comprised of macrophages 
and scaffold byproducts (autofluorescent green in the bottom left) with qualitatively fewer VSMCs (αSMA, 





Figure 22. Histological imaging of luminal ingrowth. 
Two examples of luminal ingrowth were analyzed (not TEVG type specific), Gross inspection and H&E of 
grafts with luminal ingrowth showed a dense cellular, circular formation anchored to the ES layer as shown 
in the top and middle rows. Further H&E staining showed the entire growth was cellular. 
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In cases of neotissue formation and stenosis, determination of neotissue formation versus 
stenosis was difficult after tissue processing. Results from angiography, macroscopic images, and 
staining confirm the main mechanism of failure in all graft types was stenosis. Previous studies in 
the VBL have used the presence of neotissue as an indicator of positive remodeling; however, 
excessive amounts can cause stenosis (as observed in this study) and eventual occlusion. Many 
TEVG studies from other labs have reported stenosis as the main mechanism of failure in a wide 
range of graft types98,114,258,259. However, a recent study from Dr. Breuer and Dr. Shinoka 
suggested the key to stenosis reduction and reversal may naturally occur through an inflammatory 
mediated host response over time260. 
Lastly, explants with neotissue formation but no apparent signs of stenosis showed 
localized infiltration of neotissue into the porous layer of the scaffold (Figure 23). In contrast to 
the cases of luminal ingrowth, the infiltration neotissue does not appear to penetrate the ES layer 
indicating vascular cell migration from the lumen. Although the source of vascular host cells 
infiltrating into the graft is still an area of study in the field of TEVGs, the leading theory suggests 
cellular migration from neighboring host cells from each anastomosis inwards toward the middle 
of the scaffold261,262. This theory could support the increased luminal cellularity observed in H&E 
images (Figure 23), where a distinct difference in cellularity was observed between the luminal 
neotissue and medial scaffold. Closer inspection of the proximal and distal ends revealed a 
continuous neotissue spanning both anastomoses (Figure 24), also suggesting cellular migration 






Figure 23.Histologic imaging of neotissue formation. 
 Two examples of neotissue formation (left=lyogel and right=CCL2) were chosen to display the histology of 
the explants which fell into the neotissue formation group. Gross histology (top and middle rows) showed a 
layer of neotissue within the lumen of the explant. Local infiltration of neotissue and localized “anchoring” of 





Figure 24. Macroscopic imaging of stenosis at the proximal and distal anastomoses. 
 The middle portion of the explant showed signs of stenosis through macroscopic cross sectional imaging 
(top). The proximal and distal graft portions were bisected longitudinally to observe luminal stenosis (middle 




IHC for gross tissue structure and elastic fibers showed three distinct layers in nearly all 
patent explants: an inner neo-tissue, a medial portion of unremodeled graft, and an outer ES and 
connective tissue layer (Figure 19). Previous studies have shown graft recellularization from 
circulating vascular progenitor cells126,263, beginning with cellular infiltration from the lumen and 
cellular differentiation. This potential mechanism behind cell infiltration may explain the increased 
luminal cellularity observed in the majority of 8-week explants. Alternatively, other studies have 
speculated at cellular infiltration from the anastomosis rather than the lumen264,265. In this case, 
VSMC activation and migration from the adjacent vessel is primarily immune driven due to the 
“injury” at each suture site. Both mechanisms would, theoretically, be enhanced by the delivery of 
CCL2 along the entire lumen, promoting a more rapid cellular migration towards the center of the 
graft. Initial patency results could be explained by the rapid formation of a cellular lining at the 
blood interface. To determine the true mechanism behind early graft remodeling, additional in vivo 
studies at earlier time points (days 1-6) are needed to observe the progression of recellularization. 
Regardless of the source of infiltrating cells, graft recellularization was observed 
exclusively within the intima of the 8-week explants and, in most cases, displayed excessive 
neotissue formation. In all three types of remodeling, the excessive neo-tissue formation observed 
could be due to a prolonged M1 (inflammatory) immune response, resulting in chronic vascular 
cell activation. Recent studies in the field have switched focus from promoting vascular cell 
migration to mediating the immune response to the scaffold to orchestrate host cell 
remodeling178,208,260. CCL2 alone has been shown to attract and upregulate an M1 macrophage 
phenotype266 which requires additional host cell signaling for later polarization. Other studies 
focusing on macrophage response to implanted biomaterials indicate the delivered cytokines 
should focus on polarizing the already present macrophages rather than attracting additional, 
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excessive monocytes267. In order to promote M2 polarization, a number of different factors could 
be introduced including IL-13 or IL-4268 which have been used in previous studies. However, our 
previous work with MSC seeded TEVGs have benefited from the full secretome of the implanted 
cells which includes more than two to three factors. The encapsulation and delivery of all MSC 
secretions may prove more robust in mediating graft remodeling than a mixture of a few select 
factors. 
2.4 Limitations and Future Directions  
Overall, CCL2 played an early role in preventing acute thrombosis, but no additional long-
term effects were detected. Below five limitations of this study are discussed in more detail – the 
success of lyogel without MPs, the limited time points chosen, the experimental limits of 
macrophage quantification, the relevance of the animal model used, and time constraints related 
to the COVID-19 pandemic. 
First, it was unexpected based on pilot studies (Appendix A.2) that lyogel alone remained 
patent. An initial pilot study was conducted with two goals: assessing the short-term viability of 
lyogel TEVGs and improving surgical technique. This initial study was limited to 12 implants and 
only measured patency and graft cellularity. The pilot study tested the efficacy of CCL2 loaded 
(n=6) vs. lyogel scaffolds (n=6) in vivo (Appendix A.2), resulting in an 86% and 0% patency rate 
respectively after 1 week in vivo. Based on these promising results, the study outlined in within 
this chapter was performed to better assess the remodeling of a CCL2 functionalized lyogel 
scaffold; however, lyogel scaffolds in the full study displayed nearly 100% patency instead of 0%. 
Despite this finding, this study, as well as others in the field98,114,258,259, have suggested that graft 
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success is defined by not only patency but also lack of significant stenosis. Taking this into 
account, while the lyogel scaffolds remained patent up to 8 weeks, 8 of the 9 explants displayed 
signs of severe stenosis. This increase in stenosis may be a result of a negative or prolonged host 
inflammatory response. In vitro studies observing the macrophage migration and polarization in 
response to CCL2 releasates could better indicate any negative effects. Future studies to address 
stenosis should focus on a more robust host immune response to prevent prolonged 
inflammation260.  
A second limitation was the limited amount of time points (1 and 8 weeks) observed. These 
initial two time points were chosen to observe early macrophage recruitment and late-term 
remodeling (since most of our previous studies showed extensive remodeling after 8 weeks 
[REFS]). However, further insight into the mechanism behind graft remodeling will require 
additional timepoints. Earlier times (1-6 days) would provide a clearer picture of the source and 
rate of host cell migration (both vascular and immune) and the corresponding effect on acute 
patency. Additionally, later time points (6-12 months) would determine longer-term graft patency 
and the progression of stenosis. In particular, newer studies have shown spontaneous resolution of 
stenosis in computational models that would need to be validated in vivo260. 
The results of the IFC staining were also limited by autofluorescence and nonspecific 
binding of silk to many primary antibodies. Prior to staining, several combinations of primary and 
secondary antibodies were tested for optimal cell staining, however, CD86 was found to bind the 
silk protein itself resulting in false staining. Minimal autofluorescence was observed in the CY5 
channel and was therefore used for CD68 and CD206 staining. The resulting CY5 stains produced 
quantifiable images using CD68 primaries but very low binding for CD206 allowing for only 
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qualitative analysis. Future studies should use IHC or flow cytometry to better identify M1 vs. M2 
macrophages.  
This study was also limited by the model chosen. In this study, young (<6 months old) 
Lewis rats were used; however, realistically, cohorts requiring TEVGs include diseased cohorts, 
particularly aged and diabetic. The CDC reported a staggering ~77% of individuals over the age 
of 60 diagnosed with some form of CVD93. In response, the VBL has studied the effects of elderly 
cells in TEVGs115 and shown reduced patency19. Another at-risk population studied in the VBL 
are diabetic patients with a two to four times increased risk of mortality due to CVD93. Previous 
studies from our lab have shown dysfunction in cellular migration in vitro and patency in vivo 
using diabetic ASC; however, additional studies observing diseased hosts (vs. cell source) are 
needed to explore the potential of our TEVG technology. One potential discrepancy from our 
“healthy, young” model to “aged or diabetic models” is the different immune responses, which 
could affect graft patency and stenosis267,269. Studies from Dr. Bryan Brown’s laboratory observing 
the macrophage responses to CCL2 coated mesh implanted subcutaneously showed significantly 
different M1 and M2 host reactions within young vs. aged mice, which indicates a potential 
difference in graft remodeling between the two267. Studies show old rats contain dysfunctional 
tissue-resident macrophages which hinder the remodeling process. In comparison, young, healthy 
rats contain a host of tissue-resident macrophages already present in the surrounding tissue 
eliminating the need for an attractant266,267,270,271. This indicates the need for different cytokine 
treatments specific to patient age and comorbidities. Future studies could incorporate different 
high-risk hosts, including aged and diabetic rats, to assess TEVG acceptance among different 
potential recipients. 
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Lastly, this study was limited by the experiments not able to be completed due to the 
restrictions on research during the COVID-19 outbreak. Specifically, the following experiments 
were underway/planned but unable to be completed: (1) a second ELISA measuring the exact 
release profile of CCL2 from the scaffolds, (2) IHC analysis and quantification of graft stenosis, 
and (3) additional macrophage staining for M1 type macrophages.  
Overall, this study was successful in fabricating a novel, silk based TEVG functionalized 
with CCL2. The delivery of CCL2 increased patency over 1 week as well as early macrophage 
infiltration; however, most grafts failed after 8 weeks due to stenosis. Based on these results as 
well as others from the field, future studies should focus on a broader immune response mediatory 
effect through the delivery of additional chemokines or even conditioned media (the subject of 
Chapter 3). 
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3.0 Chapter 3: Conditioned Media Functionalized Silk Scaffolds 
Results from Chapter 2 indicated delivery of CCL2 caused a dysfunctional graft healing 
response resulting in stenotic failure. Chapter 3 aims to build upon these findings by changing the 
cargo from CCL2 to conditioned media in attempts to elicit a broader and more favorable host 
response (CM). As previously discussed in the Introduction (Section 1.3.3.2), CM not only 
contains free floating factors such as cytokines and growth factors, but also EVs. The inclusion of 
EVs within the CM MPs introduces additional cellular communication including delivery of RNA 
and lipid membrane bound factors. 
Previous studies by the VBL have shown patency without stenosis in MSC seeded PEUU 
scaffolds17,19,86,127 in vivo, indicating an appropriate cell signaling effect when seeded prior to 
implant. Since CM varies with media type, cell type, and culture conditions, it is difficult to 
characterize the contents; however, the use of whole conditioned media ensures delivery of the 
entire cell secretome without the need to identify and combine individual factors. By using whole 
CM, we aim to replace cells seeded within the grafts without the need for living cells. For the 
duration of this study, lyogel scaffolds were used in combination with CM MPs to observe if the 
delivery of CM can offset stenosis. The use of lyogel allows for MP incorporation into the porous 
layer of the scaffold during fabrication while other scaffold types require vacuum seeding. Initial 
attempts to seed MPs into PEUU scaffolds are outlined in Appendix A.1. These seeding attempts 
were hindered by the inability of MPs to deform to fit through pores and the high pressures required 
to pull the rigid MPs into the scaffold resulting in burst failure of the PEUU scaffold. Additionally, 
the use of lyogel allowed for a direct comparison of CCL2 vs. CM in Chapters 2 and 3, 
respectively. Similar to Chapter 2, lyogel scaffolds were fabricated in collaboration with Dr. 
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Biman Mandal from the Indian Institute of Technology Guwahati and his PhD student Prerak 
Gupta, who spent a year working in the VBL. Silk fibroin isolation and degumming were 
performed by Prerak Gupta. 
This Chapter focuses on the delivery of MSC-derived CM from silk TEVGs in order to 
produce patent grafts with fewer occurrences of stenosis when compared to the results from 
Chapter 2. The following sections outline the in vitro and in vivo testing of CM MP, Blank MP, 
and lyogel scaffolds and comparing their results. 
3.1 Methods 
3.1.1 CM MP Fabrication 
As discussed in the Introduction, Section 1.3.3, conditioned media contains the important 
cell signaling information required to induce host cell migration, proliferation, and immune 
response; however, the signaling components vary with cell and media type. In order to optimize 
the secretome being used within this Chapter, various cell passages and media types were tested 
to increase the protein content within the CM. These parameters for conditioning media were 
optimized (Appendix A.5) using RoosterBio human Adipose Stem Cells (ASCs, RoosterVial-
hAD-1M MSC Lot #00097, RoosterBio). This commercial source of cells was chosen based on its 
thorough characterization by RoosterBio and increased potential translatability when compared to 
patient-derived cells. ASCs were plated at 1.5 million cells at passage 3 (P3) into T175 flasks. 
Cells were then cultured to 40% confluency in RoosterBio RoosterNourish MSC media (KT-001, 
RooserBio) then rinsed with 1X Hank’s buffered saline solution (HBSS, pH 7.4, Thermo Fisher 
 82 
Scientific), and new 5% harvest media was applied (Appendix A.5). Cells were cultured in harvest 
media for 48 hours, during which time the cells increased from 60 to 90% confluency. The media 
was then collected and centrifuged (5425R refrigerated microcentrifuge, Eppendorf) at 2,040 x g 
and 4°C for 5 minutes to remove debris and dead cells. After centrifugation, the supernatant (CM) 
was isolated and stored at -80°C until use.  
MP fabrication and characterization were performed in collaboration with Dr. Morgan 
Fedorchak, Dr. Steven Little, and Liza Bruk – a PhD student in Dr. Fedorchak’s laboratory – at 
the University of Pittsburgh. Briefly, CM was lyophilized in 20 mL aliquots overnight and 
resuspended at a 10x concentration. This concentrated CM was then encapsulated in PLGA MPs 
using a double emulsion procedure257. Resulting MPs were 1-10 μm in diameter (previously 
measured by Dr. Jeffrey Krawiec272). 
3.1.2 Protein Release from CM MPs 
Protein release was measured from CM and Blank MPs. 10 mg of each MP was added to 
1 mL PBS (pH 7.4, Gibco) in a 2 mL Eppendorf tube and mounted into an end-over-end turner. 
The supernatant was collected following the protocol outlined in Section 2.1.2 and stored at -80°C 
until use. Using a micro BCA kit (#23235, ThermoFisher), the total protein within each supernatant 
sample was measured (Figure 25). Just prior to measurement, samples were vortexed and added 
(150 l each) to triplicate wells in a 96 well plate. Standards of known concentration were also 
measured in triplicate following the manufacturer’s protocol. 150 μL of working solution was then 
added to each well resulting in a colorimetric reaction. Samples were incubated at 37°C for 2 hours 
before resting at room temperature for 30 minutes. The samples were then analyzed (absorbance 
measured at 562 nm) using a plate reader (BioTek). 
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3.1.3 Measuring EV Release from CM MPs 
To measure EV release from MPs, 10 mg of CM MPs and Blank MPs were each released 
into 1 mL water for 24 hours at 37°C in an end-over-end turner. The resulting releasate was 
centrifuged at 16,000 x g to pellet remaining MPs and degradation by-products. The supernatant 
was then filtered through a 0.22 μm filter (Express PES low bind membrane, Millex) to remove 
smaller debris and apoptotic bodies (Section 1.3.3.3). The filtered releasate was then measured 
using dynamic light scattering (DLS) using a Nano-ZS90 Zetasizer (Malvern Panalytical). 100 μL 
of the releasate was added to an 8.5 mm cuvette (Brandtech Scientific). Each cuvette was mounted 
into the Zetasizer and allowed to settle for 1 minute at 25°C. Using pre-set parameters, a refractive 
index, and absorption matching proteins suspended in water were set. The sample was then 
analyzed for the average size of particles within the sample.  
 
3.1.4 CM MP Toxicity Assessment 
The toxicity of releasates was measured using a LIVE/DEAD assay (R37601, 
ThermoFisher Scientific). Releasates collected from 3.0 mg MP in 1mL PBS were tested for both 
CM and Blank particles (Section 3.2). Human primary aortic smooth muscle cells (hSMCs, 
ATCC) were plated into a 24 well plate at 40,000 cells/well and incubated overnight in hSMC 
media (Cell Applications, Inc., San Diego, CA). The media was then removed, and 500μL of 
treatment was applied to each well for 12 hours (n=3). A positive viability control of supplemented 
hSMC culture media (Cell Applications) and positive cell death control of diH2O were run in 
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triplicate to confirm true staining of live and dead cells. All wells were imaged using fluorescent 
imaging (Eclipse 90i and NIS Elements, Nikon).  
3.1.5 CM MP Promotion of SMC Migration 
The ability to promote cellular migration into the scaffold in vivo is an important 
component of TEVG remodeling and was tested in vitro using a scratch wound assay adapting 
protocols previously used in the VBL115,272. CM and Blank MPs (10mg/mL) were released into 
unsupplemented hSMC media (Cell Applications, Inc.). hMSCs between P8 and P12 (ATCC) were 
plated in a 24 well plate at 75k/well. Cells were allowed to adhere overnight in hMSC media (Cell 
Applications, Inc.), yielding ~70-80% confluency. A vertical scratch was created by scraping away 
cells with a 1000μL pipette tip down the center of each well. The media and any floating cells 
were then aspirated, and 500μL of unsupplemented hMSC media and 500μL of treatment was 
added to each well. Each well was imaged every 2 hours for 24 hours in a BioSpa 8 automated 
incubator and imaging system (BioTek, in collaboration with Dr. Ioannis Zervantonakis). Percent 
wound closure was then measured at 12, 24, and 48 hours (Appendix A.5). Significance was 
determined using a repeated measure two way ANOVA (GraphPad).  
3.1.6 CM MP Promotion of SMC Proliferation 
CM and Blank MP (n=6, 10mg/mL) releasates’ ability to promote SMC proliferation was 
assessed by cellular quantification. MPs were released into unsupplemented hSMC media (Cell 
Applications, Inc.) for 24 hours at 37°C in an end-over-end turner. hMSCs between P8 and P12 
(ATCC) were plated in a 24 well plate at 10k/well. Cells were allowed to adhere overnight in 
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hMSC media (Cell Applications), yielding ~30% confluency. The media was then removed, and 
500μL unsupplemented hSMC media and 500μL of treatment were applied to each well. Images 
were taken at 0, 12, 24, and 48 hours and total cell count in each image was quantified using 
ImageJ. Proliferation was quantified as % cell count increase from time 0 when each treatment 
was applied. Significance was determined using a repeated measure two way ANOVA (GraphPad) 
and Dunnett’s multiple comparisons test to determine significance between individual groups 
(95% confidence interval).  
3.1.7 In Vivo Assessment of CM MP Functionalized Lyogel-based TEVG Constructs  
All scaffolds were implanted as abdominal, infrarenal, interposition aortic grafts into Lewis 
rats for 1 and 8 weeks following the protocol in Section 2.2.3. Patency was assessed using 
angiography (dissection of the aorta distal to the graft prior to euthanasia was not required for these 
implantations) and consultation with Dr. Tzeng as needed after 1 and 8 weeks (Section 2.1.4). The 
medial portion of each 1-week explant was analyzed for macrophages using IFC (Section 2.1.5). 
All 8-week explants were macroscopically imaged to qualitatively observe remodeling (neotissue 
formation, luminal ingrowth, and stenosis) before processing at MIRM Histology Core. Sectioned 
samples were then analyzed using IHC and IFC for vascular cells (VSMCs, ECs) and ECM 
components (Section 2.1.6). 
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3.2 Results 
3.2.1 Protein Release from CM MPs 
A burst release of cargo was observed after the initial 24 hours of release (3.76 μg μg/mg 
of MPs, n=3) normalized to Blank MP release (n=1), followed by no detectable release for the 
following days (Figure 25). We had intended on running ELISAs to further characterize the 
presence of VEGF, TGFβ, and uPA as indicators of vascular remodeling cytokines present 





Figure 25. Release profile of CM MPs. 
Protein release from MPs indicated a burst release of cargo within the first day. (A) The standard curve, (B) 
release within each sample, and (C) combined release over time is displayed above. 
3.2.2 EV Release from CM MPs 
DLS analysis showed no detectable particles within the blank releasate (note that because 
no particles were detected, the sample result quality report was poor). A population of particles 
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~243 nm in diameter was detected within the CM MP releasate (corresponding to average EV 




Figure 26. EV release from MPs using DLS. 
DLS analysis of CM (bottom) and Blank (top) MP releasates showed no release from Blank MPs and a 
population of particles ~243 nm OD from the CM MPs. 
3.2.3 CM MP Toxicity 
Results showed some toxicity in the Blank MP release (indicated in red), and no toxicity 
in CM MP release (Figure 27). Analysis of cellular morphology using brightfield imaging (Eclipse 
90i and NIS elements) showed altered cell morphology due to the treatment with Blank MPs after 
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24 hours (Figure 28). Since no toxicity was observed in response to CM MP releasates, the 




Figure 27. Toxicity of CM MP releasates on SMCs. 
A LIVE/DEAD assay was used to label dead cells red and live cells green. The columns represent each 
treatment from left to right: releasate from Blank MPs, a cell death control (Dead NC, diH20), a live cell 
control (Live PC, SMC growth media, Cell Applications), CM MP releasate (CM MPs), and PBS. The images 
shown are representative of the observed effect within the n=3 wells. Some cell death was observed after 






Figure 28. Morphology of cells in response to CM MP releasates. 
 The columns represent each treatment from left to right: releasate from Blank MPs, a cell death control 
(Dead NC, diH20), a live cell control (Live PC, SMC growth media, Cell Applications), CM MP releasate (CM 
MPs), and PBS. The images shown are representative of the observed effect within the n=3 wells. Brightfield 
imaging of SMCs treated with CM MPs showed no signs of altered morphology. Only Blank MP treated cells 
showed any morphological differences after both 12 and 24 hours of treatment. 
3.2.4 SMC Migration 
SMC migration was measured in response to one batch of CM MPs (n=1) with the intention 
of additional iterations which were halted in response to the COVID-19 pandemic. Ideally, each n 
value would represent the SMC migration in response to a single CM MP batch since CM varies 
from flask to flask. For the purpose of this section, a single batch of CM MPs was released and 
applied to six wells so “n” will represent one well of SMCs measured rather than batches of CM 
MPs. No significant difference was observed in migration between the Blank MP (n=4) and CM 
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MP (n=6). A significant difference in wound closure was observed between unsupplemented 
media (negative control, n=6) and CM (positive control, n=4) after both 12 and 24 hours of culture, 
confirming the functionality of the assay (p=0.0205). No other significant differences were 
observed between groups; however, this result must be confirmed with testing of additional 






Figure 29. SMC migration measured with a scratch wound assay. 
SMC migration was observed using a scratch wound assay. A wound was created within the cells (left 
column) and allowed to repopulate with migrating SMCs (right column). The rate of migration was measured 
in response to unsupplemented SMC media (top row, n=6), Blank MPs (second row, n=4), CM MPs (third 
row, n=6, and CM (bottom row, n=4). A significant difference was observed between the Unsupp and CM (p 
p=0.0205) only. 
 92 
3.2.5 SMC Proliferation 
Similar to Section 2.6.4, proliferation of SMCs was tested in response to n=1 batch of CM 
MPs due to limitations of the COVID-19 pandemic. For the purpose of this section, each “n” value 
will represent the proliferation of SMCs within a single well. A total of n=6 wells were analyzed 
for each of the four groups. A significant difference in proliferation (% cell count increase from 
time 0) after 48 hours was observed between the unsupplemented basal media (negative control) 
and CM groups (positive control) confirming the functionality of the assay (p=0.0043) (Figure 
30). A significant difference was also observed between the Blank MPs and CM (p= 0.0035) and 
CM MP and CM groups (p=0.0115) after 48 hours. A trend towards an increase in cell proliferation 




Figure 30. Proliferation image 
SMC proliferation in response to unsupplemented SMC media (Unsupp, n=6), Blank MPs (n=6), CM MPs 
(n=6), and CM (n=6) was measured. A significant increase in proliferation was observed from the Unsupp 
group to CM (p=0.0043), the Blank MP group to CM (p= 0.0035), and CM MP group to CM (p=0.0115) after 
48 hours of treatment (left). A trend towards overall increase in proliferation was observed with the CM MP 
group compared to Blank MP group but the difference was not significant (p=0.9553). 
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3.2.6 1- and 8-week Patency Results 
Six of the nine 8-week explants displayed stenotic angiograms, and patency was assessed 
with the assistance of Dr. Edith Tzeng. The same Blank MP and lyogel controls were used from 
Chapter 2 resulting in 50% (7/14), 100% (5/5), and 100% (9/9) patency rates for Blank MPs, lyogel 
and CM MPs, respectively, after 1 week. Patency rates of 40% (8/2), 73% (11/15), and 56% (5/9) 
for Blank MPs, lyogel, and CM MPs, respectively, were observed in the 8-week explants. Cross-
sectional imaging of the medial portions of each explant showed no signs of stenosis after 1 week 
(Figure 30). Four of the five patent grafts at 8 weeks showed signs of severe stenosis (Figure 31). 
Overall, CM MP scaffolds displayed similar patency rates to CCL2 MP scaffolds. All groups 
trended towards a decrease in patency from 1 to 8 weeks (Figure 33) (not significant), but a 
significant increase in patency was observed between the CM and Blank MP groups at 1 week 
(p=0.0189, Appendix a.3). As with CCL2 MPs, the CM MPs appeared to have an acute effect on 






Figure 31. Cross-sectional images of 1 week CM MP explants 
Cross sectional macroscopic imaging of the CM MP functionalized lyogel TEVGs (n=9) after 1 week in vivo 
showed no signs of stenosis. A thrombus was observed in one explant (bottom right) which may be due to 






Figure 32. Cross-sectional images of 8-week CM MP explants 
Macroscopic cross-sectional images of the CM MP functionalized lyogel scaffolds after 8 weeks in vivo 
remodeled in three ways (indicated in the lower left corner). Of the TEVGs, stenosis was the more commonly 





Figure 33. Patency rates for CCL2, CM MP, Blank MP, and lyogel groups at 1 and 8 weeks. 
A significant increase in TEVG patency was observed in the CM MP explants compared to Blank MP grafts 
after 1 week (p=0.0189) as well as the CCL2 to Blank MP explants (p=0.0188) after 1 week. 
3.2.7 Macrophage Activity After 1 Week In Vivo 
Similar to Chapter 2, Section 2.2.4, only CD68+ cells could be quantified in IFC images 
of explants (Figure 34). Results showed a significantly higher number of CD68+ cells within the 
outer layer of CCL2 vs CM MP explants (p=0.0023) indicating a dampened macrophage 
recruitment from CCL2 to CM delivery. Additionally, a higher number of macrophages were 
found in the Blank MP outer layer in comparison to the CM MP outer layer (p=0.0017) indicating 
a reduction of macrophage recruitment in response to CM delivery. Overall, significantly higher 
macrophage quantities were observed in the Blank and CCL2 outer layer vs. the inner layer 
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(p<0.0001) suggesting a stronger tissue resident macrophage response vs. circulating monocyte 




Figure 34. Macrophage response to CM MP functionalized lyogel scaffolds. 
TEVGs explanted after 1 week were stained using CD68 (displayed in pink) to detect macrophages and 
bisbenzimide (blue) to detect all cell nuclei. Whole cross sectional images of each explant (left, each scale bar 
represents 500 μm) were constructed by tiling higher resultion images (middle, each scale bar represents 100 
μm). Quantification of CD68+ was analyzed as positively stained cells per area of TEVG (left, shown as 
average CD68+ cells/area with SEM). A significantly lower density of macrophages were observed between 
the inner compared to outer regions of both the CCL2 and Blank MP groups (p<0.0001). A significantly 
lower density of macrophages was found in the outer layer of both the Blank MP (p= p=0.0017) and CCL2 
(p=0.0023) groups in comparison to the CM MP TEVGs. 
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3.2.8 Scaffold Remodeling After 8 Weeks In Vivo 
IFC staining of the neotissue showed contractile SMCs and a continuous endothelium 
present after 8 weeks (Figure 35). Similar to the CCL2 TEVGs (Figure 18), little cellularity was 
observed within the porous scaffold layer compared to the neotissue and ES layers (Figure 36). 
CM MP explants also showed the three distinct layers (Chapter 2, Section 2.3, Figure 23) found 





Figure 35. IFC imaging of 8 week CM MP explants. 
IFC staining for SMCs (calponin and αSMA) and ECs (vWF) of the neotissue showed the presence of 
contractile type SMCs and an endothelial lining along the lumen. All slides were stained with secondary only 
(left column) to detect nonspecific binding. All three sections (shown in the lower left) were stained with DAPI 





Figure 36. Cross sectional IFC of CM MP 8 week explants. 
Three distinct layers were observed in the 8 week CM MP explants. Scaffold autofluorescence in the FITC 
and DAPI channels (left column) shows a clear outline of the three layers. VSMCs (calponin and αSMA 
shown in pink, left column), ECs (vWF shown in green, lower left), and nuclei (blue) were mostly detected in 
the neotissue and ES layers. 
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H&E staining confirmed cellularity within the neotissue and ES layer. VVG staining 
showed signs of early ECM deposition within the neotissue (Figure 36). As discussed in Section 
2.3.4, neotissue appears to be “anchored” to the scaffold at localized points evident in both IFC 
and IHC staining (Figure 35 and 36). Luminal ingrowth remodeling was only observed in two of 
the 8-week explants (Figure 31), and both were occluded. Of the explants, luminal ingrowth and 




Figure 37. IHC analysis of neotissue formation within CM MP 8 week explants. 
Neotissue formation was observed macroscopically (left images) as well as with H&E (bottom left) and VVG 
(top right) staining of a CM MP explant. Images showed cells within the neotissue and ES layers as well as 
early ECM deposition. 
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3.3 Discussion 
In this study, we successfully loaded and released CM media from PLGA microparticles. 
A burst release of 3.7 μg/mg MP total protein was observed within the first 24 hours of release 
followed by no detectable amount after. Additionally, EV release from the MPs was confirmed 
using DLS demonstrating the successful loading and release of both free-floating proteins and 
vesicles from the MPs. No conclusions could be drawn from the scratch wound or proliferation 
assays due to limited sample size (n=1). In vivo, CM scaffolds appeared to remodel similar to 
CCL2 scaffolds. A significant increase in patency was observed (p=0.0189) with the delivery of 
CM MPs compared to Blank MPs. Of the five patent 8-week explants, four displayed severe 
stenosis confirmed through macroscopic imaging and IHC. A burst release of CM or CCL2 yielded 
a similar positive effect on acute patency after 1 week. Both graft types observed prevention of 
acute thrombosis but failed long term due mainly to stenosis. In this study, we were unsuccessful 
in reducing stenosis with the delivery of CM MPs in lyogel scaffolds. The potency of CM MPs in 
vivo may have been limited by insufficient cargo delivery or unintended components of CM being 
delivered resulting in dysfunctional TEVG remodeling. 
The in vitro assessment revealed a burst release of cargo from CM MPs, but no additional 
release was seen beyond the 24 hour time point. Many labs studying the immune response to 
implanted materials have indicated two main stages with regards to biocompatibility: the initial 
attraction of immune cells (particularly macrophages within the first 3-7 days) followed by the 
polarization of the attracted cells towards a healing phenotype (after 5-10 days)214,267,273,274. In this 
study, we have successfully achieved an initial macrophage attraction observed through IFC 
staining (Section 3.2.6); however, the later polarization may not have occurred. This switch from 
a pro-inflammatory to anti-inflammatory macrophage environment is key in the progression of 
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TEVG remodeling. In particular, the inflammatory mediated healing depends on M2 macrophages 
attracting surrounding fibroblasts to aid in new ECM deposition and VSMC regulation65,273. In the 
transition from experimentation in Chapter 2 to 3 defined by shifting from CCL2 to CM MP, we 
aimed at dampening the M1 macrophage response and increasing M2 polarization through the 
delivery of the entire cell secretome. However, a more prolonged release of factors may be needed 
in order to fully mimic this cell signaling effect with our CM MPs. 
Alternatively, the excessive stenosis and inflammatory responses observed in our CM MP 
scaffolds may be caused by the delivery of not only the cell secretome, but also culture media 
components. Previous studies have seen success with the inclusion of stem cells prior to implant 
and suggested that the role of these seeded cells is to signal for host cell immunomodulation and 
migration19,20,65,116,250. To mimic this signaling effect, we delivered CM in place of seeded cells in 
attempts to maintain the positive remodeling observed using seeded grafts without the need to the 
actual cells. However, delivery of conditioned media also means delivery of DMEM (Gibco, 
Gaithersburg, MD), FBS (Atlanta Biologics, Atlanta, GA), penicillin/streptomycin (Gibco), 
fungizone (Gibco), and dexamethasone (Gibco). The effects of delivering these components in 
vivo are unknown, and therefore the use of characterized media components could be considered 
in the future iterations of CM MPs. 
Since the goal of CM MPs is to mimic the cell signaling effect of actual stem cells within 
a TEVG, further optimization to more closely match the in vivo vascular environment may result 
in a more similar secretome. For example, studies by Dr. Kent Leach and others have looked into 
the performance of stem cells after culture in varying levels of oxygen and serum275-277. These 
studies have found enhanced in vivo performance from cells cultured in hypoxic276 and low serum 
conditions275 (in bone tissue engineering applications). In a similar way, the conditioned media 
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could be further optimized with hypoxic conditioning to match the TEVG in vivo environment. 
Additionally, the excessive neotissue formation from VSMC activation may be an unintended side 
effect of delivering components of culture media, which are intended to enhance cellular migration 
and proliferation such as dexamethasone278. While the full characterization of cell signaling in vivo 
and in vitro is beyond the scope of this project, further optimization based on the desired bioactivity 
of the CM could address some of the excessive inflammation and vascular cell activation we 
observed within our implants. 
3.4 Limitations and Future Directions 
In summary, the use of CM MPs in lyogel scaffolds has shown some success in a rat but 
requires further optimization before translation into a larger in vivo model. The delivery of CM 
MPs within the lyogel TEVGs significantly increased patency when compared to Blank MPs after 
1 week; however, no significant differences in patency were observed between CM MP, Blank 
MP, or lyogel groups after 8 weeks in vivo. The results within this study were limited by the lack 
of sustained CM release from the MPs, the use of lyogel in TEVGs, and the potency of the CM 
MPs. 
A limiting factor of this study was the lack of sustained release from the MPs. Our current 
MP technology delivers a burst release of cargo to stimulate an initial host infiltration of 
macrophages and vascular cells, which then must take over the signaling and remodeling process. 
While an initial increase in patency was observed after 1 week, potentially in response to the burst 
release of CM, no sustained patency or positive remodeling effects were observed in the 8-week 
explants. Rather, a high rate of graft stenosis was observed in the 8-week explants, similar to the 
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results observed with CCL2 delivery in Chapter 1.  The exact cause behind graft stenosis is 
unknown, however, many studies focusing on atherosclerosis and hyperplasia have indicated that 
macrophage polarization plays an important role in disease development and progression279-281. 
Studies280-283 indicate a higher presence of M2 macrophages correlates to atherosclerosis 
regression and could potential be a target for future MP designs. A sustained release of CM timed 
to initiate an ideal M2 macrophage response may help reduce the occurrence of stenosis observed 
within the 8-week explants. A potential future direction includes the optimization of CM release 
from the loaded scaffold. In this case, a target release profile could be determined by assessing the 
retention and seeded cells within a scaffold and translating this time course to a release profile. 
Initial attempts towards this approach were made using ASC seeded PEUU scaffolds but were 
halted due low scaffold quality (Section A.1).  
 In addition to MP release optimization, the scaffold material itself must also be a 
consideration. Initial results from pilot studies (Appendix A.2) showed 100% graft occlusion due 
to acute thrombosis in response to an implanted lyogel scaffold, while the study in this chapter 
resulted in 100% patency after 1 week. This difference in results could be explained by two factors 
(rat age and surgical technique) which were discussed in Section 2.4. Additionally, a majority of 
the lyogel scaffolds showed signs of stenosis after 8 weeks indicating a negative host response to 
the material type itself rather than the MP treatment. Because of increased stenotic remodeling, 
the lyogel scaffold may need further optimization for use in TEVGs. Changes in both AA and BM 
percentages could yield a more appropriate material type. Alternatively, studies using BM silk 
alone have resulted in successful TEVGs without reported stenosis15,125,149 indicating AA silk may 
be the cause of graft stenosis. 
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Lastly, this study was limited by the culture media components as mentioned in the 
discussion. A potential future direction could combine an early release CCL2 MP formulation 
(Chapter 2) with a later release of CM MP formulation – the aim of this approach would be to 
first attract host macrophage and then modulate the host macrophage response. Studies observing 
macrophage response to biomaterials have shown two main roles of macrophages: an early 
recruitment within the first days of implantations followed by a later (~1-2 weeks) polarization of 
the recruited cells towards an M2 phenotype214,267,273,274. Since increased early macrophage 
recruitment was observed within the CCL2 explants (Section 2.6.7) and previous studies from the 
VBL have shown positive remodeling at 8 weeks in response to seeded cells, this two-step 
macrophage modulation approach could be optimized with an initial recruitment of macrophages 
using CCL2 MPs combined with a later release of CM MPs.  
Lastly, this study was limited by low n numbers due to the research restrictions during 
COVID-19. In progress/planned experiments which were incomplete include: (1) additional SMC 
as well as EC migration and proliferation assays using different batches of CM MPs, and the (2) 
determination of the CM MP loaded scaffold release profile using known factors within TEVG 
remodeling (CCL2, VEGF and uPA using ELISA kits).  
Another future direction could focus on optimizing the CM itself.  While the use of CM 
allows for entire cell secretome delivery, it also contains additional culture media components such 
as FBS, fungizone, and dexamethasone which may also play a role in host response. Complete 
purification of the intended secretome from the unwanted components could be achieved through 
EV isolation226,284. While this also eliminates free floating factors, some studies suggest the 
vesicles themselves play the most important signaling role due to their ability to transfer RNA, 
free floating proteins, and cell to cell surface signaling226. Additionally, the inclusion of a lipid 
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bilayer eliminates the need for PLGA encapsulation as the EVs themselves can adhere to the 
scaffold pores.  
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4.0 Chapter 4: EV Functionalized Silk Scaffolds 
The first iteration of grafts in Chapter 2 delivered CCL2 with the goal to promote a quicker 
inflammatory mediated remodeling response within the graft. However, the early delivery of cargo 
resulted in a corresponding early effect on patency but late term stenosis after 8 weeks in vivo. To 
broaden the MP effect, CM was delivered in Chapter 3 with the goal of maintaining the early 
patency increase observed with CCL2 (as CCL2 is present within CM) and adding additional 
signaling factors to induce a more wound-healing macrophage response. The delivery of CM 
resulted in a similar increase in patency, followed by prolonged inflammation and stenosis 
observed with the CCL2 grafts. Based on these results, Chapter 4 focused on providing a more 
robust signaling effect with increased biocompatibility between graft and host. To do this, a new 
MP cargo and scaffold were designed to address the biocompatibility limitations.  
To increase the biocompatibility and robustness of the releasates being delivered, the 
PLGA MPs were replaced with purified EVs (as introduced in Section 3.4). The inclusion of EVs 
offered two distinct advantages over (1) the elimination of cell culture byproducts being delivered, 
and (2) a release profile which more closely mimics that of cells. As discussed in Section 1.3.3.3, 
there are three main classifications of EVs: microvesicles, exosomes, and apoptotic bodies. This 
study focused on the isolation of microvesicles and exosomes from the conditioned media. In 
Chapters 2 and 3, a custom blend of media was used based on total protein secretion detected in 
the CM. In Chapter 4, a new type of media was used (Protein Free RoosterNourish, RoosterBio) 
to eliminate supplemental proteins added by the manufacturer that cannot be filtered out. While 
most culture media contains FBS, this introduces unknown xenogeneic proteins as well as 
increased batch to batch variability which could affect the resulting EV isolate. Using a protein 
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free media ensures all isolated proteins intended for using are cellular secretions and not from 
culture media supplements. 
Additionally, the scaffold material itself was also changed due to the excessive stenosis 
observed in response to lyogel scaffolds. Histology from the lyogel scaffolds used in Chapters 2 
and 3 showed little to no cells within the porous scaffold after 8 weeks of remodeling. While a 
neotissue was observed, it was distinct from the scaffold itself, indicating a limited host cell 
infiltration into the scaffold pores. In addition, the use of EVs requires cell vacuum seeding, which 
causes graft rupture in lyogel scaffolds. To address both graft limitations, a different silk scaffold 
type was tested using only BM silk (see Sections 1.3.1 and 2.0 for summary of the silk types 
considered in this thesis). Originally, AA silk was included in lyogel to increase RGD cell-binding 
sites; however, no increase in cellular adhesion was observed so it was eliminated from this study. 
Previous studies using only BM have been successful in recellularization and graft success, 
indicating BM silk alone is not only sufficient, but also easier to fabricate15,16,149,285.  
The following study outlines the fabrication, and in vitro/in vivo testing of EV 
functionalized BM silk scaffolds for use as a TEVG. A total of three groups were tested: MSC 
seeded, EV seeded, and unseeded BM silk scaffolds. 
4.1 Methods 
4.1.1 Cell Culture and EV Isolation  
EV production and isolation were done in collaboration with Dr. Eoghan Cunnane – a 
postdoc in the VBL. RoosterBio (RoosterVial-hAD-1M MSC Lot #00097, RoosterBio) human 
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MSCs (P3) were cultured in growth media (RoosterNourish, SU0005, RoosterBio) in T175 flasks. 
Cells were then passaged into 5-layer tower flasks at 6M per flask in 75 mL growth media for 18 
hours to allow for cellular adhesion. After 18 hours, growth media was removed, and cells were 
washed with 15 mL PBS. Harvest media (110 mL) was then applied consisting of protein-free 
basal media (SU006, RoosterBio) supplemented with 10% EV depleted fetal bovine serum (FBS 
centrifuged at 120,000 g for 18 hours at 4°C to remove EVs, Atlanta Biologics), 1% 
penicillin/streptomycin (5000U/mL, Gibco), 0.1% fungizone (amphotericin B, Gibco), and 
10μL/L dexamethasone (Abcam). Cells were cultured in harvest media for 48 hours allowing cells 
to expand from 40% to 85% confluency. After 48 hours, the media was collected (now called CM). 
The remaining ASCs were used for the MSC seeded BM scaffold group. 
EV isolation was done as described by Dr. Cunnane286. Briefly, CM was centrifuged at 250 
x g for 20 minutes at 4°C to remove cells and large debris. The supernatant (CM free of debris) 
was then filtered (0.22 μm filters, Millex, Express PES low bind membrane) to remove any 
apoptotic bodies (Section 1.3.3.3) and split into six ultracentrifuge tubes (34 mL per tube, 
Polypropylene 25x89 mm, Beckman Coulter). Each tube was mounted into metal cases attached 
to a rotor (Sw28.1, 117.1g per case, Beckman Coulter) and centrifuged at 100,000 x g for 70 
minutes at 4°C (L8-70M, Beckman Coulter) creating an EV pellet. The resulting supernatant 
(depleted CM, dCM) was removed and stored at -80°C until use. Any remaining supernatant was 
thoroughly drained from each tube by upturning each tube over a sterile drape and aspiration of 
remaining droplets. 100 μL PBS was added to each tube to resuspend pelleted EVs over 30 minutes 
with gentle agitation. The resuspended EVs were then diluted to 1 mL in PBS. The entire process 
yielded 1 μL EV isolate from 204 mL CM (n=3). 
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4.1.2 Scaffold Fabrication and Seeding 
BM silk scaffolds were fabricated using the same protocol as lyogel scaffolds (Section 
2.1.1), substituting lyogel silk solution with a 6% w/v BM silk solution in water for the inner layer. 
The resulting bilayered scaffolds have been previously characterized by the VBL127. BM silk 
scaffolds were stored in 80% EtOH at -20°C until use. Scaffolds were then washed 3 times in PBS 
for 10 minutes on a shaker plate before seeding.  
MSCs and EV seeding was performed following established protocols within the VBL 
using our lab’s custom rotation vacuum seeding device (RVSD)17,19,20,88,250 (Figure 39). Previous 
studies have successfully seeded various cell types (ASCs19, SVF20,86, pericytes250) into PEUU 
scaffolds but not silk scaffolds. Seeding parameters including pressure, infusion volumes, and 
seeding times were adjusted to suit EV seeding into silk scaffolds. Briefly, scaffold mounts were 
made from catheter tubing (PTFE, 0.5mm ID, 1 mm OD, Aligent Technologies) cannulated with 
10 μL pipette tips. Scaffolds were then secured to the mounts with 4-0 silk sutures (S-403, Sofsilk, 
Covidien). The mounts and scaffolds were then secured into the chamber of the seeding device, 
which was then sealed using an o-ring and clamps. Prior to cell seeding, each scaffold was infused 
with 500 μL of PBS to prime the infusion tubing. Scaffolds were then “pre-seeded” with 3 mL of 
PBS infused at 1 mL/min in order to wet the scaffold prior to EV delivery. During seeding, 
scaffolds were rotated manually, and a vacuum of -5 inHg was applied. After pre-seeding, a 1 mL 
EV isolate was prepared and used to prime (500 μL) and seed (500 μL) each scaffold under the 
same rotation and vacuum as pre-seeing. After seeding, the remaining EV suspension pulled 
transmurally through the scaffold and into the chamber was collected and re-seeded a total of five 
times.  
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Since this study was the first attempt to seed EVs into silk scaffolds, seeding efficiency 
was also measured to ensure successful EV incorporation with the RVSD. Seeding efficiency 
refers to the percent of EVs within the initial EV isolate that were successfully seeded into the 
graft. This value was assessed through total protein measurement of the EV isolate prior to seeding 
and the remaining unseeded isolate after seeding. A microBCA kit (Thermofisher) was used to 
determine total protein in each solution yielding a % protein seeded. Further confirmation of 
seeding was obtained using fluorescent staining and imaging of EVs following standard IFC 
protocols. For IFC, CD63 (1:100, 10628D, ThermoFisher) and Cy5 (1:100 ab_2340820, Jackson 




Figure 38. Depiction of the rotational vacuum seeding device. 
Each scaffold was mounted into a vaccum chamber and injected with a cell or EV suspension under -5 inHg 
pressure. Scaffolds were rotated mannually to ensure even circumfrential distribution. 
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4.1.3 EV Characterization 
EVs were characterized via three main measures: morphology (done by Dr. Cunnane), DLS 
(done by me and Dr. Cunnane), and total protein detection (done by me and Dr. Cunnane). 
4.1.3.1 EV Morphology 
To validate successful EV isolation, morphology was assessed by Dr. Cunnane using 
transmission electron microscopy (JEM-1011, JOEL, Center for Biologic Imaging, University of 
Pittsburgh) as described previously286. To summarize, 5 μL of EV isolate was dropped onto a 3 
mm carbon coated grid followed by 5 μL of a 1% uranyl acetate solution to enhance contrast during 
imaging. Any excess liquids were removed with filter paper and the sample was analyzed. 
4.1.3.2 DLS 
80 μL of EV isolate was pipetted into a 8.5 mm cuvette (Brandtech Scientific). DLS was 
performed using the same protocol as outlined in Section 3.1.3. A total of n=3 samples (each 
difference batches of EV isolate) were assessed. 
4.1.3.3 Total Protein Release from the EV Isolate 
Samples of 1:9 dilution of EV isolate in PBS (regular) or sodium dodecyl sulfate (SDS, 2% 
in PBS, lysed) were prepared. Samples were then vortexed for 30 seconds prior to use to ensure 
vesicle lysing and homogenous mixing. Total protein was measured using a BCA following the 
same protocol in Section 3.2.1. Separate standard curves were measured in triplicate for the regular 
and lysed samples. The regular standards were suspended in PBS and lysed in 2% SDS. Samples 
were quantified using the corresponding standard. 
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4.1.4 SMC and EC Migration 
Scratch assays using both SMCs (#PCS-100-012, ATCC) and ECs (#300-05a, Cell 
Applications Inc.) were performed to observe the effect of EVs on cellular migration. For each 
assay, SMCs or ECs were plated into 24 well plates (50k/well for SMCs and 90k/well for ECs) in 
2 mL cell-specific growth media (Section 4.2) and allowed to adhere overnight. After cell 
adhesion, 1 mL pipette tips were dragged vertically along the bottom of the plate, creating a linear 
wound across the cells. The media was then removed (along with floating scraped cells), and 
treatment of 350 μL unsupplemented basal media (cell-specific) and 150 μL EV isolate was 
applied to each well (run in triplicate). The plate was then mounted into a stage top incubator 
(Tokai Hit Co.), maintaining 37°C and 5% CO2 culture conditions during imaging. Wells were 
imaged hourly using an inverted Nikon TiE fluorescent microscope (Nikon) and NIS Elements 
Software (Nikon). Wound closure was quantified following the same protocol used in Section XX 
and outlined in Appendix A.5 and analyzed after 24 and 48 hours. A total of five treatments were 
tested from n=3 batches of CM EV isolate: cell-specific unsupplemented basal media (UBM, 
negative control), PBS (negative control), 50μL EV isolate + 100 μL PBS (EV50), 150 μL EV 
isolate (EV150), and supplemented cell-specific basal media (SBM, positive control). Statistical 
significance between groups was performed using GraphPad Prism 8 (GraphPad Software). 
Normality was assessed using Shapiro-Wilk tests before analysis. After normality was assessed, 
significant differences in migration between groups were determined using 2-tailed unpaired t-
tests (normally distributed data) and exact 2-tailed Mann-Whitney U-tests (non-normal data). One-
way ANOVAs were used to determine significance between more than two groups of variables. 
For all tests, p<0.05 was considered significant. 
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4.1.5 SMC and EC Proliferation 
Proliferation assays were also run using ECs (Cell applications) and SMCs (ATCC) at P4. 
Cells were plated into 48 well plates coated in collagen. To coat wells, collagen (type I rat tail 
collagen A10483, Gibco) was mixed in 0.02 M acetic acid at 50 μg/mL. 500 μL of the collagen 
solution was then placed in each well and incubated at room temperature for 1 hour before 
thorough washing with PBS. SMCs and ECs were plated at 4k and 5k per well, respectively, in 
cell-specific growth media and allowed to adhere overnight. After cellular adhesion, cell quantity 
at time 0 was determined using Alamar blue (DAL 1100, Invitrogen, Carlsbad, CA) diluted 11:1 
in BM. 330 μL of the diluted solution was applied to each well and incubated at 37°C and 5% CO2 
for 4 hours. After incubation, 100 μL from each well was transferred to a 96 well plate, and the 
absorbance was measured according to the manufacturer's protocol (570/600 nm). Readings were 
then normalized to blank wells. Well plates containing the remaining cells were washed with PBS, 
and treatments were applied (Section 4.2.2) for 24 hours before re-analysis. All 24-hour readings 
were normalized to the initial time 0 reading for that well to account for a base number of cells. 
Significance was determined using the same method as cellular migration (Section 4.1.4).  
4.1.6 In Vivo Evaluation of EV and MSC Seeded BM Silk Scaffolds 
Three scaffold types were assessed for 8 weeks as abdominal aortic grafts following the 
protocol in Section 2.3: EV seeded BM silk scaffolds (EV, n=16), RoosterBio MSC seeded BM 
silk scaffolds (ASC, n=10), and BM silk scaffolds (BM, n=11). After 8 weeks, patency was 
determined through angiography (Section 2.3), and remodeling was observed through histology 
(Section 2.3.3).  
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Explants were analyzed using IFC and IHC (Section 2.3.3). Sections from each medial 
portion were analyzed for cell phenotype and ECM content (IFC performed by myself and Dr. 
Cunnane and IHC at the MIRM Histology Core, Section 2.3.3).  
4.1.7 Elastin and Collagen Quantification 
 
Insoluble elastin and collagen content of explanted TEVGs were quantified by Dr. Aneesh 
Ramaswamy using ninhydrin and hydroxyproline assays. Two small rings of tissue were isolated 
from the proximal and distal portions of the explanted graft for analysis. Soluble and insoluble 
elastin content of each tissue sample (normalized to weight) was then measured using previously 
established protocols87,287.  
4.2 Results 
4.2.1 EV Characterization 
TEM imaging performed by Dr. Cunnane displayed successful detection of EVs (Figure 
39). TEM showed distinct cup like circular particles characteristic of vesicles284. Examples of the 





Figure 39. TEM imaging of EV isolate. 
TEM imaging of the EV isolate showed distinct EVs as cup like particles. The overall size (~40 m) indicates 
the imaged Evs are within the exosome and microvesicle size range286. 
 
Further characterization using DLS showed two distinct particle sizes: 42.67±4.09 and 





Figure 40. DLS detection of EVs. 
DLS analysis of the EV isolate showed a population of exosomes (42.67±4.09 nm OD) and microvesicles 
(215.94±34.78 nm OD) within the isolate286. 
 
BCA analysis for total protein within the unlysed and lysed EV isolates resulted in 
159.31±5.03 and 170.47±3.58 μg/mL of protein detected (Figure 41). This increase in protein due 





Figure 41. Total protein within the EV isolate. 
Total protein increased after lysis indicating release of protein content from within the EVs286.  
4.2.2 EV Seeding 
Previously published studies from the VBL have confirmed the successful seeding of ASCs 
into BM127 and PEUU scaffolds20,86,250; however, EV seeding was first attempted in this study. All 
previous studies determined seeding efficiency by counting the number of cells within the isolate 
before and after seeding; however, this method could not be used in this study due to the small 
size of Evs. To determine efficiency, the total protein within the unseeded EV isolate was measured 
using a BCA following the manufacturer’s protocol (Section 3.1.2), resulting in 45.69% of the 
total protein content from the EV isolate successfully seeded. IFC staining of seeded scaffolds 






Figure 42. EV seeded scaffold IFC.  
Left: staining of a seeded scaffold without a primary to detect any non-specific binding. Right: staining of an 
EV seeded scaffold showed homogeneous seeding throughout the porous layer of the scaffold. Pink indicates 
stained EVs and green indicates scaffold autofluorescence (AF)286. 
4.2.3 SMC and EC Migration 
A significant increase in SMC migration was found in the EV50 group versus PBS 
(p=0.0209) and EV150 group versus PBS (p=0.0013). Similarly, a significant increase in EC 
migration was observed in the EV50 group versus PBS (p=0.047) and EV150 group versus PBS 





Figure 43.SMC and EC migration assay 
 Scratch assays showed a dose dependedent increase in cellular migration in response to EVs286. 
4.2.4 SMC and EC Proliferation 
A significant increase in SMC proliferation was observed between PBS and EV150 
(p<0.0001). A similar increase in EC proliferation was found from PBS to either EV50 (p=0.0011) 





Figure 44. SMC and EC proliferation assays. 
Both SMC and EC proliferation increased significantly between PBS and EV150 treatment286. 
 
The combined promotion of SMC and EC migration and proliferation in response to EVs 
suggests potential host cell chemoattractant and mitogenic roles in vivo. To test this possibility 
and the efficacy of EVs as a payload for our TEVG, EVs were seeded into BM silk scaffolds and 
assessed in vivo. 
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4.2.5 8-week Patency Results 
Patency results showed 56% (9/16), 81% (9/11), and 100% (10/10) patency in the MSC, 
BM, and EV groups, respectively. A significant difference in patency was found between the MSC 
and EV groups (p=0.0189, Appendix A.3, Figure 45). A total of two BM TEVGs was not patent 
due to intimal hyperplasia. A total of seven MSC grafts failed, 3 due to acute thrombosis and 4 




Figure 45. Patency rates of the EV functionalized BM silk scaffolds after 8 weeks.  
Patency of the grafts after 8 weeks were determined through angiography (left) and cross-sectional images 
(middle). Patency rates showed significantly higher patency rates in the EV seeded scaffolds (p=0.0437)286. 
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4.2.6 TEVG Remodeling and Histology 
Medial portions of the grafts were macroscopically imaged to observe any signs of stenosis 
(Figure 44). Explants showed no obvious signs of stenosis in the cross-sectional imaging (Figure 
46). One of the blank explants showed signs of dilation, possibly due to loss of mechanical strength 
as the ES layer degraded.  
Histology showed similar remodeling in all grafts remaining patent until 8 weeks (Figure 
47). Neotissue formation containing VSMCs and endothelium was detected in all groups. VVG 
staining showed early elastic fiber formation, and picrosirius red (PSR) staining showed aligned 
collagen fibers within the neotissue. IFC and IHC staining revealed VSMCs, ECs, collagen (PSR), 
elastin (VVG), and overall cellular infiltration (H&E) in each of the three groups after 8 weeks 
(Figure 47). Qualitative assessment showed a higher level of VSMCs (SMA and Calponin) 
within the EV functionalized group when compared to both the BM and MSC groups. 
Additionally, an incomplete endothelium (vWF) was observed within the MSC group indicating 
insufficient remodeling. The highest level of cellularity was observed within some of the EV 
functionalized group (H&E) as well as the most elastin formation (VVG) which could suggest a 
greater degree of positive remodeling. Lastly, a lower level of macrophages (CD68) were observed 
in the EV group suggesting no prolonged inflammatory response. Overall, the higher cellularity 
(H&E), elastin (VVG), VSMCs (SMA and calponin), and full endothelium (vWF) combined 
with the lowered macrophage presence (CD68) indicates a further level of remodeling within the 






Figure 46. Macroscopic imaging of the 8 week explants. 
Cross-sectional images of the 8 week MSC seeded (top three rows), blank silk (middle two rows), and EV 
seeded (bottom two rows) showed varying levels of remodeling within each group. (patent = green border, not 





Figure 47. Histology of the explants 
IHC (H&E and VVG columns) and IFC (PSR, αSMA, calponin, vWF, and CD68 columns) staining were used 
to observe graft remodeling after 8 weeks. All groups showed signs of cellular neotissue formation (H&E) and 
elastic fiber formation (VVG).  A qualtitatively higher level of staining was observed in the αSMA, calponin 
and vWF stains within the EV seeded group possibly indicating a higher level of remodeling. A qualitatively 
lower amount of macrophages (CD68) was observed in the EV group possibly incdicating a more progressed 





Figure 48. H&E of EV BM silk vs. CM MP lyogel silk 8-week explants 
EV functionalized BM silk scaffolds showed greater cellular infiltration into the scaffold pores (left) 
compared to CM MP lyogel silk scaffolds (right) after 8 weeks in vivo. 
4.2.7 Elastin Quantification 
Results showed a significantly higher amount of elastin and collagen (126.46% p=0.0015 
and 44.59% p=0.0386, respectively) in the EV group compared to UBM. No significance was 





Figure 49. Ninhydrin and hydroxyproline assays were used to quantify ECM within the explant grafts286. 
Significantly more elastin (126.46, p=0.0015) and collagen (44.59%, p=0.0386) was observed in the EV group 
compared to the UBM. 
4.3 Discussion 
This chapter attempted to assess the viability of an EV functionalized silk based vascular 
graft. EVs were isolated from ASCs and tested for in vitro bioactivity. A significant increase in 
SMC and EC migration and proliferation was observed in response to EVs in comparison to PBS, 
indicating a positive pro-remodeling potential. Bilayered BM scaffolds were successfully 
fabricated, seeded with EVs, and implanted into a rat aortic model for 8 weeks. Angiography at 
explant showed a patency rate of 56%, 81%, and 100% for the ASC, BM, and EV groups. The 
delivery of EVs was successful in increasing patency and reducing stenosis in comparison to both 
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BM and ASC groups. Histology showed positive remodeling based on neotissue formation 
(VSMCs, ECs, and ECM present) in all groups without the obvious signs of stenosis observed in 
the TEVGs assessed in Chapters 2 and 3. Additionally, overall cellularity within the remaining 
scaffolds at 8 weeks increased in comparison to results from Chapters 2 and 3, indicating increase 
biocompatibility within this iteration of TEVGs. Two main changes were observed within EV 
seeded BM and lyogel explants from Chapters 2 and 3: increased cellularity within the scaffold 
pores and decreased stenosis after 8 weeks.  
From the previous studies, the scaffold material and cargo incorporated into the scaffold 
were changed resulting in an increased overall biocompatibility; however, since multiple 
components were modified, the exact cause of behind the remodeling changes was difficult to 
isolate. However, when comparing the lyogel to BM silk alone after 8 weeks in vivo, a qualitative 
increase in cellular infiltration into the porous layer of the scaffold was observed in the BM graft 
(Figure 50). The lyogel silk explants all contained distinct boundaries between the neotissue 
formation and scaffold layer whereas the BM explants showed integration of the neotissue into the 
scaffold itself. This increase in cellularity without any treatment indicates the effect was due to the 





Figure 50. H&E of BM vs. Lyogel scaffolds after 8 weeks in vivo. 
 
Initially, AA silk was utilized because of its RGD binding sites127 to increase the potential for 
cellular migration and binding to the scaffold. The in vivo assessment of AA silk appears to have 
had the opposite effect by preventing cellular migration. This unexpected effect may be due to 
changes in pore interconnectivity between lyogel and BM silk or decreased luminal porosity of the 
lyogel scaffolds due to gelation in contact with the metal rod. Additional analysis of BM vs. lyogel 
porosity, pore interconnectivity, seeding, and cellular binding would be needed to gain a clearer 
picture of host cell infiltration. 
The second difference, decreased stenosis, may be due to a decreased inflammatory 
response to the scaffold material and treatment. In particular, the BM silk scaffolds alone showed 
no signs of stenosis, while the lyogel scaffolds alone showed nearly 100% stenosis (Figure 51). 
This decrease in stenosis between lyogel and BM silk may be due to an altered immune response 
to the material type. While an initial immune response to any implanted graft should be 
characterized by an influx of macrophages, a later stage immune response (after 8 weeks) should 
show a decrease in macrophage presence. The inclusion of RGD binding sites within the lyogel 
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scaffold could have increased immune cells binding and caused a prolonged presence within the 
scaffold. Lastly, the decrease in stenosis could be a result of material property changes, particularly 
differences in scaffold stiffness and compliance, which could be determined with additional 




Figure 51. Cross sections of BM vs. lyogel silk scaffolds after 8 weeks in vivo. 
Cross sectional images of BM silk vs lyogel silk scaffolds after 8 weeks show increased stenosis in the lyogel 
groups. A distinct lumen can be seen in within the BM silk grafts while a nearly occluded lumen is less visible 
in the lyogel grafts. 
 
Overall, the EV functionalized BM silk scaffolds produced a patent, remodeled graft with 
positive neotissue formation after 8 weeks in vivo. Based on the patency, histology, and ECM 
characterization, EV BM scaffolds are a promising option for TEVGs. EVs offer a cell-free graft 
option while still leveraging the immunomodulatory effects of cell-seeded grafts.  
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4.4 Limitations and Future Studies 
The main limitations to this study were the few timepoints observed in vivo and the healthy 
animal model chosen. An 8-week timepoint was chosen for in vivo studies in order to observe 
remodeling within a reasonable timeframe but this single timepoint fails to capture the initial host 
response and the long-term remodeling that would happen in a patient. Based on the promising 
result of this study, longer timepoints would provide information such as a timeline for full scaffold 
degradation, the potential of late-term stenosis, and mature ECM deposition. In addition to later 
timepoints, an earlier timepoint assessing the inflammatory response to EV functionalized TEVGs 
would provide information on the mode of graft remodeling and the host response to the EVs. 
While 1-week explants were included within Chapters 2 and 3, they were not assessed in this 
study due to time and cost restraints. In general, additional shorter timepoints to observe 
inflammation and longer timepoints to observe potential stenosis could further demonstrate the 
potential of EV functionalized BM silk scaffolds before testing in a larger, more expensive animal 
model. 
These studies were also limited by the healthy model chosen. A healthy model was chosen 
to observe the initial potential of EV functionalized BM silk scaffolds, however, as previously 
discussed, the graft remodeling response is likely to vary in patients with comorbidities such as 
diabetes. To fully understand the potential TEVG remodeling within appropriate cohorts, the grafts 
should be tested in more appropriate recipients such as aged and diabetic rats (Section 2.4). This 
inclusion of high-risk cohorts and longer in vivo durations would provide a better idea of graft 
viability before scaling up to a more clinically relevant model. 
Additional studies should also investigate different sources of EVs. Since EV application 
in tissue engineering is a newer field of study, no single established protocol exists for EV 
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isolation284. Because of this, additional studies testing different cell types, culture environments 
(hypoxia), and isolation techniques should be tested geared towards TEVG application. Similar to 
CM, EV signaling has been shown to change in response to culture conditions288. Changes in EV 
concentration, size, morphology, and surface markers have been observed with hypoxia289 and 
must, therefore, be optimized based on the intended function.  
Lastly, EV translation to a clinically relevant quantity must be considered. Current methods 
for EV isolation are labor and cost-intensive, yielding relatively small quantities of vesicles as 
displayed in this study. To translate this technology, a method for EV storage must be explored to 
create a stock of EVs prior to seeding. The motivation behind using RoosterBio cells throughout 
the entirety of this dissertation was to provide an easier path for clinical translation. Further studies 
towards clinical translation have been discussed with RoosterBio and potential collaborations 
including developing methods of EV freezing, EV viability before and after storage (SMC 
migration, protein content), and batch to batch variability after thawing.   
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5.0 Chapter 5: Additional Contributions to TEVG Translation 
This chapter focuses on three collaborations focusing on different TEVG designs that the 
author contributed to over the course of this dissertation. These projects focused on the 
development and testing of a cell seeded PEUU construct (Section 5.1), a cell seeded large animal 
sized PEUU construct (Section 5.2), and a cell seeded silk based construct (Section 5.3).  
A previous area of focus in the VBL has been the development of a TEVG using a cell-
seeded PEUU construct17,19,88,250. Previous studies have used muscle derived stem cells (in 
collaboration with Dr. Johnny Huard)17, pericytes (in collaboration with Dr. Huard)250, adipose 
derived stem cells19,115 (in collaboration with Dr. Kacey Marra and Dr. Peter Rubin), and the 
stromal vascular fraction (SVF)86 (in collaboration with Dr. Marra and Dr. Rubin) seeded into a 
bilayered, PEUU scaffold (developed in collaboration with Dr. William Wagner). These scaffolds 
were fabricated following the paradigm shown in Figure 52 to produce a rapidly seeded, 
autologous graft. The first study (Section 5.1) was aimed at streamlining this paradigm to produce 
an autologous, SVF seeded PEUU scaffold that could be fabricated within 24 hours. The work 
within this study was performed in collaboration with Dr. Darren Haskett (experimental design, in 
vitro assays, and in vivo surgeries), Dr. Marra and Dr. Rubin (SVF isolation and characterization), 





Figure 52. Cell-seeded PEUU scaffold paradigm. 
(1) Cells are isolated from the patient, (2) culture expanded and purified into stem cells, (3) rapidly 
seeded into a PEUU scaffold, (4) cultured in a spinner flask for 48 hours to allow for cellular 
adhesion, then implanted back into the patient.  
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The second study (Section 5.2) built upon previous VBL studies utilizing PEUU scaffolds 
by scaling up the TEVGs from a rat size to a sheep size. Over the past decade, the cell seeded 
PEUU construct has been studied in a rat model to evaluate both the cell type and paradigm of 
fabrication (Figure 52) with the end goal of clinical translation. The multiple iterations of cell 
seeded PEUU constructs have demonstrated positive remodeling and 8-week patency in a rat 
model; however, the next step towards translation is testing a more size relevant model. 
Considerations when scaling up include scaffold design, seeding device scale up, cell sourcing (3 
million cells for a rat vs. 200 million for a sheep), and in vivo complications associated with longer 
grafts (increased risk of thrombosis and graft kinking). The goal of the study outlined in Section 
5.2 was to address these concerns and scale up the cell seeded PEUU graft into a sheep model. 
This work was done in collaboration between the author (experimental design, graft seeding, and 
histology), and Dr. Cunnane (experimental design, graft seeding, mechanical testing), Dr. Wagner 
(large PEUU scaffold fabrication), Dr. Marra and Dr. Rubin (sheep SVF isolation), and Dr. Tzeng 
(implantation into a sheep model). 
Lastly, in addition to the development of a cell-free, silk based TEVG described in 
Chapters 2-4, this dissertation included work towards a cell-seeded, silk based TEVG. Section 5.3 
outlines additional silk TEVG studies focusing on the development and in vivo testing of two cell-
seeded, silk grafts fabricated with (1) BM silk alone, and (2) a combination of BM and AA silk 
(using a different silk percentage and fabrication technique compared to lyogel). Both scaffold 
types were tested in the rat model used in Chapters 2-4 to determine their potential as a TEVG 
material. The work within Section 5.3 was performed by the author (graft implantation, histology) 
in collaboration with Prerak Gupta (scaffold design and fabrication), Dr. Mandal (silk fibroin 
isolation), Dr. Haskett (graft implantation), and Dr. Ramaswamy (ECM analysis). 
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5.1 Same Day Cell Seeded PEUU TEVG 
Previous studies within the VBL have developed and optimized an autologous, cell-seeded 
PEUU TEVG which has shown promising patency and remodeling in a rat model after 8 
weeks17,18,86,88,115. Since the end goal of this technology is clinical application, considerations 
towards translation must be considered. The two main hurdles towards clinical translation that 
limited the technology were (1) FDA regulations regarding cell culture200,202, and (2) the time 
constraints of construct fabrication.  Specifically, FDA regulations strictly govern the implantation 
of stem cells that have been exposed to culture expansion due to the increased risk of cell 
phenotypic change and contamination200-202. Additionally, patients requiring a graft often cannot 
wait the days or weeks required for cell expansion and graft seeding. To address these limitations, 
a study was designed to alter the previously followed TEVG fabrication paradigm (Figure 52). 
Briefly, (1) cells were isolated from a patient, (2) culture expanded and purified into adipose 
derived stem cells (MSCs), (3) rapidly seeded into a PEUU scaffold, (4) cultured in a spinner flask 
for 48 hours to allow for cellular adhesion before implantation into the patient. This entire process 
takes approximately 1-2 weeks depending on culture expansion rates. 
The study outlined in this section focused on modifying step 2 from Figure 52 utilizing 
the stromal vascular fraction (SVF) of cells and thereby eliminating the need for culture expansion. 
Step 4 was also eliminated by replacing the 48-hour dynamic culture period with a 4-hour static 
culture. Both modifications resulted in a more translatable, “same day” TEVG which is described 
below.  
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5.1.1 SVF Isolation and Characterization 
SVF describes the cellular population found within adipose tissue. Cell phenotypes within 
SVF include preadipocytes, adipocytes, perivascular cells, fibroblasts, adipose derived MSCs, 
ECs/EPCs, SMCs, and immune cells (macrophages, monocytes, lymphocytes, etc.)290,291. Previous 
studies using patient derived cells required culture purification of the stem cells, while this study 
utilized SVF, thereby eliminating time/culture and also introducing additional cell types known to 
be beneficial in TEVGs50,185,188,265.  
SVF was isolated from donor adipose tissue (<45 years old and non-diabetic) following 
standard protocols at the Adipose Stem Cell Center (University of Pittsburgh, Pittsburgh, PA)292. 
Within the isolate, three cell populations are most relevant to TEVGs: “mature endothelial,” 
“endothelial stem,” and “adipose stem cell,” identified through surface markers CD31+/34-, 
CD31+/CD34+, and CD34+/CD31- respectively203,291,293. The isolated cells were passaged once and 
characterized through flow cytometry (Figure 53). Two samples of 2.5 million cells were 
suspended in a mixture of 1 mL PBS (Gibco) and 2% FBS (Premium Select, Atlanta Biologics) in 
1.5 Eppendorf tubes. Each sample was then stained for 45 minutes at 4°C in the dark. Sample 1 
was mixed with one drop of compensation beads OneComp eBeads (#01-1111, Invitrogen), and 
stained with CD34 (mouse anti-human IgG1, #560940, BD Biosciences) and CD31 (mouse anti-
human IgG, #564630, BD Biosciences). Sample 2 served as a control and was stained with a 
viability dye (PI, anti-all species, 556463, BD Biosciences). After 45 minutes, sample 1 was 
washed and resuspended in 2mL PBS + 2% FBS. Both samples were analyzed using a 
BDFACSAria II SORP cell sorter by the Flow Cytometry Lab in the McGowan Institute of 
Regenerative Medicine (University of Pittsburgh, PA). Results showed a large population of ASC 





Figure 53. SVF phenotypic characterizion using flow cytrometry. 
Three distince populations of cells were detected: ECs ( CD31+/34-), EPCs ( CD31+/CD34+), and adipose 
derived MSCs ( CD34+/CD31-) 
5.1.2 Cell Seeding into PEUU Scaffolds 
PEUU scaffolds were fabricated by Dr. William Wagner’s laboratory. Each scaffold was 
designed to fit the size of the infrarenal rat aorta (~1.3 mm ID, 1 cm long) and consisted of two 
layers: an inner porous layer fabricated using thermally induced phase separation (TIPS), and an 
outer ES layer providing mechanical support. The VBL has used this scaffold for several published 
studies17,19,20,88.  
SVF was resuspended at 1 million cells/mL in a 1:1 mixture of Dulbecco’s modified 
Eagle's medium (DMEM, #11965, Gibco) and DMEM/F12 (#113300, Gibco) supplemented with 
10% FBS (Premium Select, Atlanta Biologics), % penicillin/streptomycin (5000U/mL, Gibco), 
0.1% fungizone (amphotericin B, Gibco), and 10μL/L dexamethasone (Abcam). The cells were 
then rapidly seeded into PEUU scaffolds of rat aortic size using previously established protocols 
(Section 4.2.3)88. Validation of successful seeding was confirmed through fluorescent staining of 





Figure 54. SVF seeded scaffolds showed homogenously seeded cells throughout the inner layer. 
A section of a SVF seeded PEUU scaffold was stained with bisbenzimide to detect cell nuclei (blue). The 
scaffold autofluoresced (green) which showed the dense ES layer (outer) and porous TIPS layer (inner). 
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5.1.3 In Vivo Evaluation of SVF Seeded PEUU Scaffolds 
SVF seeded grafts were assessed in an abdominal rat aortic model previously 
described19,86,88,250 (Section 2.3) for 8 weeks in vivo (n=7 total). Angiography showed 5 of 7 grafts 
patent with varying degrees of remodeling (Figure 5520). Both non-patent grafts failed due to 





Figure 55. Patency of SVF seeded PEUU scaffolds. 
(A) Angiography was used to determine graft patency after 8 weeks in vivo. Cross-sectional images 
revealed different levels of remodeling ranging from (B) remodeled, (C) partially remodeled, and (D) 
occluded due to anastomotic hyperplasia.20  
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5.1.4 Overview and Future Directions 
The concept of a “same day” vascular graft was validated through this study with the close 
coordination and collaboration between Dr. Marra and Dr. Rubin with the Adipose Stem Cell 
Research Laboratory (SVF isolation) and the VBL (author included, graft seeding and 
implantation). SVF isolation expertise from the Adipose Stem Cell Research Laboratory and 
improvements in surgical techniques and skill made a 24-hour scaffold fabrication and 
implantation possible20.  
In summary, similar patency rates were observed with SVF compared to previously 
published results using adipose derived MSCs19,20, with the added benefit of reduced time and 
culture. Future studies towards translation include scaling of the technology into a clinically 
relevant size. Preliminary work has been done towards this translation outlined in Section 5.2. 
Additional studies may include observing the effects of frozen SVF to eliminate the need for same-
day cell isolation and further streamline the benchtop to the bedside process.  
5.2 Large Scaffold and TEVG Pilot Study 
Using the concept of cell seeded PEUU TEVGs, the VBL has been working towards the 
end goal of clinical translation for the past 10 years. From graft seeding optimization to efficient 
cell sourcing, each iteration of the technology has produced a faster, more relevant model. The 
recent design of the TEVG summarized in Section 5.1, comprised of SVF seeded PEUU scaffolds, 
can be created and implanted on the same day without cell culture, making it one appealing option 
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for translation20; however, ultimately all combinations of cells/cell replacements and scaffolds 
could be tested in a larger model to assess the translational potential of each. 
One remaining step in testing the potential of seeded grafts is scaling the technology 
towards a clinically relevant size. The study outlined here focused on scaling the cell source and 
graft size to a sheep carotid graft. This bulk of this study was done in collaboration with Dr. 
Cunnane (scaled up seeding device design, mechanical testing, and scaffold seeding) and Dr. 
Haskett (scaled up seeding device design), two post-docs in the VBL.  
5.2.1 Scaling Up of the Scaffold Design and Cell Source 
Sheep sized biodegradable, bilayered PEUU scaffolds were fabricated in collaboration 
with Dr. William Wagner using modified protocols294 previously described for rat size scaffold 
fabrication17,88. The tubular scaffolds were 4.7 mm ID and 10 cm in length (compared to ~4-5mm 
ID of native sheep carotid). A custom seeding device to mimic the rapid rotational vacuum seeding 
device used for rat size scaffolds was designed by former VBL PhD graduate, Dr. Lorenzo 
Soletti294, and built and validated by Drs. Cunnane and Haskett. The device seeded cells through 
a diffuser stylet, which moved linearly and coaxially through the lumen, spraying a cell suspension 
as the scaffold rotated under -5inHg vacuum pressure. The linear speed of the stylet (2.5 mm/s) 
and cell quantity (200 million cells/scaffold) was optimized by Dr. Cunnane using RoosterBio 
MSCs (RoosterBio). Scaffold seeding using RoosterBio cells was observed (n=2) along the length 
and circumference of the scaffold (Figure 56) with H&E. Even seeding was observed along the 
length with some variation in circumferential distribution. Metabolic activity for each section was 
also assessed by Dr. Cunnane using Alamar Blue (DAL 1025, ThermoFisher Scientific) with no 





Figure 56. Histological imaging of the allogenic ASC seeded PEUU scaffold after 10 weeks in vivo. 
Seeded scaffolds were divided into seven sections, and cellularity was observed through H&E staining. 
 
 Seeding optimization was performed using RoosterBio cells due to ease of access, 
however, the end goal was an autologous seeded scaffold using sheep SVF. Sheep SVF isolation 
was performed using the same protocol as human SVF isolation292. Cells were isolated from the 
adipose tissue of one donor sheep and cultured in a 1:1 mixture of Dulbecco’s modified Eagle's 
medium (DMEM, #11965, Gibco) and DMEM/F12 (#113300, Gibco) supplemented with 10% 
FBS (Premium Select, Atlanta Biologics), % penicillin/streptomycin (5000U/mL, Gibco), 0.1% 
fungizone (amphotericin B, Gibco), and 10μL/L dexamethasone (Abcam). Due to the increased 
cell quantities required, culture expansion was required for a trial run due to limited adipose tissue 
available. Cells were cultured on collagen-coated (rat tail type I, Sigma) T175 flasks for a single 
passage. After P1, cells were cultured in collagen-coated 5-layer tower flasks to P4, at which point 
a sufficient quantity of cells was achieved.  
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5.2.2 Pilot In Vivo Testing of a Seeded “Human-sized” Scaffold in a Large Animal Model 
An initial pilot study of a single sheep was performed to assess the potential of the large 
scaffold design. Two million cells were seeded into a 9cm long scaffold and incubated at 37°C in 
culture media overnight. The seeded construct was then placed on ice during surgery for ease of 
access. The scaffold was implanted as a carotid bypass graft in a 9-month-old Suffolk sheep (Rojo 
Stock Farm, New Castle, PA) by Dr. Tzeng at the McGowan Institute of Regenerative Medicine 
facilities. The sheep was intubated and anesthetized with atropine (0.03-0.06 mg/kg), 
oxytetracycline (20-27 mg/kg) and heparin (5000 IU). Just prior to surgery, morphine was 
administered (0.2-0.5 mg/kg). Throughout the procedure, anesthesia was maintained with 
isoflurane (1.5-5% inhaled) and monitored through vitals. The operation site was shaved and 
prepared with a 7.5% povidone-iodine solution and by 70% ethanol. A 14 cm incision was made 
longitudinally along the neck over the sternocleidomastoid muscle over the carotid. A 10 cm 
portion of the carotid was exposed and isolated from surrounding tissues. Vascular clamps were 
placed at each end of the isolated vessel to stop blood flow, and an 8 cm portion of the carotid was 
removed. The 9 cm construct was implanted in the void space as a carotid interposition graft, 
sutured to the carotid at each end using a running suture (7-0 prolene, Ethicon 8696G, Cincinnati, 
OH) (Figure 57). The additional 1 cm of scaffold (8 cm void bypassed using a 9 cm construct) 
allowed for graft stretching after clamp removal. The clamps were then removed, and flow was 
confirmed through graft distention and ultrasound. The skin and muscle layers were closed, using 





Figure 57. Depiction of an ASC seeded PEUU graft implant as a carotid bypass graft in a sheep model. 
The graft maintained flow after clamp removal (top) with no signs of leaking. Graft diameter was slightly 
larger than the native carotid as observed in the proximal (lower left) and distal (lower right) anastomoses. 
 
After the implant, graft patency was monitored weekly with ultrasound (Titan, Sonosite) 
with no detection of occlusion. After 10 weeks, the sheep was euthanized, and the graft explanted. 
Euthanasia was performed in accordance with the IACUCs regulation of ethical treatment. After 
euthanasia, the initial incision site was re-opened, and the graft was isolated (Figure 58). The 
TEVG and surrounding carotid was isolated and divided into 7 portions for histological analysis 





Figure 58. Explant and macroscopic imaging of the ASC seeded PEUU TEVG after 10 weeks in vivo. 
The graft at explant (top) was covered in a thin, fibrous layer of connective tissue. The graft diameter 
appeared to have increased and was comprable in diameter to the jugular vein after 10 weeks in vivo (top). 
The explanted graft was ~7.5 cm in length (middle left) and ranged in diameter due to graft dilation (middle 
right). The graft appeared slightly more dilated towards the ends of the explants in sections L1 (proximal) 
and L6 (distal). A luminal ingrowth was observed in the medial L3 portion of the explant. *Blood flow 





Figure 59. IFC and IHC imaging of the explanted ASC seeded PEUU scaffold. 
Each section of explanted TEVG (far left column) was stained for cellularity (H&E), elastin (VVG) and 
remaining scaffold portions/elastin (FITC autofluorescence). Higher amounts of elastic fiber formation 
(VVG) were observed towards the anastomoses (L1, 2, 6, and 7) indicating cellular infiltration from the 
surrounding vasculature. Cells were observed within each portion of the graft (H&E) indicating successful 
recellularization. Elastin was observed in the L1 and L7 portions, likely due to overlapping carotid tissue. 
Autofluoresence showed more remaining scaffold within the middle portion of the graft (L3,4, and 5) 
compared to the ends (L1,2,6 and 7). 
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Cross-sectional imaging of each explant section showed no signs of stenosis except in L3. 
The sections closest to each anastomosis (L1 and L7) appeared dilated with a noticeably increased 
ID in comparison to the medial portion of the TEVG and carotid. IHC staining for cellularity 
(H&E) showed full re-cellularization of the scaffold throughout the length and circumference. 
Varying levels of remodeling was observed with distance from the anastomosis. VVG staining 
showed early elastin deposition within the neotissue with qualitatively more deposition towards 
the ends of the scaffold (L1 and L7). Scaffold sections were also imaged in the FITC channel for 
autofluorescence of both elastin and remaining scaffold. Portions of the remaining scaffold were 
found mostly within the center of the TEVG (L3-5) with higher levels of scaffold degradation 
towards the anastomoses (Figure 58).  
5.2.3 Overview and Future Directions 
We were able to successfully develop and test a scaled-up model of our cell-seeded PEUU 
scaffold both in vitro and in vivo. Initial in vitro results demonstrated the ability to rapidly vacuum 
seed SVF and MSCs into the pores of a bilayered scaffold. Histologic analysis showed even 
cellularity along the length, however, an uneven distribution of cells was observed radially. 
Additional optimization of seeding parameters (linear speed, rotational speed, injection rate, 
vacuum pressure) specific to cell type may improve radial distribution but may not be required if 
the current quantities and distribution of cells is sufficient in promoting in vivo patency and 
remodeling as indicated by a pilot study.  
Pilot in vivo testing of a single allogenic ASC seeded PEUU scaffold resulted in a patent, 
partially remodeled graft after 10 weeks. Even cellularity and neotissue formation were present in 
each longitudinal section and with evidence of early ECM deposition throughout; however, vessel 
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dilation was observed in cross-sectional images of each section. A slight diameter difference was 
observed (4.7 mm construct ID vs. ~4 mm carotid ID) at the time of implant, which, in cases of 
more drastic mismatch, often leads to flow disruption and stenosis which was observed within the 
L3 potion of the graft. While carotid diameter varies from animal to animal, future studies should 
use ultrasound prior to scaffold preparation to determine diameter and adjust the scaffold 
accordingly. The explanted TEVG also appeared dilated, potentially due to a compliance 
difference between carotid and construct. Future studies may include testing more compliant 
matched grafts to reduce dilation. Overall, this pilot study showed promising results in graft 
seeding and early observations of remodeling.  
5.3 Cell Seeded Silk Scaffolds 
A study exploring cell-seeded silk scaffolds127 was performed in collaboration with Dr. 
Biman Mandal at the Indian Institute of Technology Guwahati and Prerak Gupta, his PhD student 
who was a visiting scientist in the VBL for a year. This study combined the VBL’s cell seeding 
technology with Dr. Mandal’s silk scaffold design and fabrication expertise.  
5.3.1 BA and BM Silk Scaffold Fabrication and Seeding 
Two bi-layered silk based TEVGs were fabricated for testing by Prerak Gupta. The first 
type consisted of BM (6% w/v) silk protein isolated from silk cocoons and the second from a 1:1 
blend of BM (10% w/v) and AA (2% w/v) silk. The inner layer of both types was fabricated by 
injecting the silk solution into custom molds (see Section 2.1), forming a tubular structure with a 
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lumen defined by a center rod. The filled molds were sealed with a cap and frozen at -20°C 
overnight. After freezing, the mold cap and center rods were removed the scaffolds were 
lyophilized for 24 hours. After lyophilization, the scaffolds were removed from the molds and 
soaked in 80% (v/v) EtOH producing a tubular structure of ~40 μm pores. This inner layer was ES 
with a mixture of PCL and BM silk following the protocol in Section 2.1. Mechanical 
characterization and in vitro assessment of scaffold properties was done by Prerak Gupta to ensure 
scaffold suitability for TEVG implant. Briefly, both scaffolds had a 918±82 μm ID and 718±65μm 
wall thickness. The porosity of the inner layer was 53±30μm and 43±24μm for BM and BA 
scaffolds respectively with an overall porosity of ~90% for both. Suitable suture retention and 
burst strengths were observed (827±68 mmHg for BM and 798±100 mmHg for BA). 
Scaffolds were seeded with human SVF isolated from healthy donors under 45 years old 
following established protocols292. Silk scaffolds were seeded using the VBL’s custom rotational 
vacuum seeding88. A 1 million/mL cell suspension of SVF was luminally injected at 1mL/min, 
and a -5inHg vacuum pressure was applied. Successful seeding (>90% efficiency) was achieved 
in both scaffold types. After validation of graft seeding, the constructs were tested in a rat model. 
5.3.2 In Vivo Assessment of BA and BM Scaffolds 
Four groups were tested in vivo: (1) unseeded BA (n=2), (2) unseeded BM (n=3), (3) BA 
seeded with SVF (n=9), and (4) BM seeded with SVF (n=8). SVF constructs were seeded and 
placed in culture 48 hours before surgery to allow for cellular adhesion. The constructs were 
implanted as abdominal aortic interposition grafts (Section 2.2) for 1 and 8 weeks, followed by an 
angiogram to determine patency (Figure 60127). No significant difference in patency was observed 
between any of the groups (Fisher’s test, Appendix A.3, p=0.4894). In summary, 0% (n=0/2, 
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patent/total), 66% (2/3), 43% (3/7), and 33% (3/9) of the explanted grafts were patent for BA, BM, 
BA+SVF, and BM+SVF respectively. Of the 13 not patent grafts, 6 failed due to acute thrombosis 




Figure 60. Patency of BM and BA cell seeded silk scaffolds. 
Macroscopic imaging of explant cross sections showed neotissue formation after 8 weeks indicated by the 
black arrows. Patency (graph) based on angiography was assessed for all explants. No significant differences 
in patency was observed (p=0.4894). 
 
All medial portions of the grafts were sectioned and stained following established protocols 
(Section 2.3.3) for VSMCs (1:100, calponin and SMA), ECs (1:100 vWF), and macrophages 
(1:100 CD68) (Figure 60, from published manuscript127). Explants increased in overall cellularity 
from 1 to 8 weeks in both the BA+SVF and BM+SVF groups. After 8 weeks, neotissue within the 
remodeled grafts contained VSMCs (shown by calponin and SMA) and an endothelial lining 
(vWF). Additionally, a decrease in macrophage presence was observed from 1 to 8 weeks in both 
SVF scaffold types. The highest quantity of positive macrophage staining was found in BA+SVF 
scaffolds after 1 week. 
IHC for overall structure and cellularity (H&E), collagen (PCRO), and elastin (VVG) 
showed increased graft remodeling from 1 to 8 weeks indicated by increased cell count and ECM 
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positive staining (Figure 61). Additional elastin and collagen quantification using a ninhydrin and 
hydroxyproline assay (performed by Dr. Ramaswamy) also showed a higher amount of collagen 
production within both SVF groups after 1 week (p<0.05, Figure 62). Increased elastin was found 
within the BA+SVF group after 8 weeks (p<0.05) in comparison to the BM+SVF group. All results 








Figure 61. IFC analysis of BM and BA cell seeded silk scaffolds after 1 and 8 weeks in vivo. 
IFC staining showed increase cellularity between 1 to 8 weeks in vivo in both the BMES+SVF and 
BAES+SVF groups. Neotissue after 8 weeks stained positive for VMSCs (calponin, SMA) and an endothelial 





Figure 62. IHC analysis of BA and BM cell seeded scaffold after 1 and 8 weeks in vivo. 
(A) IHC staining of explants for cellularity (H&E), collagen (PCRO), and elastin (VVG) showed an 
increased level of ECM deposition and cellularity in the 8-week explants of both seeded scaffold 
types.  (B) A significantly higher collagen content was measured within BAES+WVF samples vs. 
BMES+SVF after 1 week in vivo. (C)ECM quantification showed a significantly higher amount of 
elastin deposition in the BAES+SVF group vs. BMES+SVF after 8 weeks. #p<0.05, ##p<0.01, n.s.= 
not significant. 
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5.3.3 Overview and Future Directions 
This study tested the viability of cell-seeded silk scaffolds for use as TEVGs. Previous 
studies of cell-seeded synthetic scaffolds have shown increased patency and remodeling with the 
inclusion of cells leading to the question: Will cell seeding also improve patency and remodeling 
of silk, a natural material? To answer this question, each graft type was tested in vivo with 
unseeded controls and measured for patency (angiography), immune response (macrophage 
staining), and quality of remodeling (presence of contractile VSMCs, and EC lining, and ECM 
deposition) within a rat aortic model. Analysis of each of these components was aimed at observing 
two particular effects of cells within TEVGs: (1) antithrombogenicity, and (2) encouragement of 
early host macrophage infiltration to mediate graft remodeling. 
No significant differences in patency were observed between any of the four groups. In 
contrast to the previous cell seeded PEUU studies, the inclusion of SVF had no significant effect 
on graft patency. No antithrombotic effect was observed in cell-seeded scaffolds; rather, acute 
thrombosis was the mode of failure for 5 (n=4 for BM and n=1 for BA) of the 10 failed grafts. Of 
the patent grafts, an increased macrophage presence was found in BA+SVF grafts after 1 week 
possibly due to the presence of RGD binding sites (Section 1.3.1.1) associated with AA silk; 
however, this additional biocompatibility attribute did not increase patency in the blank (n=0/2 
patent) or seeded scaffolds (n=3/9 patent). In addition to thrombosis, grafts also failed due to 
hyperplasia localized around the anastomosis indicating damage to the intima during implant. 
Because of the higher degree of hyperplasia at the suture sites, failure of grafts due to hyperplasia 
could be associated with surgical technique rather than graft properties. Despite this, the grafts 
maintaining patency to 8 weeks contained remodeled neotissue with contractile VSMCs, ECs, and 
ECM deposition.  
 157 
This study was able to demonstrate rapid cell seeding of silk scaffolds and in vivo 
assessment of remodeling after 10 weeks. Future studies exploring a higher number of implants 
are needed to determine significance in patency between seeded and unseeded groups. 
Additionally, longer time points would allow for better characterization of whole scaffold 
degradation, ECM maturation, and any prolonged inflammatory response.  
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6.0 Chapter 6: Overall Summary and Future Directions 
Cardiovascular disease is currently the leading cause of death worldwide21 encompassing 
many different afflictions requiring revascularization. Current revascularization strategies utilize 
a synthetic or autologous graft which are associated with high failure rates mainly due to re-
occlusion over time66,99,103-105; thus, there is a need for a more suitable vascular graft option. This 
dissertation focused on the development and testing of three different graft types for use in small 
diameter vascular bypass surgeries: (1) lyogel silk functionalized with CCL2, (2) lyogel silk 
functionalized with conditioned media, and (3) bombyx mori silk functionalized with extracellular 
vesicles.  
The studies outlined in Chapters 2-4 focusing on the development of a cell-free, silk based 
TEVG showed a successful increase in acute (1 week) patency with the delivery of either CCL2 
or CM from a lyogel scaffold. Despite this initial effect, the increased patency was not maintained 
after 8 weeks, and all four (Blank MP, CCL2 MP, CM MP, and lyogel) scaffolds showed similar 
patency rates. Remodeling of the lyogel scaffolds after 8 weeks was characterized by the presence 
of new tissue vascular tissue formation within the scaffold combined with scaffold degradation. In 
comparison, graft failure occurred through acute thrombosis, and excessive tissue growth into the 
lumen of the graft without scaffold degradation leading to stenotic failure. A high occurrence of 
stenosis was observed in response to the lyogel itself, which was reduced when we introduced a 
scaffold made of BM silk alone. Overall, an increase in patency and reduction in stenosis after 8 
weeks in vivo was observed using EV functionalized BM silk scaffolds in comparison to all lyogel 
groups. Chapter 5 outlined three additional TEVG studies performed with collaborators: (1) testing 
of an autologous cell seeded graft fabricated and implanted within 1 day, (2) design and testing of 
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a sheep sized allogeneic cell seeded graft, and (3) design and testing of cell seeded silk scaffold. 
Studies 5.1 and 5.2 were a continuation of a well-established TEVG design previously developed 
in the VBL where a PEUU bilayered scaffold was rapidly seeded with allogenic ASCs and 
implanted into rat (Chapter 5.1) and sheep (Chapter 5.2) models. Both studies showed promising 
results which will serve as the foundation for future studies to optimize a clinically relevant sized 
graft. Additionally, Chapter 5.3 focused on applying similar cell seeding to silk scaffolds resulting 
in a decrease in graft remodeling and patency with the inclusion of cells. This study emphasized 
the interconnected nature of the scaffold treatment (i.e., cells, coatings or MPs) and material type. 
While previous PEUU scaffolds observed an increase in patency and remodeling with cell seeding, 
the opposite effect occurred in silk-based scaffold.  
The varied results of Chapters 2-4 and 5.3 focusing on silk based scaffolds lend to many 
different future directions, including an extended-release of cargo from the MPs, incorporation of 
the MPs into a different base scaffold type, scaling up of the EV functionalized scaffold, and 
considerations towards clinical translation (i.e. shelf life, reproducibility, etc.). The studies 
utilizing PEUU and cells (Chapter 5.1-5.2) have also shown promise towards clinical translation. 
The next steps using this technology include large scaffold optimization and additional in vivo 
testing. Additionally, while this dissertation includes two distinct graft types (silk and PEUU) with 
many different treatment types (CCL2, CM, EVs, autologous cells, and allogeneic cells), future 
studies may look at testing various combinations to produce the most translatable option. Overall, 
future studies can be divided into silk-based grafts, PEUU based grafts, combination grafts, and 
translational considerations. 
Silk based scaffolds functionalized with CCL2 and CM MPs showed a burst release of 
cargo within the first 24 hours of release, which corresponded to an increase in 1-week patency 
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but not 8-week patency. One potential future direction could explore the effects of a sustained 
release of cargo from the MPs. A high tissue-resident macrophage response was observed after 1 
week with the delivery of CCL2 and CM; however, very little macrophage infiltration into the 
porous layer of the scaffold was observed, resulting in low scaffold cellularity. A longer release of 
either cargo may increase cellular infiltration into the porous layer through the recruitment of 
circulating macrophages which may then lead to increased graft remodeling. Future studies 
focusing on a sustained release should start with CCL2 rather than CM due to its higher 
translatability. Additionally, a more porous scaffold could encourage cellular infiltration of the 
host cells. As previously discussed (Section 1.3.1), scaffold porosity plays an important role in 
graft remodeling by encouraging host cell migration into the pores; however, ideal porosity can 
vary with different material types and treatments. Future studies should test different pore sizes to 
better optimize the ideal pore size for lyogel, BM, and BA silk scaffolds. Alternatively, a combined 
early release of CCL2 to first recruit macrophages followed by a later release of an 
immunoregulatory factor, such as IL-4, to polarize the cells may also increase graft remodeling. 
While the exact mechanism behind remodeling is still unknown, many studies focusing on 
biomaterial and host interactions indicate that macrophage polarization towards an M2 phenotype 
is key in successful biomaterial incorporation213,267,280,281. The combined release of two 
characterized factors may provide sufficient remodeling (i.e. neotissue formation and reduced 
stenosis) and would be a more clinical translatable option due to the elimination of unknown and 
xenogeneic factors present within CM (FBS, apoptotic bodies). Additionally, the use of two known 
factors could be easily characterized reducing potential FDA hurdles. Another important 
consideration for future studies utilizing MPs is the scaffold material itself. The increased stenosis 
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observed in Chapters 2 and 3 was observed in the majority of lyogel explants indicating a negative 
response to the lyogel rather than the MPs.  
The studies focusing on cell seeded PEUU grafts also showed positive patency, remodeling 
and potential for clinical translation within a rat model resulting in scaling up of the technology 
and pilot testing within a sheep model (more clinically appropriate sizing). The initial large 
scaffold fabrication and implant resulted in a patent graft with vascular neotissue formation and 
no signs of stenosis indicating the potential as a new TEVG option. Future studies should test 
additional scaffolds at longer timepoints to better observe the risk of stenosis since it is a main 
mode of failure in clinically available grafts. Additionally, a slight dilation was observed after 
implantation of the graft for 10 weeks possibly due to rapid degradation of the ES layer and loss 
of mechanical stability before sufficient neotissue formation (i.e. before collagen deposition). A 
prolonged presence of the ES by increasing the thickness could prevent this dilation and should be 
explored in future attempts. 
Overall, many different scaffolds and treatments were assessed within this study with 
varying levels of patency and remodeling. Since the time, funds, and effort was spent to develop 
and test each element (silk, PEUU, CCL2 MPs, CM MPs, EV isolations, cell seeding, etc.), future 
studies should observe combinations of different scaffold bases and treatment types. For example, 
both the CCL2 and CM MPs successfully prevented acute thrombosis, a common mode of small 
diameter TEVG failure, but later failed due to stenosis from the lyogel. Future studies should test 
the anti-thrombotic properties of the CCL2 and CM MPs in a new scaffold type (PEUU or BM 
silk previously used in the VBL) to observe if a reduction in stenosis can be achieved through 
altering the graft material. Another future study should observe the potential of EVs within a PEUU 
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scaffold since previous studies within the VBL have focused on cell seeded PEUU scaffolds with 
consistent success.  
The last consideration for future studies is the potential for clinical translation. All future 
studies based on the work outlined in this dissertation should account for the potential for clinical 
translation. These factors may include existing FDA regulations (i.e. BM silk is already approved 
but lyogel silk is not), shelf life and storage of the resulting graft (i.e. can pre-seeded grafts be 
stored? For how long?), and feasibility in a clinically relevant sized graft (i.e. can enough 
cells/MPs, or EVs be isolated for a large scaffold?). For example, future studies building upon the 
EV functionalized BM silk scaffold (Chapter 4) results should focus on: (1) scaling up the EV 
isolation from rat-sized to a clinically relevant model (e.g. sheep size), (2) scaling up the graft 
itself from rat aorta dimensions to human/sheep dimensions, and (3) the potential storage and 
longevity of the resulting large TEVGs. While rat size scaffolds were seeded with an isolate from 
~200mL of CM, scaling to a clinically relevant size would require cell culture on a mass scale. 
Initial attempts towards increased EV isolation have been made in collaboration with RoosterBio 
resulting in a grant to explore the use of EVs within TEVGs. Future studies with RoosterBio should 
explore the potential of both a scaled-up cell culture method and EV storage in order to obtain 
enough isolate for large scaffold seeding. The optimization of EV storage would also determine 
the potential storage method and shelf life of a EV functionalized BM silk scaffold.  
Overall, many future directions could be pursued focusing on the work within this 
dissertation. With each of these potential studies, the potential for clinical translation must be the 
main consideration during experimental design. Such considerations include the cost of 
fabrication, batch to batch variability (CM), shelf life (silk vs. PEUU, MPs vs EVs), and potential 
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FDA regulations (cell culture byproducts, already approved vs. new material). All future studies 
based on this work should keep the end goal of a clinically viable, small diameter TEVG in mind. 
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Appendix A Supplementary Materials and Experiments 
Appendix A.1 PEUU Scaffold Optimization and Troubleshooting Quality Control Issues 
The development and translation of a bilayered, biomimetic PEUU scaffold have been 
studied through a collaborative effort between Dr. William Wagner’s laboratory and the VBL. 
Previous studies within the collaboration have demonstrated that PEUU scaffolds alone fail due to 
acute thrombosis nearly 100% of the time while cell-seeded (pericyte, SVF, adipose derived 
MSCs, MSCs) PEUU scaffolds remain patent nearly 100% of the time20,86,88,250. Chapters 2-4 of 
this dissertation mimicked this effect artificially through scaffold functionalization with cytokine 
loaded MPs or MSC-derived EVs in silk scaffolds. This section outlines the early attempts towards 
functionalizing PEUU scaffolds with MPs to determine the potential of cytokine loaded MPs for 
use in different graft materials. 
Appendix A.1.1 MP-seeded PEUU Graft and Seeding Considerations 
This study focused on the development of CM MP-seeded and RoosterBio MSC-seeded 
PEUU scaffolds to directly compare the differences in patency and remodeling between delivery 
of seeded cells (RoosterBio MSCs (RBMSCs)) vs. CM (RoosterBio MSC CM). The development 
of both types required changes in both the seeding method and graft qualities from previous 
studies.  
The previously mentioned rapid cell seeding (Section 3.2.2) method has been used with 
pericytes250, SVF20,86, and adipose derived MSCs19 because the cells can deform and squeeze 
 165 
through smaller pores. In comparison, rigid MPs cannot deform requiring not only smaller 
diameters of the particles themselves, but also a higher external vacuum to force the MPs into the 
pores. The standard protocol for cell seeding uses -5 inHg pressure which was insufficient for MP 
seeding. In collaboration with Dr. Krawiec, an increased seeding pressure of -10 inHg was found 
to successfully seed MPs but also increase of risk of graft rupture and pore damage during seeding. 
Additionally, initial attempts at RBMSCs seeding also resulted in an increased occurrence of graft 
rupture and pore damage due to the larger size of RBMSCs compared to previous cell types 
(Appendix Figure 1). Seeding these larger cells resulted in either graft rupture or only luminal 




Appendix Figure 1. Imaging of cell morphology before seeding. 
 Brightfield imaging of SVF at passage 1 (left), RoosterBio MSCs at passage 1 (middle), and RoosterBio 
MSCs at passage 8 (right), were used to assess cell diameters. SVF cell diameters were smaller than 





Appendix Figure 2. Cross-sectional images of failed PEUU graft seeding. 
PEUU scaffolds seeded with P3 RBMSCs resulted in either luminal seeding only (left) or graft rupture 
(right). 
 
Based on these results, a new type of PEUU scaffold was developed by Dr. William 
Wagner’s group to increase porosity. All previous PEUU scaffolds were consisted of an inner 
porous layer formed using TIPS and an outer ES layer for mechanical stability (Appendix A.1.2). 
To increase the pore size and interconnectivity, the inner layer was instead formed using a 
combination of TIPS and salt leaching, then ES. The resulting SL+TIP+ES scaffolds were able to 
successfully seed RBMSCs (Appendix Figure 3); however, in vivo pilot implantation studies 
resulted in aneurysmal graft dilation (Appendix Figure 4) observed macroscopically. Cross-
sections of the explanted grafts appeared showed nearly 3x graft dilation (Appendix Figure 4E) 
in comparison to previously explanted TEVGs (Appendix Figure 4F, note scale bar). 
Additionally, upon implantation, grafts were similar in diameter to native rat aorta but markedly 
larger at explant (Appendix Figure 4A-D). Grafts explanted after 8 weeks showed apparent signs 





Appendix Figure 3. Cross-sections imaging of SL + TIPS cell seeding 
SL+TIPS+ES scaffolds seeded with P3 RBMSCs showed improved cell seeding and less graft damage 





Appendix Figure 4. Patency and macroscopic imaging of SL + PEUU scaffolds implanted for 8 weeks. 
Implantation of SL+TIPS+ES scaffolds (unseeded) resulted in graft dilation. (A) A depiction of the graft after 
8 weeks just prior to explant shows graft dilation which was confirmed using (C) angiography and 
macroscopic analysis of the (B) cross section of the explanted graft. (D) A cross section of the distal portion of 
the graft showed a drastically dilated graft in comparison to the distal aorta. This difference was confirmed 
using IFC to compare medial cross sections of the (E) SL+TIPS+ES explanted graft from this study vs. (F) 
previously explanted TIPS+ES grafts. 
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Appendix A.1.2 Overview and Future Directions 
The new approach to fabrication incorporating salt leaching was successful in increasing 
inner layer porosity but also produced a mechanically weaker graft compared to previous TIPS+ES 
models. A new iteration of SL+TIPS+ES grafts is under development, focusing on increasing the 
strength of the ES layer to prevent graft dilation. Future studies in this project include continued 
graft optimization with the long-term goal of assessing patency and graft remodeling between 
RBMSC and CM MP seeded SL+TIPS+ES scaffolds in a rat model. 
Appendix A.2 Pilot Studies Observing CCL2 Loaded vs. Unloaded Lyogel Scaffolds as 
Abdominal Aortic Grafts 
An initial pilot study was performed where CCL2 MP loaded lyogel, and lyogel scaffolds 
were tested in 10-12-month-old Lewis rats as abdominal aortic interposition grafts following the 
procedure in Section 2.3. Lyogel (n=5) and CCL2 loaded lyogel (n=4) grafts were implanted for 
1 week, and patency was measured. Additionally, n=2 CCL2 loaded scaffolds were implanted for 
8 weeks to determine their long-term potential. At 1 week, all the lyogel scaffolds failed due to 
acute thrombosis determined through the presence of a clot while only one CCL2 functionalized 
graft (1/7) similarly clotted. A summary of the total implants is displayed in Appendix Table 1 
below. Of the attempted implants recorded, five were excluded due to surgical error. Note: 
implants were performed by myself and Dr. Haskett and were early attempts (i.e. before I became 
fully comfortable with the surgeries) leading to higher surgical complications. All excluded 
attempts denoted “Euthanized due to surgical error” in Appendix Table 1 correspond to signs of 
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leaking at the anastomosis upon explant or signs of damage to surrounding organs during implant 
(obstructed bowels, leak in vena cava).  
 
Appendix Table 1 Pilot study summary of implanted lyogel and CCL2 functionalized lyogel scaffolds. 
The rows highlighted in green represented successful surgeries while those in were elimated from the study 








Lyogel 8 weeks 2 days Euthanized due to infection 
Lyogel 8 weeks 2 days Acute thrombosis 
Lyogel 8 weeks 2 days Acute thrombosis 
Lyogel 8 weeks 1 day Euthanized due to hernia 
Lyogel 8 weeks 1 day Acute thrombosis 
Lyogel  8 weeks 1 day Acute thrombosis  
Lyogel 8 weeks  1 day Acute thrombosis  
Lyogel+CCL2 8 weeks  8 weeks Patent 
Lyogel+CCL2 8 weeks 8 weeks Patent 
Lyogel+CCL2 1 week 1 week Patent 
Lyogel+CCL2 1 week 5 days Euthanized due to surgical error 
Lyogel+CCL2 1 week 5 days Euthanized due to surgical error 
Lyogel+CCL2 1 week 1 week Patent 
Lyogel+CCL2 1 week 1 day Euthanized due to surgical error 
Lyogel+CCL2 1 week 1 day Euthanized due to surgical error 
Lyogel+CCL2 1 week 1 week Not patent 
Lyogel+CCL2 1 week 1 week Patent 
 
 
Total macrophage staining using CD68 IFC staining (1:100 ab31630, monoclonal, 
Abcam)/Cy5 (1:100 ab_2340820, Jackson ImmunoReseach Laboratories Inc.) showed 
qualitatively more macrophages within the CCL2 group (Appendix Figure 5); however, an equal 
time comparison was not possible since none of the lyogel scaffolds remained in vivo until the 





Appendix Figure 5. IFC staining for total macrophages within explant CCL2 lyogel scaffolds 
IFC staining of all macrophages (CD68 in pink) showed qualitatively higher amounts of macrophages within 
the CCL2 explants vs. lyogel alone. 
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Two CCL2 scaffolds were implanted for 8 weeks and remained patent during this time. 
One showed promising signs of recellularization while the other showed signs of stenosis 
(Appendix Figure 6). The promising early patency and potential for long term remodeling lead to 




Appendix Figure 6. IFC imaging of CCL2 functionalized grafts after 8 weeks in vivo. 
Two CCL2 scaffolds were explanted after 8 weeks showing different levels of remodeling. One scaffold 
showed signs of recellularization (left) while the other contained fewer engrafted cells and showed signs of 
stenosis. 
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Appendix A.2.1 Surgical Technique and Progress 
A major component of this study and indeed the entire dissertation was implantation of 
various scaffolds into a rat model. This microsurgery procedure and technique improved with 
practice, as can be seen in this study (Appendix Table 1 showed many instances of euthanasia 
due to surgical error early in the process). In each surgery, the success was dependent on three 
main components: (1) limiting the time that blood supply was restricted to the lower extremities 
after aortic clamping,  (2) limiting disruption of the endothelium at each anastomosis through 
practiced suturing, and (3) aligning the sutures from graft to the aorta to avoid “folds” which may 
cause disruptions in blood flow.  
Initial surgeries, such as the pilot studies described in this section, were limited by surgical 
technique. In the context of the three success criteria, these early surgeries (1) required ~45-60 
minutes of restricted blood flow, (2) had more damage at each anastomosis due to multiple suture 
attempts, and (3) may have been slightly unaligned. All these factors resulted in increased graft 
failure due to occlusion at the anastomoses rather than failure due to graft material/treatment itself. 
Over the course of this dissertation (including studies within the appendices) and additional studies 
for other collaborations, a total of ~200 surgeries were performed, resulting in improved outcomes 
based on technique alone. Later surgeries (such as those from Chapter 4), required only (1) 15-
20 minutes of limited flow due to clamping, (2) had little damage to the aortic endothelium due to 
practiced suturing, and (3) were aligned due to practice which could be observed through a 10x 
microscope. The overall time of each surgery decreased from ~90 minutes to 25-40 minutes total 
allowing for faster recovery as well. This decreased time also allowed for a higher level or rigor 
within each experiment as implants could be performed in larger numbers from the same litter of 
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rats. Overall, surgical technique and progress was a major component of this study and was 
reflected in the design and outcome of each study.   
Appendix A.3 Statistical Analysis of Binary Results 
Graft patency was assessed as binary data where outcomes must be “patent” or “not 
patent.” Using GraphPad Prism 8 (GraphPad Software), patency data was entered into a 
contingency table and analyzed using a Fisher’s exact test to determine significance (Appendix 
Figure 7). This test is used to determine significance between two classifications (patent vs. not 
patent) in small sample sizes of categorical data (i.e., data that can only have a small, consistent 
number of outcomes). Fisher’s exact test was used to determine differences in patency. Each test 





Appendix Figure 7. GraphPad input of patency data to determine significance. 
All 1 week explants were labeled patent or not patent and entered into Graphpad as binary data 
 
Fisher’s exact test for 1-week explants resulted in p=0.0115, indicating a significant 
difference between the three groups. Additional Fisher’s tests were performed between each group 
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to determine significance between individual groups. A significant difference in patency was 
determined between the CCL2 and Blank scaffolds (p=0.0188) but no other groups. 
The same method was used to determine significant differences in 8-week explant patency. 
A Fisher’s exact test determined a significant difference between the three groups (p=0.040) and 
between Blank MP and Lyogel groups (p=0.0288). 
Appendix A.4 Macrophage Stain Optimization and Quantification 
First, IFC staining of macrophages was optimized using rat spleens. Sections of rat spleens 
were stained by IFC following standard protocols. After testing, total macrophage or CD68 (1:100 
ab31630, monoclonal, Abcam)/Cy5 (1:100 ab_2340820, Jackson ImmunoReseach Laboratories 
Inc.), M1 type macrophages or CD86 (NBP2-25208, monoclonal, Novus Biologicals)/Cy3 (1:100 
ab6939, Abcam), and M2 type macrophages or CD206 (1:100 18704-1-AP, polyclonal, 
ProteinTech)/Cy5 (1:100 ab_2340820, Jackson ImmunoReseach Laboratories Inc.) markers were 





Appendix Figure 8. IFC staining for macrophages was optimized using rat spleens. 
An M2 type macrophage marker (CD206, row 2), a pan macrophage marker (CD68, row 4) and an M1 type 
macrophage marker (CD86, row 6) were tested. Each stain was run with a section of spleen only stained with 
secondary antibody (rows 1, 3, and 5) to determine nonspecific binding. Positive staining for all three 
markers was observed using rat spleens.  
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Each CD68 image was then manually segmented into “inner” and “outer” portions 
containing the porous and ES layers of the scaffold, respectively (Appendix Figure 9). Since 





Appendix Figure 9. Image segmentation to quantify macrophages. 
Each stained section was imaged (left) for macrophages (pink) and cell nuclei (blue). Images were then 
manually segmented into inner (middle) and outer (left) masks. 
 
The inner and outer masks were then applied to both the DAPI and stained images (CD68, 
86 or 206). The nuclei stain corresponding to each of the three stains were used to determine an 
overall cellularity. Each image was then run through a custom Matlab code developed by Dr. 
Timothy Chung (Appendix B.2), producing a series of 80 images for each image with varying 





Appendix Figure 10. Thresholded images for macrophage quantification. 
Fluorescently stained images for CD68 and DAPI were run through a custom Matlab code which provided 
varying thresholds with corresponding cell counts. 
 
Each file was then blinded by assigning a random number to each. A threshold for each 
image was determined by comparing the original image to the different level of threshold 





Appendix Figure 11. Determining a threshold for each IFC image. 
Threshold IFC images were blinded and compared to the original to determine a threshold which best fit. 
 
The custom Matlab code assessed cellularity based on the chosen threshold for each image 
yielding cell counts per area for each of the twelve images.  Images were then unblinded and 
overall cell counts were calculated. Significance was determined using GraphPad Prism 8 
(GraphPad) via a one-way ANOVA followed by Tukey post hoc testing between groups. 
Appendix A.5 CM Optimization 
CM was optimized in two ways: determining the passage at which the highest amounts of 
protein secretions were observed and basal media formula. Both tests were aimed at maximizing 
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cellular secretions to produce a more potent CM. Both metrics were optimized using RoosterBio 
MSCs (RoosterBio).  
Appendix A.5.1 Determining Cell Passage Secretions 
RoosterBio MSCs were purchased at passage 0 (P0). With each passage, cells were grown 
to 40% confluency in T175 flasks and rinsed. New media (RoosterBio RoosterNourish MSC (KT-
001, RooserBio, Fedrick, MD)) was then applied and conditioned for 48 hours at which time cells 
reached 80-90% confluency. Conditioned media was collected and centrifuged at 2,040 x g and 
4°C for 5 minutes to remove debris and dead cells. After centrifugation, the supernatant (CM) was 
isolated and stored at -80°C until use. Remaining cells were lifted using 5mL per flask 0.025% 
EDTA trypsin (ThermoFisher Scientific) incubated at 37°C for 3-5 minutes. After cell detachment 
was observed, trypsin was quenched with a 1:5 ratio of FBS (Atlanta Biologics, Flowery Branch, 
GA). Cells were then replated at 1.5M/T175 flask, and the process was repeated for 7 passages.  
ELISAs were performed on the CM to observe protein levels: VEGF (DVE00, R&D 
Systems), HGF (DHG00, , R&D Systems), IL-8 (D8000C, , R&D Systems), TIMP1(DTM100, 
R&D Systems), and TIMP2 (DTM200, R&D Systems). These proteins were chosen based on 
relevance to vascular remodeling (VEGF and HGF) and comparison to RoosterBio pre-
characterized data (IL-8, TIMP1, and TIMP2). ELISA results showed increased secretions of all 





Appendix Figure 12. Characterization of cellular secretions based on the cellular passage of RBMSCs. 
Conditioned media from RoosterBio cells was collected at passages 1-8. The amount of HGF (left, blue), IL8 
(left, orange), VEGF (left, grey), TIMP1 (right, blue), and TIMP2 (right, yellow) was determined for each 
sample using ELISA kits. The highest overall levels were detected in passage 3 conditioned media. 
 
Appendix A.5.2 Determining Basal Media Type 
Six types of media were tested (n=4):  
1. RoosterBio Media – RoosterBio RoosterNourish MSC (KT-001, RoosterBio, 
Fedrick, MD)  
2. RoosterBio Conditioned Media – RoosterBio RoosterNourish MSC media (KT-
001, RoosterBio, Fedrick, MD) conditioned for 48 hours on RoosterBio ASC (P3) 
3. 10% FBS Harvest media: 
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▪ DMEM, high glucose, HEPES, no phenol red (Lot 2046800, Gibco, 
Gaithersburg, MD) (+4.5 g/L D-Glucose, + L-Glutamine, +25 mM HEPES, 
- Sodium Pyruvate) 
▪ 10% FBS (Lot K17139, Atlanta Biologics, Flowery Branch, GA)  
▪ 1% P/S (Gibco) 
▪ 0.1% Fungazone (Gibco) 
▪ 10 uL/L dexamethasone (Gibco) 
4. 10% FBS Harvest media conditioned for 48 hours on RoosterBio MSCs (P3) 
5. 5% Harvest Media: 
▪ DMEM, high glucose, HEPES, no phenol red (Lot 2046800, Gibco, 
Gaithersburg, MD) (+4.5 g/L D-Glucose, + L-Glutamine, +25 mM HEPES, 
- Sodium Pyruvate) 
▪ 5% FBS (Lot K17139, Atlanta Biologics, Flowery Branch, GA) 
▪ 1% P/S (Gibco) 
▪ 0.1% Fungazone (Gibco) 
▪ 10 uL/L dexamethasone (Gibco) 
6. 5% Harvest Media conditioned for 48 hours on RoosterBio MSCs (P3) 
A scratch assay was performed following the protocol outlined in Chapter 3.1.5. Results 
were quantified based on the percent wound closure in response to treatment. For each image, a 
wounded region of interest (ROI) was manually segmented using ImageJ (Madison, Wisconsin). 
For images with ragged boundaries, a line was estimated to represent the level of overall migration 





Appendix Figure 13. A wounded ROI was manually segmented for each image at 0 (left) and 12 hours (right) 
to determine percent wound closure after 12 hours. 
 
% 𝑤𝑜𝑢𝑛𝑑 𝑐𝑙𝑜𝑠𝑢𝑟𝑒 =  
(𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑅𝑂𝐼 𝑎𝑟𝑒𝑎−12 ℎ𝑜𝑢𝑟 𝑅𝑂𝐼 𝑎𝑟𝑒𝑎)
𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑅𝑂𝐼 𝑎𝑟𝑒𝑎
× 100       Appendix Eq. 1 
 
Samples were run in n=6 wells and analyzed in GraphPad Prism (GraphPad). All values 
were entered at percent wound closures as grouped sets of data and analyzed using a two-way, 
repeated measures ANOVA to determine significance. Significant differences between groups was 
determined using Dunnett’s test (p<0.05). 
The largest difference basal and conditioned media was observed in the cells conditioned 
with 5% Harvest Media (Appendix Figure 14). Additionally, the highest percent wound closure 
was measured in response to 5% Harvest Media. Based on these results, 5% Harvest Media was 





Appendix Figure 14. SMC migration after treatment with different conditioned media types. 
SMC migration in response to conditioned media was tested between six groups. Increased migration was 

































Appendix B Raw Data 
Appendix B.1 CCL2 Release Profile ELISA Data  
A release profile of CCL2 functionalized scaffolds was performed using an ELISA kit 
(R&D Systems). Total CCL2 release was measured normalized to scaffold weight prior to release 
(n=12, Appendix Table 2). Raw data is displayed in Appendix Table 3, with each well labeled 
“tube # D (day) #.” 
Appendix Table 2. Dry weights of each scaffold prior to release for protein quantification. 
 
 










1 14.8 13 25.6 25 18.5 
2 20.3 14 23.2 26 14.3 
3 10.3 15 20.7 27 21.8 
4 19.6 16 22.5 28 18.2 
5 19.2 17 23.2 29 23.7 
6 23.1 18 16.9 30 14.4 
7 17.8 19 25.6 31 14.2 
8 17.2 20 15.9 32 13 
9 10.4 21 23.6 33 16.9 
10 13.5 22 23.4 34 17.5 
11 14 23 27.1 35 15.4 







Appendix Table 3. ELISA raw data and standards. 
Three separate 96 well plates were analyzed. The plate set up, raw data and corresponding standards are 
shown above. All data highlighted in red represents data below the level of detection. The working range of 
the assay is bolded in each standard shown on the right. 
 
 
PLATE 1 RAW DATA 
  1 2 3 4 5 6 7 8 9 10 11 12 
A 2.689 3.749 3.627 3.732 3.586 3.664 3.507 3.709 3.554 3.406 3.095 3.424 
B 0.113 0.114 0.113 0.107 0.112 0.118 0.114 0.122 0.113 0.115 0.12 0.129 
C 0.197 0.126 0.13 0.151 0.132 0.125 0.129 0.132 0.194 0.124 0.125 0.12 
D 0.223 0.761 0.772 0.859 1.333 0.601 1.258 1.298 0.661 0.87 0.743 1.227 
E 0.048 0.107 0.11 0.108 0.116 0.112 0.132 0.117 0.109 0.117 0.123 0.115 
F 0.105 0.108 0.113 0.1 0.107 0.123 0.114 0.131 0.121 0.114 0.119 0.124 
G 2.358 1.693 1.114 0.597 0.37 0.232 0.176 0.115         
H 2.448 1.663 0.738 0.633 0.37 0.249 0.173 0.119         
PLATE 2 SETUP 
  1 2 3 4 5 6 7 8 9 10 11 12 
A 1 D5 2 D5 3 D5 4 D5 5 D5 6 D5 7 D5 8 D5 9 D5 10 D5 11 D5 12 D5 
B 13 D5 14 D5 15 D5 16 D5 17 D5 18 D5 19 D5 20 D5 21 D5 22 D5 23 D5 24 D5 
C 25 D5 26 D5 27 D5 28 D5 29 D5 30 D5 31 D5 32 D5 33 D5 34 D5 35 D5 36 D5 
D 1 D6 2 D6 3 D6 4 D6 5 D6 6 D6 7 D6 8 D6 9 D6 10 D6 11 D6 12 D6 
E 13 D6 14 D6 15 D6 16 D6 17 D6 18 D6 19 D6 20 D6 21 D6 22 D6 23 D6 24 D6 
F 25 D6 26 D6 27 D6 28 D6 29 D6 30 D6 31 D6 32 D6 33 D6 34 D6 35 D6 36 D6 
G A B C D E F G H         
H A B C D E F G H         
             
       pg/mL abs      
     A 2000 2.403      
     B 1000 1.678      
     C 500 0.926      
     D 250 0.615      
     E 125 0.37      
     F 62.5 0.2405      
     G 31.3 0.1745      
     H 0 0.117      
             







Appendix Table 3 (continuted) 
 
 
PLATE 2 SETUP 
  1 2 3 4 5 6 7 8 9 10 11 12 
A 1 D5 2 D5 3 D5 4 D5 5 D5 6 D5 7 D5 8 D5 9 D5 10 D5 11 D5 12 D5 
B 13 D5 14 D5 15 D5 16 D5 17 D5 18 D5 19 D5 20 D5 21 D5 22 D5 23 D5 24 D5 
C 25 D5 26 D5 27 D5 28 D5 29 D5 30 D5 31 D5 32 D5 33 D5 34 D5 35 D5 36 D5 
D 1 D6 2 D6 3 D6 4 D6 5 D6 6 D6 7 D6 8 D6 9 D6 10 D6 11 D6 12 D6 
E 13 D6 14 D6 15 D6 16 D6 17 D6 18 D6 19 D6 20 D6 21 D6 22 D6 23 D6 24 D6 
F 25 D6 26 D6 27 D6 28 D6 29 D6 30 D6 31 D6 32 D6 33 D6 34 D6 35 D6 36 D6 
G A B C D E F G H         
H A B C D E F G H         
PLATE 2 RAW DATA 
  1 2 3 4 5 6 7 8 9 10 11 12 
A 0.077 0.094 0.082 0.077 0.115 0.082 0.063 0.097 0.06 0.077 0.099 0.112 
B 0.067 0.09 0.068 0.072 0.084 0.056 0.059 0.058 0.056 0.055 0.062 0.069 
C 0.075 0.078 0.088 0.066 0.068 0.05 0.061 0.065 0.087 0.079 0.072 0.071 
D 0.063 0.095 0.084 0.06 0.075 0.089 0.075 0.067 0.077 0.076 0.08 0.103 
E 0.054 0.066 0.093 0.072 0.069 0.078 0.073 0.057 0.062 0.059 0.079 0.099 
F 0.058 0.065 0.065 0.078 0.072 0.07 0.074 0.087 0.091 0.066 0.067 0.089 
G 1.172 1.29 0.761 0.483 0.247 0.167 0.138 0.069         
H 1.499 1.326 0.756 0.464 0.263 0.171 0.123 0.064         
             
       pg/mL abs      
     A 2000 1.3355      
     B 1000 1.326      
     C 500 0.756      
     D 250 0.464      
     E 125 0.263      
     F 62.5 0.171      
     G 31.3 0.123      
     H 0 0.064      
             
PLATE 3 SETUP 
  1 2 3 4 5 6 7 8 9 10 11 12 
A 1 D7 2 D7 3 D7 4 D7 5 D7 6 D7 7 D7 8 D7 9 D7 10 D7 11 D7 12 D7 
B 13 D7 14 D7 15 D7 16 D7 17 D7 18 D7 19 D7 20 D7 21 D7 22 D7 23 D7 24 D7 
C 25 D7 26 D7 27 D7 28 D7 29 D7 30 D7 31 D7 32 D7 33 D7 34 D7 35 D7 36 D7 
D 1 D8 2 D8 3 D8 4 D8 5 D8 6 D8 7 D8 8 D8 9 D8 10 D8 11 D8 12 D8 
E 13 D8 14 D8 15 D8 16 D8 17 D8 18 D8 19 D8 20 D8 21 D8 22 D8 23 D8 24 D8 
F 25 D8 26 D8 27 D8 28 D8 29 D8 30 D8 31 D8 32 D8 33 D8 34 D8 35 D8 36 D8 
G A B C D E F G H         
H A B C D E F G H         
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Appendix Table 3 (continuted) 
 
 
PLATE 4 RAW DATA 
  1 2 3 4 5 6 7 8 9 10 11 12 
A 0.065 0.071 0.064 0.057 0.072 0.084 0.078 0.085 0.074 0.064 0.081 0.069 
B 0.08 0.076 0.087 0.08 0.119 0.067 0.088 0.072 0.08 0.067 0.079 0.081 
C 0.14 0.083 0.098 0.065 0.079 0.07 0.097 0.088 0.148 0.074 0.078 0.067 
D 0.085 0.167 0.135 0.122 0.23 0.15 0.124 0.179 0.124 0.092 0.116 0.072 
E 0.097 0.072 0.094 0.095 0.1 0.083 0.092 0.105 0.082 0.067 0.064 0.061 
F 0.072 0.102 0.086 0.077 0.08 0.101 0.14 0.075 0.08 0.08 0.08 0.071 
G 1.116 1.102 0.797 0.464 0.32 0.193 0.121           
H 1.59 1.212 0.788 0.421 0.25 0.143 0.11           
        
 
       
       pg/mL abs      
     A 2000 1.353      
     B 1000 1.212      
     C 500 0.788      
     D 250 0.421      
     E 125 0.25      
     F 62.5 0.143      
     G 31.3 0.11      








Appendix B.2 Macrophage Quantification for 1-week CCL2 Explants 
Macrophages were counted using based on thresholding averaged between two blinded 
users (Appendix Table 4). 



























889 153 521 1235 1369 1302 50 202 BLANK 
73 676 374.5 585 367 476 55 74 BLANK 
230 107 168.5 2388 2969 2678.5 31 702 BLANK 
88 489 288.5 3415 4280 3847.5 66 1588 BLANK 
610 248 429 3565 4949 4257 41 1115 BLANK 
640 329 484.5 3581 3390 3485.5 39 1144 BLANK 
220 162 191 3562 3286 3424 23 743 BLANK 
485 107 296 4207 3473 3840 36 1078 BLANK 
235 79 157 4350 3655 4002.5 22 517 BLANK 
7 5 6 88 12 50 1 23 BLANK 
55 15 35 1286 1449 1367.5 3 568 BLANK 
338 238 288 2640 1779 2209.5 33 566 CCL2 
134 77 105.5 2077 2376 2226.5 13 701 CCL2 
334 512 423 1395 1675 1535 37 545 CCL2 
359 113 236 3417 4944 4180.5 22 1044 CCL2 
286 276 281 4382 4877 4629.5 36 985 CCL2 
167 203 185 1232 1551 1391.5 19 593 CCL2 
298 229 263.5 1696 1577 1636.5 22 853 CCL2 
379 440 409.5 1100 1218 1159 39 558 CCL2 
254 112 183 989 1297 1143 22 495 CCL2 
294 239 266.5 2292 2377 2334.5 22 714 CCL2 
15 65 40 763 478 620.5 6 161 CM MP 
65 38 51.5 954 338 646 7 190 CM MP 
555 47 301 2394 1376 1885 34 311 CM MP 
79 91 85 1215 1336 1275.5 7 243 CM MP 
551 81 316 2493 1593 2043 23 483 CM MP 
39 212 125.5 306 371 338.5 15 222 CM MP 
36 19 27.5 2438 651 1544.5 3 151 CM MP 
169 151 160 1241 1567 1404 19 507 CM MP 
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Appendix Table 4 (continued) 
 
 
51 25 38 1258 750 1004 4 229 CM MP 
136 181 158.5 1545 1317 1431 21 384 LYOGEL 
143 69 106 1942 3270 2606 12 290 LYOGEL 
118 77 97.5 1526 1801 1663.5 13 551 LYOGEL 
168 19 93.5 949 870 909.5 12 306 LYOGEL 
 
Cell counts were then generated using a custom code written by Dr. Timothy Chung: 
%MAIN Run through all Images 
clear 
all_files = inside_files;  
inside_files   = all_files(:,1) 
outsides_files = all_files(:,2) 







for i = 1:length(RGB_files); 
     
    try 
        temp_inside  = char(inside_files{i}); 
        temp_outside = char(outsides_files{i}); 
        temp_RGB     = char(RGB_files{i}); 
  
        where_space = strfind(temp_RGB,' '); 
        tag = temp_RGB(1:where_space(2)-1); 
  
        TI = imread(temp_inside);  
        TI = TI(1:end,1:end,end); 
        TI(TI >0) = 1; TI = logical(TI); 
  
        TO = imread(temp_outside); 
        TO = TO(1:end,1:end,end); 
        TO(TO >0) = 1; TO = logical(TO); 
  
        TRGB = imread(temp_RGB); 
        TR = TRGB(1:end,1:end,1); %DAPI 
        TG = TRGB(1:end,1:end,2); %BLANK 
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        TB = TRGB(1:end,1:end,3); %RED 
  
        TI_DAPI = TB.*uint8(TI); 
        TO_DAPI = TB.*uint8(TO); 
  
        TI_RED  = TR.*uint8(TI); 
        TO_RED  = TR.*uint8(TO); 
  
        tkc_get_inside_outside([tag '_DAPI'], TI_DAPI, TO_DAPI); 
        cd .. 
  
        tkc_get_inside_outside([tag '_206'], TI_RED, TO_RED); 
        cd .. 
    catch 
       disp('Something went wrong'); 
       wrong_cases(i,:) = 1; 
       cd .. 





function tkc_get_inside_outside(tag, TI, TO); 
  
  
TII = TI; %make copy of inner mask 
TOO = TO; %make copy of outer mask 
  
TII(TII >0) = 1; TII = logical(TII); %create binary regions 
TOO(TOO >0) = 1; TOO = logical(TOO); %create binary regions 
inside_pixel_area = sum(sum(TII));   %calculate inner pixel area 
outside_pixel_area = sum(sum(TOO));  %calculat outer pixel area 
%% 
mkdir(tag) %Creates a new folder of cell image of interest 
cd(tag) 
fid = fopen([ tag '_data.csv'],'w+'); %create data file 
fprintf(fid,'Inside Pixel Area, Outside Pixel Area, Inside Cell Count (Area), Outside Cell 
Count (Area), Inside Cell Count (Boundaries), Outside Cell Count (Boundaries),threshold\n'); 
%create headers for data file. 
fclose('all'); 
  
for i = 1:1:82 %threshold ranges from 1 to 82 
     
    try 
    threshold = i/100; %threshold rescaling from i, to be between 0.00 - 1.00 
    temp_TI = im2bw(TI,threshold); %im2bw to binarize image 
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    temp_TO = im2bw(TO,threshold); 
     
    temp_inside_borders = bwboundaries(temp_TI); %retrieves boundary regions from 
inner cross-section 
    temp_outside_borders = bwboundaries(temp_TO); %retrieves boundary regions from 
outer cross section 
     
    for j = 1:length(temp_inside_borders); 
        inside_lengths(j,:) = length(temp_inside_borders{j}); %retrieve boundary lengths 
    end 
     
    for k = 1:length(temp_outside_borders); 
        outside_lengths(k,:) = length(temp_outside_borders{k}); %retrieve boundary lengths 
    end 
     
    where_is_bad = inside_lengths >= 5; %filter out non cell regions 
    where_is_bad_2 = outside_lengths >=3; %filter out non cell regions for outer 
     
    final_inside  = temp_inside_borders(where_is_bad,:); 
    final_outside = temp_outside_borders(where_is_bad_2,:); 
    
    h = figure; %create new image 
    imshow(TI+TO,[]); hold on; %show combined image 
     
    for l=1:length(final_inside) %plot cell boundaries 
       b = final_inside{l}; 
       plot(b(:,2),b(:,1),'b','LineWidth',1); hold on; 
    end 
     
    for m=1:length(final_outside) %plot cell boundaries 
       b = final_outside{m}; 
       plot(b(:,2),b(:,1),'r','LineWidth',1); hold on; 
    end 
    set(gcf,'color','black'); 
     
    title_stuff = sprintf('Threshold: %0.2f || Inside Count: %d || Outside Count: 
%d',threshold, length(final_inside), length(final_outside)); 
    image_title = sprintf('Thresh_IC_OC_%0.2f %d %d.png',threshold, 
length(final_inside), length(final_outside)); 
    title(title_stuff) 
    set(h, 'Color',[1, 1 ,1]) 
    saveas(gcf,[image_title]); 
     
    dlmwrite([tag '_data.csv'],[inside_pixel_area outside_pixel_area sum(sum(TI)) 
sum(sum(TO)) length(final_inside) length(final_outside) threshold],'-append'); %appends to csv 
file stats per threshold 
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    close('all') 
    clear final_inside final_outside temp_inside_borders temp_outside_borders 
outside_lengths inside_lengths %reset variables for conflict reduction 
    catch 
       disp('There are no cells at this threshold level');  





function [maximum second] = tkc_get_2_boundaries(inside_boundaries); 
  
    for i = 1:length(inside_boundaries); 
        lengths(i,:) = length(inside_boundaries{i}); %creates list of boundaries 
    end 
  
maximum = dsearchn(lengths, max(lengths)); %recovers max length 
max_copy = maximum;  
  
lengths_copy = lengths; 
lengths_copy(lengths_copy == max(lengths_copy)) = []; %removes max length 
  
second = dsearchn(lengths, max(lengths_copy)); %retrieves second max length of entire 
set 
sec_copy = second; 
  
temp_1 = inside_boundaries{maximum}; %boundary cell to array 
temp_2 = inside_boundaries{second};  %boundary cell to array 
  
area_1 = polyarea(temp_1(:,1), temp_1(:,2)); %Measures area that the boundary 
encompasses 
area_2 = polyarea(temp_2(:,1), temp_2(:,2)); %Measures area that the boundary 
encompasses 
  
if area_2 > area_1 
    maximum = sec_copy; 




Appendix B.3 Protein Release from CM MPs 
Samples of 10 mg of CM MPs were released into 0.5 mL PBS (pH 7.4, Gibco) in triplicate. 
Appendix Table 5 displays the well plate set up and raw data. The samples were normalized to the 





Appendix Table 5. Protein release from CM MPs raw data. 
The well plate setup (top) used the nomenclature: sample number (N#) day of releasate collection (D#) or 
standard label (STD) which corresponds to the standards displayed in the bottom table. Raw data is 
displayed in the middle table. 
 
  1 2 3 4 5 6 7 8 9 
A STD A STD A STD A STD I STD I STD I N1 D16 N2 D16 N3 D16 
B STD B STD B STD B N1 D1 N2 D1 N3 D1 N1 D18 N2 D18 N3 D18 
C STD C STD C STD C N1 D2 N2 D2 N3 D2 N1 D21 N2 D21 N3 D21 
D STD D STD D STD D N1 D4 N2 D4 N3 D4 B D1 B D2 B D4 
E STD E STD E STD E N1 D7 N2 D7 N3 D7 B D7 B D9 B D11 
F STD F STD F STD F N1 D9 N2 D9 N3 D9 B D14 B D16 B D18 
G STD G STD G STD G N1 D11 N2 D11 N3 D11 B D21     
H STD H STD H STD H N1 D14 N2 D14 N3 D14       
  1 2 3 4 5 6 7 8 9 
A 2.139 2.077 2.09 0.099 0.098 0.099 0.108 0.14 0.11 
B 0.588 0.554 0.574 0.499 0.467 0.519 0.128 0.135 0.149 
C 0.357 0.343 0.34 0.179 0.117 0.117 0.148 0.151 0.165 
D 0.211 0.209 0.204 0.108 0.104 0.127 0.107 0.104 0.11 
E 0.134 0.133 0.138 0.111 0.11 0.161 0.116 0.122 0.108 
F 0.118 0.11 0.111 0.142 0.122 0.149 0.137     
G 0.105 0.106 0.106 0.117 0.139 0.12       
H 0.104 0.106 0.106 0.131 0.126 0.343       
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Appendix Table 5 (continued) 
   Standard     
   STD ug/mL Abs     
   A 200 2.102     
   B 40 0.572     
   C 20 0.347     
   D 10 0.208     
   E 5 0.135     
   F 2.5 0.113     
   G 1 0.106     
   H 0.5 0.105     














Appendix B.4 CM MP Scratch Assay Migration Quantification 
SMC migration was assessed using a scratch wound assay (Section 3.1.5). Treatments of 
unsupplemented SMC media (negative control, Cell Applications), RoosterBio CM (positive 
control, RoosterBio), 500 μL of 10 mg/mL Blank MP releasate, and 500 μL of 10 mg/mL CM MP 
releasate were applied to SMCs. All images were blinded before quantification to ensure non-
biased measurements. Percent wound closure after 18 and 24 hours were quantified (Appendix 





Appendix Table 6. Scratch assay quantification represented as % wound closure after 18 and 24 hours. 
User #1 Measurements 
  18H % 18H STD 24H % 24H STD 
UNSUPP 68 28 83 20 
BLANK MP 62 26 73 19 
CM MP 72 23 87 14 
CM 86 17 97 6 
User #2 Measurements 
UNSUPP 59 16 78 25 
BLANK 59 28 82 22 
CM MP 71 23 77 19 
CM 71 8 96 8 
Combined Measurements 
UNSUPP 64 6 81 4 
BLANK 60 2 77 7 
CM MP 72 1 82 7 





Appendix B.5 CM MP Proliferation Quantification 
SMC proliferation in response to CM MPs was quantified in Section 3.2.5. Appendix 
Table 7 displays the raw data. 
 




























32 39 22 51 59 60 88 
63 79 25 81 29 90 43 
49 64 31 68 39 100 104 
73 89 22 101 38 114 56 
61 100 64 125 105 132 116 
54 63 17 77 43 82 52 
27 36 33 40 48 42 56 
56 61 9 76 36 75 34 
30 35 17 46 53 51 70 
57 74 30 103 81 114 100 
29 35 21 49 69 55 90 
22 27 23 30 36 33 50 
32 52 63 65 103 71 122 
34 52 53 76 124 82 141 
39 56 44 76 95 86 121 
28 34 21 50 79 64 129 
35 41 17 65 86 77 120 
26 31 19 45 73 55 112 
15 29 93 46 207 56 273 
40 71 78 106 165 112 180 
48 72 50 118 146 128 167 
16 24 50 41 156 57 256 
31 42 35 66 113 70 126 
37 58 57 99 168 125 238 
 198 
Appendix B.6 EV Scratch Assay Migration  
Averages of percent wound closure after 24 hours are listed in Appendix Table 8 (SMCs) 
and 9 (ECs). Each row represents one batch of EV isolate. 
 
Appendix Table 8. . SMC migration with EV treatment. 
Values represent percent wound closure after 24 hours. SBM=supplemented basal media, CM=conditioned 
media, dCM=conditioned media with EVs depleted, nCM=non conditioned media, PBS=phosphate buffered 
saline, UBM=unsupplemented basal media (SMC specific), EV150= 150μL of EV isolate, EV50=100μL PBS + 
50μL EV isolate. 
 
SBM CM dCM nCM PBS UBM EV150 EV50 
78.8 66.6 43.6 41.2 27.9 27.9 48.7 50.6 
88.9 88.2 60.0 43.1 30.3 37.1 63.2 47.3 





Appendix Table 9. EC migration with EV treatment. 
Values represent percent wound closure after 24 hours. SBM=supplemented basal media, CM=conditioned 
media, dCM=conditioned media with EVs depleted, nCM=non conditioned media, PBS=phosphate buffered 
saline, UBM=unsupplemented basal media (EC specific), EV150= 150μL of EV isolate, EV50=100μL PBS + 
50μL EV isolate. 
 
 
SBM UBM PBS EV150 EV50 nCM CM dCM 
65.6 18.4 17.0 48.5 36.1 59.9 99.0 72.5 
58.9 26.4 19.9 39.9 31.8 78.6 84.2 71.1 
69.8 19.1     30.2 78.5 86.4 63.8 
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Appendix B.7 EV Stimulation of Cell Proliferation  
Averages of cellular proliferation measured using Alamar blue assays (Chapter 4.2.4) after 
24 hours are listed in Appendix Table 10 (SMCs) and 11 (ECs). Each row represents one batch 
of EV isolate. 
 
 
Appendix Table 10. SMC proliferation with EV treatment. 
Values represent SMC proliferation measured using alamar blue after 24 hours of treatment. 
SBM=supplemented basal media, UBM=unsupplemented basal media (SMC specific), PBS=phosphate 
buffered saline, EV150= 150μL of EV isolate, EV50=100μL PBS + 50μL EV isolate, nCM=non conditioned 
media, CM=conditioned media, and dCM=conditioned media with EVs depleted. Each column represents one 
EV isolation and black boxes indcate no sample was run for that assay. 
 
SBM UBM PBS EV150 EV50 nCM CM dCM 
0.134           0.598 0.276 
0.111 0.692 0.932   0.898   0.650 0.210 
0.174 0.659   0.753 0.689   0.583 0.324 
0.217 0.718 1.083 0.964   0.407   0.274 
0.113 0.755 1.073 0.986   0.454   0.243 










Appendix Table 11. EC profilferation with EV treatment. 
Values represent EC proliferation measured using alamar blue after 24 hours of treatment. 
SBM=supplemented basal media, UBM=unsupplemented basal media (SMC specific), PBS=phosphate 
buffered saline, EV150= 150μL of EV isolate, EV50=100μL PBS + 50μL EV isolate, nCM=non conditioned 
media, CM=conditioned media, and dCM=conditioned media with EVs depleted. Each column represents one 
EV isolation and black boxes indcate no sample was run for that assay. 
 
 
SBM BM PBS EV150 EV50 nCM CM dCM 
0.465 1.1     0.986 0.665 0.577 0.356 
0.413 1.23 1.196 1.051 1.061 0.657 0.588 0.268 
0.387 1.26 1.213 1.1976 1.032 0.706 0.526 0.27 
0.448 1.3 1.335 1.36 1.185     0.27 
0.416 1.52 1.263 1.2181 1.152     0.186 











Appendix B.8 EV Functionalized Lyogel Explants Elastin and Collagen Quantification 
Elastin was quantified by Dr. Ramaswamy using a ninhydrin assay. Raw data is displayed 
in Appendix Table 12 in μg ELN/μg Total Protein.  
 
 
Appendix Table 12. Elastin quantification of 8 week explanted EV funcionalized TEVGs. 
Elastin content of 8 week explanted TEVGs was measured for the Blank (BM silk alone), MSCs (MSCs 
seeded BM silk), and EV (EV functionalized BM silk) groups. Measurements are in μg ELN/μg Total Protein. 
Black boxes represent no sample or damaged sample with no quantification. 
 
Blank MSC EV 
0.25455 0.13994 1.256 
0.09562 1.53869 0.77858 
0.352 0.60799 0.57855 
0.44249 0.42626 0.84499 
  0.31541 0.429 
0.30031 0.77829 2.3275 
0.51079 1.09735 0.69113 
0.56923 0.43749 0.48298 
0.52518 0.40403 0.96114 
0.45109 0.59783 0.81695 
0.54665 0.55469   
  0.7592   
 
 
Collagen was quantified by Dr. Ramaswamy using a hydroxyproline assay. Raw data is 






Appendix Table 13. Collagen quantification of explanted 8 week EV functionalized TEVGs. 
Collagen content of 8 week explanted TEVGs was measured for the Blank (BM silk alone), ASC (adipose 
stem cell seeded BM silk), and EV (EV functionalized BM silk) groups. Measurements are in μg ELN/μg 
Total Protein. Black boxes represent no sample or damaged sample with no quantification. 
 
Blank MSC EV 
1.03302 1.13763 1.49222 
1.18234 0.96027 1.20808 
0.44285 1.32416 2.21491 
0.88415 0.51389 0.98837 
0.63624 1.34319 2.35643 
1.15698 1.01944 1.11923 
1.54355 1.047 1.48447 
0.86367 1.2778 1.9777 
1.44409 1.48796 0.66902 
1.01422 0.6472 1.23973 
  1.5727   









Appendix B.9 EV Seeding Efficiency  
Seeding efficiency was measured by comparing the protein content of the EV isolate before 
and after seeding. Raw data is displayed in Appendix Table 14 in μg/mL.  
 
 
Appendix Table 14. Protein content of EV isolate pre and post seeding. 
Seeding efficiency was measured by detecting the amount of protein within the EV isolate before and after 
seeding. A portion of each sample was also lysed to release protein content previously encapsulated within the 











57.238 84.65461 163.879 170.8257 
77.8568 92.41623 160.132 166.729 
73.0037 68.0177 153.922 173.8641 
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Appendix C Summary of Accomplishments 
The work within this dissertation resulted in the following manuscripts: 
1. Darren G Haskett, Kamiel S Saleh, Katherine L Lorentz, Alexander D Josowitz, 
Samuel K Lueketich, Justin S Weinbaum, Lauren E Kokai, Antonio D’Amore,  
Kacey G Marra, J Peter Rubin, William R Wagner, David A Vorp; An exploratory 
study on the preparation and evaluation of a “same-day” adipose stem cell-based 
tissue-engineered vascular graft (JTCVS, November 2018) 
2. Aneesh K Ramaswamy, Rachel E Sides, Eoghan M Cunnane, Katherine L 
Lorentz, Leila M Reines, David A Vorp, Justin S Weinbaum; Adipose-Derived 
Stromal Cell Secreted Factors Induce the Elastogenesis Cascade within 3D Aortic 
Smooth Muscle Cell Constructs (Matrix Biology Plus, Sept 2019)  
3. Prerak Gupta, Katherine L Lorentz, Darren G Haskett, Eoghan M Cunnane, 
Aneesh K Ramaswamy, Justin S Weinbaum, David A Vorp, Biman B Mandal; 
Bioresorbable Silk Grafts for Small Diameter Vascular Tissue Engineering 
Applications: In vitro and In vivo Functional Analysis (Acta Biomaterialia, March 
2020) 
4. Eoghan M Cunnane, Katherine L Lorentz, Aneesh K Ramaswamy, Prerak Gupta, 
Biman B Mandal, Fergal J O’Brien, Justin S Weinbaum, David A Vorp; 
Extracellular vesicles enable remodeling of cell-free silk vascular scaffolds in rat 
aortae (ACS, accepted May 2020) 
5. Eoghan M Cunnane, Niall F Davis, Alan J Ryan, Katherine L Lorentz, Jochen 
Hess, Justin S Weinbaum, Michael T Walsh, Fergal J O’Brien, David A Vorp; 
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Biomechanical and micromorphological characterization of the human male 
urethra for the development of a biomimetic tissue engineered urethral scaffold (in 
preparation) 
6. Katherine L Lorentz, Eoghan M Cunnane, Aneesh K Ramaswamy, Timothy K 
Chung, Darren G Haskett, Samuel K Luketich, Lorenzo Soletti, Edith T Tzeng, 
Antonio D’Amore, William R Wagner, Justin S Weinbaum, David A Vorp; 
Seeding Tubular Scaffolds with Adipose Stromal Cells for Large Animal Model 
Implantation of Tissue Engineered Vascular Grafts (in preparation) 
7. Katherine L Lorentz, Prerak Gupta, Mostafa S Shehabeldin, Emily M Lickert, 
Brittany R Rodriguez, Eoghan M Cunnane, Aneesh K Ramaswamy, Morgan V 
Fedorchak, Steven R Little, Justin S Weinbaum, Charles S Sfier, Biman B Mandal, 
David A Vorp; Testing the efficacy of CCL2 to prevent acute thrombosis in silk 
vascular grafts in vivo (in preparation) 
8. Katherine Lorentz, Liza A Bruk, Prerak Gupta, Eoghan M Cunnane, Aneesh K 
Ramaswamy, Biman B Mandal, Morgan V Fedorchak, Steven R Little, Justin S 
Weinbaum, David A Vorp; Validation of artificial MSCs for use in tissue 
engineered vascular grafts (in preparation)  
The following patent applications were filed as a result of this work: 
1. Artificial cells and delivery devices for use in tissue engineering, and related 
methods (PCT/US2017/039973) 
2. Biodegradable, porous, tubular silk scaffold for tissue engineering applications (in 
preparation) 
3. Extracellular vesicle augmentation of vascular grafts (in preparation) 
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National Institutes of Health grant to the Vascular Bioengineering laboratory 
awarded July 2016. 
2. Bevier Award, Swanson School of Engineering, University of Pittsburgh, awarded 
to author September 2016. 
3. World Congress of Biomechanics Grant; Retention of seeded mesenchymal stem 
cells within an implanted elastomeric vascular scaffold, awarded to author in July 
2018. 
4. Undergraduate Summer Research Internship; Swanson School of Engineering, 
University of Pittsburgh 6/2018-8/2018, awarded to Abigail Snyder (mentored 
undergraduate student). 
5. Undergraduate Summer Research Internship; Swanson School of Engineering, 
University of Pittsburgh 6/2018-8/2018, awarded to Meara Sedlak (mentored 
undergraduate student). 
6. Undergraduate Summer Research Internship; Swanson School of Engineering, 
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